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 Abstract: 
Insights into the Structural Basis for Activity and Selectivity of P450 BM3 
Monooxygenase 
 
P450 BM3, as an important member of the cytochrome P450 superfamily of monooxygenases, 
preferentially catalyzes the subterminal hydroxylation of long chain fatty acids by sourcing 
electrons from the natural cofactor, NADPH. P450 BM3 variants which exhibit altered and 
inverted enantiopreference for styrene epoxidation have been previously reported. Furthermore, 
variants are known which can be catalytically driven based on alternative cofactor systems. In 
this thesis, crystal structures were determined to rationalize the function of P450 BM3 variants.  
Chapter I of this thesis has been dedicated to describing results originating from the 
crystallization of styrene epoxidation variants. For P450 BM3, it is known that an exchange of a 
single amino acid to a positively charged residue at position 184 in P450 BM3 variant 5F5 (heme 
domain substitutions: F87A, T235A) inverts the enantioselectivity of styrene epoxidation 
towards S-styrene oxide; even though Ala184 is located far from the active site. In order to 
explain mechanistic roles of individual substitutions in governing the enantiopreference, crystal 
structures of P450 BM3 heme domain variants have been successfully determined in complex 
with styrene, illustrating the bound substrate (styrene) in hitherto unobserved productive and 
non-productive substrate binding modes in the active site of P450 BM3. The structural data 
reveal the formation of a new inter-helical salt-bridge at the surface in S-selective variants, which 
causes the repositioning of the structural elements that are adjacent to the active site and, as a 
consequence, styrene binding geometries are altered as compared to the R-selective 5F5 variant. 
Chater II of this thesis describes results obtained from the crystallization of the P450 BM3 M7 
heme domain variant (substitutions: F87A, V281G, and M354S) in complex with cobalt (III) 
sepluchrate (Co(III)Sep), the mediator of electronic transactions in the zinc (Zn) based 
alternative cofactor system. The mediator binds on the surface of the protein at the entrance of 
the substrate access channel, a position far from the active site, suggesting new routes for 
shuttling electrons to the active site heme-iron and implying that the electronic communication 
between the protein and the mediator is facilitated by the bound substrate in the active site. The 
structural evidence helps diagnose the molecular basis for ‘addiction’ of P450 BM3 variants to 
Co(III)Sep, and opens avenues for the future design of highly selective variants of P450 BM3 or 
structurally related monooxygenases towards alternative and cost-effective cofactor systems.  
In Chapter III, the crystal structure of the wild-type FAD/NADPH binding domain has been 
presented which sheds light on the cofactor selectivity in P450 BM3. The structure explains the 
role of individual residues which influence the crystallization process, and rationalizes the 
importance of substitutions previously reported to switch the cofactor specificity in P450 BM3. 
Towards the end are highlighted important structural features of the wild-type and T577G FMN 
domains, and the heme domains of aromatic hydroxylation variants of P450 BM3. Solved crystal 
structures of these variants reveal that the introduced substitutions do not cause any significant 
structural perturbations, and hence these variants resemble the corresponding wild-type domains. 
The obtained knowledge in understanding the enantioselective styrene epoxidation and the 
cofactor selectivity in P450 BM3 variants can very likely be generalized to structurally related 
monooxygenases, substrates, and cofactors.  
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Introduction 
 
1. Introduction: 
 
1.1 Cytochromes P450
Cytochromes P450 (P450s) are one of the oldest and largest protein superfamilies ubiquitously 
distributed in almost all domains of life 
experimentally first realized in 1955 as an enzyme system functionalizing xenobiotic compounds 
in the endoplasmic reticulum of the liver 
P450s were shown to exhibit an absorption maximum at 450 nm in carbon monoxide (CO) 
complexed form (Garfinkel 1957
cysteine-liganded heme macrocycle, a feature ultimately leading them to be named as 
cytochromes P450 (Omura and Sato 1962
 
1.1.1 Catalytic mechanism
P450s generally catalyze the incorporation of one atom of molecular oxygen into various 
substrates. For this reaction, P450s source electrons from NADPH or NADH via electron 
transfer proteins (Ortiz de Montellano 1995
The reaction mechanism of P450s has been extensive
Denisov, Makris et al. 2005; 
been summarized here. The general scheme of reaction
P450s is shown in Figure 1. 
exists  as  a  mixture  of  a hexacoordinated low
Fe(III). In the former case, a water molecule acts as the sixth ligand while in the latter the 
proximal cysteine acts as the only axial ligand. The equilibrium shifts toward the 
pentacoordinated complex upon binding of the substrate in close proximity of the heme. This 
results in substantially elevated redox potential of the heme
electron from the redox partner. Depending upon the origin of the cytochrome P450, the latter 
can be i) an FMN and FAD harboring reductase domain (CPR, 
present either as a membrane-
iron-sulfur (Fe-S) electron shuttling protein that transfers electron from an FMN containing 
 
 
(Degtyarenko and Archakov 1993
(Axelrod 1955; Brodie, Axelrod et al. 1955
; Klingenberg 1958), and were also demonstrated to contain a 
; Omura and Sato 1964).  
 
). 
ly investigated (Ortiz de Montellano 1995
Ortiz de Montellano 2010; Whitehouse, Bell et al. 2012
 mechanism regarded to be common to all 
In  the substrate-free resting  state  (ferric  form),  the heme
-spin Fe(III) and a pentacoordinated high
-iron, enabling it to accept one 
Cytochrome 
bound complex or covalently fused to the heme domain, and ii) an 
1  
).  Their existence was 
). Later, 
 
; 
), and has 
-iron 
-spin 
P450 Reductase) 
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flavoprotein. The main function of the electron donor partner(s) seems to be uncoupling two 
electrons from the reducing equivalents (NADPH or NADH) and funneling them singly to the 
heme containing P450 catalytic domain. Thus, a pentacoordinate high-spin Fe(II) complex, 
which is able to bind many ligands including molecular oxygen (O2), is produced upon reduction 
by one electron. Binding of oxygen leads to the formation of a ferrous dioxy Fe(II)-OO or ferric 
superoxide Fe(III)-OO- complex which can revert back to ferric iron Fe(III) state with the loss of 
a superoxide (O2
-) anion upon autoxidation. Alternatively, the oxygen bound complex can be 
subsequently activated by one-electron reduction to an oxygen species, ferric peroxo-iron 
Fe(III)-OO-2 complex. The transfer of second electron has been generally regarded as the main 
rate limiting step in the overall catalytic cycle. Protonation of the peroxo-iron complex produces 
a highly unstable hydroperoxo-iron species Fe(III)-OOH- (compound 0) which upon further 
protonation results in the heterolytic scission of O-O bond and formation of iron-oxo Fe(IV)=O 
complex (compound I) with concomitant release of a water molecule. Two major possible 
abortive reactions, often termed as uncoupling, during protonation are i) a peroxide shunt, where 
the peroxide or hydroperoxide anion leaves the heme-iron forming hydrogen peroxide (H2O2) if 
water molecules encroach into the active site due to a loosely fitting substrate, and ii) an oxidase 
shunt, where the compound I is oxidized to release a water molecule and the ferric Fe(III) state is 
attained again if the substrate is not properly positioned for hydrogen abstraction. Interaction of 
the substrate with compound I through radical rebound mechanism leads to the formation of a 
monooxgenated product. It has been proposed that a carbon radical on the substrate is generated 
through abstraction of a hydrogen atom by the ferryl oxygen. This radical then reassociates with 
the equivalent of a hydroxyl radical (compound II) ligated to the heme iron to yield a 
hydroxylated product (Ortiz de Montellano 1995; Denisov, Makris et al. 2005; Ortiz de 
Montellano 2010 ; Whitehouse, Bell et al. 2012). 
 
1.2 P450 BM3  
P450 BM3 is a 119 kDa water-soluble monoxygenase originating from the soil bacterium 
Bacillus megaterium (Narhi and Fulco 1986; Narhi and Fulco 1987). As it was the third P450 
identified in this bacterium, it was named as ‘P450 BM3’ (also termed as CYP102A1) (Fulco 
1991; Whitehouse, Bell et al. 2012). P450 BM3 has attracted considerable interest from an 
application point of view due to its excellent enzymatic properties such as higher catalytic 
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efficiency compared to other P450s, increased thermal resistance, ability of engineered variants 
to catalyze subterminal hydroxylation of short-, medium- and long-chain fatty 
acids/alkanes/alcohols, epoxidation of medium- and long-chain unsaturated fatty acids, as well as 
hydroxylation of polyaromatic compounds and heteroarenes (Miura and Fulco 1975; Boddupalli, 
Estabrook et al. 1990; Capdevila, Wei et al. 1996; Ost, Miles et al. 2000; Appel, Lutz-Wahl et al. 
2001; Carmichael and Wong 2001; Li, Schwaneberg et al. 2001). 
 
Figure 1: General scheme of the reaction cycle common to all P450s. Figure has been reproduced from 
(Ener, Lee et al. 2010).  
 
1.2.1 P450 BM3 domains  
P450 BM3 is one of the rare examples among P450s that harbors its catalytic heme and the 
electron shuttling FMN/FAD-containing diflavin reductase domains naturally fused on a single 
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polypeptide chain (Figure 2; Narhi and Fulco 1986). A linker peptide connects both the domains, 
and it has been sugested that the length, and not the sequence, of the linker is crucial for flavin-
to-heme electron transfer (Govindaraj and Poulos 1995), as the linker does not fold into any 
regular secondary structure necessary for activity (Govindaraj and Poulos 1996). In P450 BM3, 
reducing equivalents are transferred from the obligate hydride donor, NADPH, first to FAD and 
then electrons are relayed, one at a time, to FMN within the reductase domain and ultimately to 
the heme cofactor (Whitehouse, Bell et al. 2012). 
Figure 2: Modular arrangement of P450 BM3 domains. P450 BM3 consists of an N-terminal catalytic 
heme binding domain which is naturally fused to an electron shuttling diflavin reductase domain through 
a polypeptide linker (Narhi and Fulco 1986).  
 
1.2.2 P450 BM3 crystal structures 
Likely due to the intrinsic flexibility associated with the electron transfer from the reductase 
domain to the heme domain, the full-length P450 BM3 has not been structurally resolved yet 
(Girvan, Seward et al. 2007; Huang, Westlake et al. 2007). To date, most of the solved structures 
consist of the heme domain or its variant in the presence or absence of ligands (Table 1; 
Whitehouse, Bell et al. 2012), with one structure describing the heme-FMN domain complex 
(Sevrioukova, Li et al. 1999), and two structures reported on the FAD/NADPH binding domain 
(Joyce, Ekanem et al. 2012). Interestingly, substrate-complexed crystal structures of the wild-
type (WT) and some variants have been solved only in the presence of fatty-acids or structurally 
related substrates, and none of the deposited structures of P450 BM3 depicts for fatty-acid-like 
substrates productive binding modes, suggesting that structures were crystallized in a ‘pre-
catalytic’ conformation (Whitehouse, Bell et al. 2012). The first structure of P450 BM3 
deposited in the Protein Data Bank (PDB), the world-wide repository for macromolecular 
structures of biomolecules (Bernstein, Koetzle et al. 1977; Berman, Westbrook et al. 2000), was 
the WT heme domain (PDB code: 2HPD) that showed marked differences around the substrate 
binding pocket upon superposition of two molecules in the asymmetric unit (Ravichandran, 
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Boddupalli et al. 1993). The structure also revealed that, besides the substrate binding pocket, the 
other region that substantially differed from that of P450cam (Poulos, Finzel et al. 1985) was the 
putative docking site for the redox partner (Ravichandran, Boddupalli et al. 1993). Subsequently, 
a 2.7 Å resolution substrate (palmitoleic acid)-bound crystal structure of the heme domain was 
reported (PDB code: 1FAG) that highlighted susbtrate-induced conformational changes (Li and 
Poulos 1997). A major milestone in the structural biology of P450 BM3 was achieved when a 
truncated complex of the heme and FMN binding domains was successfully crystallized and 
diffracted to 2.03 Å resolution (PDB code: 1BVY; Sevrioukova, Li et al. 1999). The structure 
depicted FMN binding domain at the proximal face of the heme domain, with FMN ligand 
positioned at a distance of 18.4 Å from the heme-iron (Sevrioukova, Li et al. 1999). It was 
observed that the environment surrounding the FMN ligand significantly differed from other 
P450 reductases, leading to altered redox properties of P450 BM3 (Sevrioukova, Li et al. 1999). 
A better resolved (1.65 Å) substrate-bound crystal structure of the heme domain (PDB code: 
1JPZ) was reported in the presence of a novel substrate N-palmitoylglycine, which binds the 
enzyme with higher affinity than many other substrates, and revealed detailed features of the 
active site reorganization upon substrate binding (Figure 3; Haines, Tomchick et al. 2001). 
Important to mention are substantially reduced I-helical kink angle due to interruption of the 
given hydrogen bonding pattern by an inserted water molecule, and the lateral displacement of 
the axially coordinated water molecule to an ‘off-axial’ position, leading to a shift from low-to-
high spin state of the heme-iron upon substrate binding (Figure 4; Haines, Tomchick et al. 2001; 
Whitehouse, Yang et al. 2011; Whitehouse, Bell et al. 2012). Furthermore, the proton transfer 
pathway that would lead to heterolytic cleavage of molecular oxygen was proposed (Haines, 
Tomchick et al. 2001). Crystal structures of the heme domain complexed with two other tightly 
binding substrate analogues (N-Palmitoyl-L-leucine and N-Palmitoyl-1-methionine) helped 
identify a hydrophobic pocket near Arg47 assumed to be responsible for increasing the affinity 
of substrates for the enzyme (Hegde, Haines et al. 2007). Further high-affinity substrate-binding 
variants (A82F/W) were structurally solved that depicted the endogenously produced palmitate 
bound to the enzyme, showing that filling a hydrophobic pocket in the active site with bulky side 
chains of phenylalanine or tryptophan significantly improved the affinity for the natural substrate 
(Huang, Westlake et al. 2007). The variants were also hydroxylating indole more efficiently than 
the WT enzyme (Huang, Westlake et al. 2007). However, the role of structural changes in 
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modulating the electronic properties of the heme was put into question when the crystal structure 
of F393H variant was solved (PDB code: 1JME; Ost, Munro et al. 2001), as the structure 
demonstrated that the histidine replaced the substituted phenylalanine in exactly the same fashion 
on the proximal side without causing any apparent conformational change, suggesting that the 
structural environment on the proximal side should remain intact in order to enhance catalytic 
properties (Ost, Munro et al. 2001). Phe393 substitution variants (F393A, F393W, and F393Y) 
and I401E variant, exhibiting elevated redox potential than the WT, were also crystallized (Ost, 
Clark et al. 2003; Girvan, Levy et al. 2010), again indicating no structural perturbations. This 
was further evidenced by the crystal structure of A264E heme domain variant (PDB code: 1SMI) 
which depicted the enzyme to be in the substrate-bound conformation in the absence of the 
substrate, and heme-iron to be in the low-spin state with Glu264 ligating the heme-iron (Joyce, 
Girvan et al. 2004). Upon addition of the substrate (palmitoleic acid), the high-spin state was 
achieved (Joyce, Girvan et al. 2004), and the substrate-complexed crystal structure (PDB code: 
1SMJ) revealed negligible structural differences when compared to wild-type substrate-bound 
(WTSB) forms (Li and Poulos 1997; Haines, Tomchick et al. 2001; Joyce, Girvan et al. 2004; 
Hegde, Haines et al. 2007; Whitehouse, Bell et al. 2012), indicating that spin-state shift is mainly 
a consequence of the presence of substrate in the active site environment (Joyce, Girvan et al. 
2004). Furthermore, the variant was catalytically active, implying that the displacement of 
glutamate ligand allows the binding of molecular oxygen for catalysis to proceed (Joyce, Girvan 
et al. 2004). Crystal structures of A264H and A264K, and later of A264M/Q variants, further 
supported these findings (Girvan, Seward et al. 2007; Girvan, Toogood et al. 2009). However, 
the crystal structure of I401P variant (PDB code: 3HF2), which is highly active towards non-
natural substrates, showed structural similarities with WTSB forms (Li and Poulos 1997; Haines, 
Tomchick et al. 2001; Hegde, Haines et al. 2007; Whitehouse, Bell et al. 2009). Moreover, the 
substrate-free crystal structure of an ‘activity-enhancing’ variant (PDB code: 3PSX), containing 
five substitutions in the heme domain, was reported which displayed structural features 
resembling the WTSB forms (Li and Poulos 1997; Haines, Tomchick et al. 2001; Hegde, Haines 
et al. 2007; Whitehouse, Yang et al. 2011), suggesting that increased catalytic efficiency might 
originate due to the ‘catalytically ready conformation’ of the substrate-free form of the variant 
(Whitehouse, Yang et al. 2011). On the other hand, WT crystal structure complexed with N-(12-
imidazolyldodecanoyl)-L-leucine inhibitor revealed, similar to wild-type substrate-free (WTSF) 
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forms (Sevrioukova, Li et al. 1999
2007), a surprisingly open substrate
2008). Crystal structure of A330P variant, exhibiting substantially enhanced catalytic activity 
towards small substrates, displayed a constricted active site due to encroachment of the substrate
access channel by Pro329 (Whitehouse, Yang et al. 2010
act on selected human administered drugs was structurally solved to 3.2 Å resolution (PDB code: 
3QI8), and showed an increased structural flexibility for the L75R substitution
helix (Ser72-Gly83) in the active site 
substrate specificity. 
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Table 1: Overview of P450 BM3 crystal structures in the presence and absence of ligands. 
No. PDB ID Domain Substitution Ligand Resolution 
1 1BU7 Heme WT - 1.65 
2 1BVY 
Heme/ 
FMN WT - 2.03 
3 1FAG Heme WT Palmitoleic acid 2.70 
4 1FAH Heme T268A - 2.30 
5 1JME Heme F393H - 2.00 
6 1JPZ Heme WT N-palmitoylglycine 1.65 
7 1P0V Heme F393A - 2.05 
8 1P0W Heme F393W - 2.00 
9 1P0X Heme F393Y - 2.00 
10 1SMI Heme A264E - 2.00 
11 1SMJ Heme A264E Palmitoleic acid 2.75 
13 1YQP Heme T268N - 1.80 
12 1YQO Heme T268A - 1.90 
14 1ZO9 Heme WT 
N-palmitoyl-L-
methionine 1.70 
15 1ZO4 Heme A328S - 1.46 
16 1ZOA Heme A328V N-palmitoylglycine 1.74 
17 2HPD Heme WT - 2.00 
18 2IJ2 Heme WT - 1.20 
19 2IJ3 Heme A264H - 1.90 
20 2IJ4 Heme A264K - 2.40 
21 2J1M Heme WT DMSO 1.70 
22 2J4S Heme WT - 2.10 
23 2BMH Heme WT    - 2.00 
24 2NNB Heme Q403K - 1.90 
25 2UWH Heme A82F Palmitic acid 2.80 
26 2X7Y Heme F87A DMSO 2.10 
27 2X80 Heme F87A DMSO 2.30 
28 3BEN Heme WT 
N-(12-imidazolyl-
dodecanoyl)-L-
leucine 
1.65 
29 3CBD Heme 
V78A, H138Y, T175I, V178I, 
A184V, H236Q, E252G, R255S, 
A290V, A295T, L353V 
N-palmitoylglycine 2.65 
30 3DGI Heme F87A, T268A DMSO 1.95 
31 3EKB Heme A264C - 2.30 
32 3EKD Heme A264M Palmitoleic acid 2.50 
33 3EKF Heme A264Q - 2.10 
34 3HF2 Heme I401P - 2.20 
35 3KX3 Heme L86E N-palmitoylglycine 1.80 
36 3KX4 Heme I401E - 1.95 
37 3KX5 Heme F261E - 1.69 
38 3M4V Heme A330P - 1.90 
39 3NPL Heme C62A, K97C, C156S Ru(bpy)2(A-Phen) 2.40 
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40 3PSX Heme A191T, N239H, I259V, A276T, 
L353I - 
1.90 
41 3QI8 Heme 
I58V, L52I, L75R, F87A, H100R, 
S106R, F107L, A135S, F162I, 
A184V, N239H, S274T, L324I, 
V340M, I366V, K434E, E442K, 
V446I 
- 3.20 
42 4DQK FAD/ 
NADPH 
C774A - 2.40 
43 4DQL 
FAD/ 
NADPH WT NADP
+ 2.15 
44 4DTW Heme 
L75P, Q189R, I263A, T268A, 
V286E 
Serotonin 1.80 
45 4DTY Heme L75P, Q189R, I263A, T268A, 
V286E - 
1.45 
46 4DTZ Heme L75P, Q189R, I263A, T268A, 
V286E 
L-dopamine 
 
1.55 
 
47 4DU2 Heme L75P, F81L, Q189R, I263A, T268A, 
V186E, Y305H, I366V 
L-dopamine 
 
1.90 
48 4DUA Heme I263A, T268A, A328G, T438V - 2.00 
49 4DUB Heme I263A, T268A, A328G, T438V L-dopamine 1.70 
50 4DUC Heme R50C, F87L, T268S, T438L - 1.92 
51 4DUD Heme R50C, F87L, T268S, L437Q, T438L - 1.85 
52 4DUE Heme R50C, F87L, T268S, L437Q, T438L Serotonin 1.70 
53 4DUF Heme R50C, F87L, T268S, T438L Serotonin 1.80 
 
 
The crystal structure of a heme variant conjugated to Ru-photosensitizer [Ru(bpy)2(A-phen)]
2+ 
via non-native Cys97 was solved (PDB code: 3NPL) in order to obtain insights into light-
triggered electron transfer from photogenerated Ru(I) to the heme (Ener, Lee et al. 2010). The 
electron density for Ru-potosensitizer was well-defined in one of the monomers, and the Ru-Fe 
distance was 24 Å, revealing that the protein backbone was ‘electronically’ linked to one of the 
heme-propionics through Trp96 side (Ener, Lee et al. 2010). 
Crystal structures of P450 BM3 variants bound to small inhibitors such as DMSO (dimethyl 
sulfoxide) (Kuper, Wong et al. 2007; Kuper, Tee et al. 2012), serotonin, and dopamine (Brustad, 
Lelyveld et al. 2012) have been recently reported. In these cases, the bound ligand is directly 
coordinated to the active site heme-iron. Moreover, a double variant (C773A/C999A) of the 
FAD/NADPH binding domain has been solved that was specifically engineered aimed at 
yielding successful crystals for diffraction (Joyce, Ekanem et al. 2012). 
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1.2.3 Substrate interactions in P450 BM3 
The active site of P450 BM3 is regarded as ‘open’ in the substrate-free form (Ravichandran, 
Boddupalli et al. 1993). Upon substrate binding the enzyme undergoes substantial 
conformational changes which are more conspicuous in the F- (Pro172-Gln189) and G- (Glu200-
Ser226) surface helices, the loop joining the β1-1 and β1-2 sheets, and parts of the I-helix (Glu252-
Lys282) adjoining the active site (Figure 3; Li and Poulos 1997; Haines, Tomchick et al. 2001; 
Whitehouse, Bell et al. 2012). All these segments come closer to each other, and the enzyme 
changes its conformation from an ‘open’ to a ‘closed’ form upon substrate binding (Li and 
Poulos 1997; Haines, Tomchick et al. 2001; Whitehouse, Bell et al. 2012). P450 BM3 harbors a 
long binding cavity termed as substrate access channel which accommodates the substrate, and 
traverses from the surface of the enzyme to the active site (Ravichandran, Boddupalli et al. 1993; 
Li and Poulos 1997; Haines, Tomchick et al. 2001; Whitehouse, Bell et al. 2012). The only polar 
interactions with the fatty-acid substrate are formed at the entrance of the substrate access 
channel by residues Tyr51 and Arg47 with the carboxyl group of the substrate (Li and Poulos 
1997; Haines, Tomchick et al. 2001; Hegde, Haines et al. 2007; Whitehouse, Bell et al. 2012), 
while the alkyl tail of the substrate is tethered in the binding pocket by hydrophobic residues (Li 
and Poulos 1997; Li and Poulos 1999). Both residues at the opening of the access channel are 
also implicated in modulating the entry of water molecules and cosolvents into the enzyme (Ost, 
Miles et al. 2000; Carmichael and Wong 2001). Furthermore, mutagenesis studies have revealed 
that these residues are not only involved in substrate binding but are also responsible for 
attracting substrates to the substrate access channel (Ost, Miles et al. 2000; Dennig, Marienhagen 
et al. 2012). Another surface residue, Phe42, has been shown to acts as a phenyl ‘cap’ over the 
‘mouth’ of the substrate-binding channel (Noble, Miles et al. 1999). Upon substrate binding, a 
notable difference can be observed in the side-chain orientation of Phe87, located in the active 
site just above the heme cofactor, which rotates from a position almost perpendicular to the heme 
in the substrate-free form to a more parallel position upon substrate binding, effectively limiting 
the access of the ω-terminal methyl group of fatty-acid from approaching the heme and 
preventing its hydroxylation (Figure 4; Li and Poulos 1997; Haines, Tomchick et al. 2001; 
Whitehouse, Bell et al. 2012). Therefore, Phe87 has long been regarded to be responsible for 
sub-terminal oxidation of substrates in P450 BM3 (Whitehouse, Bell et al. 2012). This was also 
substantiated by a study which demonstrated that F87A variant yielded > 90% ω-hydroxylation 
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for fatty acids (Oliver, Modi 
change its rotamer conformation with Phe87 in a concerted manner 
2011).  
Figure 4: Structural overlay of the key active site residues in the wild
1BU7 (Sevrioukova, Li et al. 1999)
substrate-bound (blue; PDB code 1JPZ
Thr268 is hydrogen bonded to 
cofactor is depicted in red color. 
 
Substrate binding also causes active site water mo
2001; Whitehouse, Bell et al. 2012)
heme-iron in the substrate-free form is laterally displaced to an ‘off
substrate binding (Haines, Tomchick et al. 2001;
Bell et al. 2012). Another water molecule enters into the I
bonding pattern, and results in a substantially reduced I
 
et al. 1997). Leu437, an active site residue, has been shown to 
(Whitehouse, Yang et al. 
-type substrate
) and the NPG (N-palmitoylglycine; magenta
 (Haines, Tomchick et al. 2001)) forms of P450 BM3. In the latter
laterally displaced and helix interrupting water molecules. The heme 
WH: water in the I-helix.  
lecules to rearrange (Haines, Tomchick et al. 
. A water molecule (the sixth ligand) coordinated to the 
 Whitehouse, Yang et al. 2011
-helix to interrupt the given hydrogen 
-helical kink angle in the substrate
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-free (gray; PDB code 
) complexed wild-type 
, 
-axial’ position upon 
; Whitehouse, 
-bound 
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form (13° in substrate-free form vs 5° in substrate-bound form; Haines, Tomchick et al. 2001; 
Whitehouse, Bell et al. 2012). In the WTSF forms (PDB codes: 1BU7 (Sevrioukova, Li et al. 
1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 2IJ2 (Girvan, Seward et al. 2007)), the I-
helical kink stems from the failure of two successive hydrogen bonds (Ile263CO-Glu267NH and 
Ala264CO-Thr268NH) to form among the backbone atoms (Whitehouse, Yang et al. 2011; 
Whitehouse, Bell et al. 2012). 
Substrate-binding has also been associated with ‘sinking’ of the proximal loop containing the 
cysteine ligand, and the heme-iron lies slightly out of the heme plane as compared to substrate-
free form (Whitehouse, Bell et al. 2012). One of the few polar residues in the active site, Thr268, 
is responsible for proper positioning of water molecules needed for functionalization of 
substrates (Cryle and De Voss 2008; Whitehouse, Bell et al. 2012). It is also implicated in 
functions as diverse as proton delivery, oxygen activation, and the stabilization of reactive 
oxygen species (Volz, Rock et al. 2002; Clark, Miles et al. 2006; Cryle and De Voss 2006; 
Whitehouse, Bell et al. 2012). Thr268, together with Glu267, represents a member of the highly 
conserved acid-alcohol pair in the I-helix (Whitehouse, Bell et al. 2012). In the substrate-free 
form, it interacts with at least one water molecule, and a subtle substitution such as to Gln has 
been suggested to impair proton delivery (Whitehouse, Bell et al. 2012). 
 
1.2.4 P450 BM3 towards non-natural substrates  
WT P450 BM3 and engineered variants known to functionalize non-natural substrates which are 
immensely attractive from an application point of view have been excellently reviewed 
elsewhere (Whitehouse, Bell et al. 2012), and are summarized here.  
 
1.2.4.1 Aliphatic hydrocarbons 
 
1.2.4.1.1 Alkanes 
 A highly efficient P450 BM3 variant 139-3, carrying 11 amino acid substitutions in the heme 
domain, was generated by directed evolution strategy (Glieder, Farinas et al. 2002). The variant 
is not only efficient in hydroxylating alkanes as small as butane but also greatly surpasses the 
WT enzyme in hydroxylating long chain fatty acids (Glieder, Farinas et al. 2002). By using the 
same approach, a ‘laboratory-evolved’ propane monooxygenase was obtained which harbors 20 
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substitutions in the catalytic heme domain, and theoretical studies suggested minimal structural 
perturbations in the overall structure of the variant for switching substrate specificity (Fasan, 
Meharenna et al. 2008). Subsequent directed evolution endeavors by targeting residues within 5 
Å vicinity of terminal eight carbon atoms of the bound substrate in palmitogylcine-complexed 
structure in P450 BM3 yielded 53-5H variant which contains three active site substitutions, all of 
them to larger amino acids compared to the WT, and has been shown to hydroxylate propane to 
propanol and ethane to ethanol (Meinhold, Peters et al. 2005). Another variant, 35-E11, differing 
from 53-5H by two substitutions: one in the reductase domain and the other in the linker peptide 
joining the latter with the heme domain, has been reported that exhibits five-fold improved total 
turnover numbers as compared to the parent 53-5H variant in converting ethane to ethanol 
(Meinhold, Peters et al. 2005). Interestingly, methane hydroxylation has been observed in the 
WT P450 BM3 which can hydroxylate methane in the presence of chemically inert activating 
‘guests’, perfluoro carboxylic acids, under high pressure (Zilly, Acevedo et al. 2011). Perfluoro 
carboxylic acids occupy more space in the substrate binding pocket and mimic substrates by 
inducing low-spin to high-spin transition of the heme-iron (Zilly, Acevedo et al. 2011). 
 
1.2.4.1.2 Alkenes 
The variant 139-3, an excellent alkane hydroxylase, (Glieder, Farinas et al. 2002) is also known 
to be active towards 1-hexene and propylene, converting them exclusively to 1-hexene-3-ol and 
propylene oxide, respectively (Farinas, Alcalde et al. 2004). For cyclohexene, the same variant 
produces a mixture of cyclohexene oxide (85%) and 2-cyclohexene-1-ol (15%) (Farinas, Alcalde 
et al. 2004). Two P450 BM3 variants, SH-44 and RH-47, have been subsequently reported which 
can enantioselectively epoxidize a number of terminal alkenes with high turnover numbers 
(Kubo, Peters et al. 2006). 
 
1.2.4.1.3 Alkynes 
WT P450 BM3 has been reported to hydroxylate 1-hexyne and 1-octyne to form 1-hexyne-3-ol 
and 1-octyne-3-ol as major products, respectively, though hydroxylation of non-terminal alkynes 
does not result in high turnovers (Waltham, Girvan et al. 2011). In comparison to F87G variant, 
the aromatic side chain of Phe87 in the WT seems to form stabilizing interactions with the π 
electrons of the acetylene triple bond and protects ω-1 carbon of terminal alkyne substrates from 
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the oxidative attack of compound I, which otherwise would lead to the heme chromophore 
destruction by alkylation (Waltham, Girvan et al. 2011). 
 
1.2.4.2 Aromatic compounds  
Substitution of Phe87 with valine in the WT has also been shown to improve activity towards a 
number of aromatic and phenolic compounds such as benzothiophene, indane, 2,6-
dichlorophenol, and 2-(benzyloxy) phenol (Sulistyaningdyah, Ogawa et al. 2005). A smaller 
residue, alanine, at position 87 also results in 8-fold increase in 3-phenoxytoluene hydroxylation 
(Wong, Wu et al. 2005). WT P450 BM3 has been reported to be catalytically incompetent 
towards indole hydroxylation (Li, Schwaneberg et al. 2000). However, multiple variants with 
substitutions at positions 74 (A74G), 87 (F87V), and 188 (L188Q) have been reported that can 
hydroxylate indole, ultimately leading to indigo and indirubin formation (Li, Schwaneberg et al. 
2000). Further improvements in the indole hydroxylation have been achieved by screening error-
prone and site-saturation mutagenesis libraries, resulting in the identification of variants 
containing either D168H or E435T substitution in the starting variant, A74G/F87V/L188Q, and 
exhibit up to six-fold higher catalytic efficiency and higher regioselectivity compared to the 
parent variant (Li, Mei et al. 2008). However, the latter is also very active towards oxidizing 
polycyclic aromatic hydrocarbons (PAHs) such as naphthalene, fluorine, acenaphthene, 
acenaphthylene, and 9-methylanthracene as compared to the WT (Li, Ogawa et al. 2001). 
Furthermore, the variant also exhibits activity towards metabolizing polychlorinated dibenzo-p-
dioxins (PCDDs) which are extremely toxic environmental pollutants (Sulistyaningdyah, Ogawa 
et al. 2004). Variants have been reported which can form dimethylphenols from xylene 
(Whitehouse, Rees et al. 2011; Dennig, Marienhagen et al. 2012). Increased activity towards 
oxidizing PAHs such as phenanthrene, fluoranthene, and pyrene has also been achieved by 
recombining R47L/Y51F, F87A, and A264G substitutions (Carmichael and Wong 2001). For 
fluorene oxidation to fluoren-9-ol, the product-formation rate (PFR) substantially enhanced (188 
min-1) by a single substitution (I401P) as compared to the WT (0.1 min-1) (Whitehouse, Bell et al. 
2009). The same variant also shows significantly improved PFRs for the oxidation of 
propylbenzene (3578 min-1) which is also higher when compared to previously obtained best 
variant, RLYF/KT2 (2688 min-1), harboring seven substitutions (Whitehouse, Bell et al. 2008; 
Whitehouse, Bell et al. 2009). Naphthalene and p-cymene can also be oxidized at much higher 
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PFRs by employing RLYF/A330P and KSK19 variants, respectively (Whitehouse, Bell et al. 
2008).                                                    
 
1.2.4.2.1 Enantioselective styrene epoxidation 
Styrene epoxidation by WT P450 BM3, though with very low enantiospecificity, was 
experimentally first realized in 1994 (Fruetel, Mackman et al. 1994). WT P450 BM3 has also 
been shown to oxidize propylbenzene and 3-chlorostyrene with high turnovers, and residue at 
position 87 has been suggested to be important in modulating the enantioselectivity of such 
oxidations (Li, Ogawa et al. 2001). Whereas WT P450 BM3 coverts propylbenzene to (R)-(+)-1-
phenyl-1-propanol with high enantiopreference (90% e.e.), the optical purity diminishes by 
substituting Phe87 with smaller residues (Val, Ala, Gly) (Li, Ogawa et al. 2001). On the other 
hand, the production of (R)-(-)-3-chlorostyrene oxide gets gradually promoted by introducing 
smaller residues at position 87 in the WT P450 BM3 (Li, Ogawa et al. 2001). Moreover, two 
double variants, A82F/T438L and A82F/T438F, have been reported which produce 48% and 
64% R-styrene oxide, respectively (Huang, Cullis et al. 2011). Interestingly, an exchange of a 
single amino acid to a positively charged residue at position 184 in P450 BM3 variant 5F5 
(F87A, T235A) inverts the enantioselectivity of styrene epoxidation toward S-styrene oxide, 
even though Ala184 is located far from the active site (~18 Å; Tee and Schwaneberg 2006).    
 
1.2.4.3 Drugs and drug-metabolites 
The first report describing an engineered variant of P450 BM3 with improved affinity for a drug 
or a drug-like compound appeared quite recently (van Vugt-Lussenburg, Damsten et al. 2006). A 
P450 BM3 variant, but not the WT, carrying three substitutions R47L/F87V/L188Q was shown 
to metabolize substrates known to be metabolized by mammalian P450s (Yamazaki and Shimada 
1997; Keizers, Lussenburg et al. 2004) such as testosterone, acetaminophene (APAP), 
amodiaquine, dextromethorphen, and 3,4-methylenedioxymethylamphetamine (MDMA) (van 
Vugt-Lussenburg, Damsten et al. 2006). The latter two substrates are even more efficiently 
converted by an evolved variant obtained after random mutagenesis of the triple variant, and 
shows 200-fold improved turnover (van Vugt-Lussenburg, Stjernschantz et al. 2007). 
Interestingly, non-active site substitutions (F81I, L86I, and E267V) have been demonstrated to 
have the most pronounced effect on the activity (van Vugt-Lussenburg, Stjernschantz et al. 
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2007). Investigation of fused holoenzymes constructed by recombining 17 heme domains to 
P450 BM3 reductase domain helped identify chimera that are capable of metabolizing drugs not 
accepted by parent enzymes (Landwehr, Carbone et al. 2007). Drugs such as chlorzoxazone, 
aniline, p-nitrophenol, propanolol, and nifedipine, all of which act as typical substrates for 
human cytochromes CYP2E1 and CYP3A4, have also been shown to be accepted by WT P450 
BM3 (Di Nardo, Fantuzzi et al. 2007). CYP102A1 M11 variant, harboring eight substitutions 
compared to the WT, efficiently produces human drug metabolites and other valuable 
intermediates (Damsten, van Vugt-Lussenburg et al. 2008). Introduction of F87Y substitution 
into CYP102A1 M11 increased activity towards alkoxyresorufins and testosterone (Vottero, Rea 
et al. 2011). The latter was also reported to be hydroxylated with high (96-97%) regio- and 
enantioselectivity by P450 BM3 variants generated by directed evolution strategy (Kille, Zilly et 
al. 2011). A single active-site substitution, S72I, has been shown to be sufficient for inverting 
enantioselectivity of 16-β hydroxylation of testosterone in favor of 16-α hydroxylation in M01 
A82W and M01A82W/S72V variants (Venkataraman, Beer et al. 2012). P450 BM3 variants 
have also been successfully applied to oxidize organic molecules that can be subsequently 
fluorinated by deoxofluorination agents to yield mono- and polyfluorinated membrane 
permissive drugs (Rentmeister, Arnold et al. 2009). A number of P450 BM3 variants are also 
involved in the synthesis of mammalian metabolites of verapamil (a calcium channel blocker 
extensively prescribed against hypertension), astemizole (an antagonist used to cure sinus allergy 
symptoms), and LZ294002 (a potent drug used in research to treat malignancies) (Sawayama, 
Chen et al. 2009). A correlation has been figured out between indole oxidation by P450 BM3 
variants and the production of drug metabolites obtained from human P450s (Park, Kim et al. 
2010). Specifically, variants leading to indigo formation are also capable of oxidizing human 
P450 substrates such as coumarin, 7-ethoxycoumarine, phenacetin, ethoxyresorufin, and 
chlorzoxazone (Park, Kim et al. 2010). It has been further shown that WT P450 BM3 and its 
engineered variants, generated by rational design and random mutagenesis, can produce human 
chiral metabolites of simvastatin and lovastatin, pharmaceuticals best known for their use as 
cholesterol-lowering agents (Vickers, Duncan et al. 1990; Caron, Ermondi et al. 2007; Kim, 
Kang et al. 2011). Two negatively charged non-steroidal anti-inflammatory drugs (NSAIDs), 
naproxen and ibuprofen, belonging to the profen family that are substrates of hepatic human 
CYP2C9 are actively metabolized by P450 BM3 variants obtained through directed evolution 
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approach (Miners and Birkett 1998; Rentmeister, Brown et al. 2011). Natural variants identified 
in a species of B. megaterium are also able to metabolize human P450 substrates such as 
phenacetin, coumarin and its derivatives, and chlorzoxazone (Kang, Kim et al. 2011).    
 
1.2.4.4 Other compounds 
Subjecting P450 BM3 heme domain to directed evolution experiments resulted in the generation 
of variants which are able to bind dopamine, a neurotransmitter, with high affinity, enabling the 
variants to be employed as contrast agents in the magnetic resonance imaging (MRI) technique 
(Shapiro, Westmeyer et al. 2010). Further rounds of structure-guided directed evolution based on 
dopamine and serotonine complexed crystal structures of P450 BM3 variants helped identify 
improved variants with sub-micromolar binding affinities for these neurotransmitters (Brustad, 
Lelyveld et al. 2012). α- and β-ionone (components used in perfumery) have been reported to be 
hydroxylated by a triple variant (A74G, F87V, and L188Q) (Appel, Lutz-Wahl et al. 2001). β-
ionone can be actively hydroxylated by two other triple variants, A74E/F87V/P386S and 
R47L/Y51F/F87V (Urlacher, Makhsumkhanov et al. 2006). The latter is also actively involved 
in the oxidation of geranylacetone and related compounds (Watanabe, Laschat et al. 2007). 
Based on a screening system which involves the detection of the decomposition product of 
NAD(P)H oxidation during the catalysis, sodium dodecyl sulfate (SDS) and 1,1,2,2-
tetrachloroethane (TCE) (substrates of environmental significance) were shown to be oxidized 
by WT P450 BM3 (Tsotsou, Cass et al. 2002). Swapping homologous residues from CYP4C7, 
the insect terpenoid hydroxylase, on the B’-helix generated chimera P450 BM3 variants which 
are competent-enough to oxidize farnesol to yield novel products unobtainable from the WT 
P450 BM3 (Murataliev, Trinh et al. 2004). Further work carried out in this regard revealed that a 
single substitution F87L in one of the chimeric proteins is sufficient to switch the substrate 
selectivity from fatty acid to farnesol in  P450 BM3 (Chen, Shokhireva et al. 2008; Chen, Berry 
et al. 2010). Though with less selectivity, WT P450 BM3 and its variants have been 
demonstrated to actively transform (+)-valencene, an ingredient of orange oil, into a number of 
other useful products (Sowden, Yasmin et al. 2005). P450 variants can also oxidize terpene 
substrates such as guaiol, limonene, and valencene (Fasan, Meharenna et al. 2008). The latter 
two substrates together with geranyl- and nerylactone are actively oxidized by a majority of 
variants belonging to a minimal library constructed by combining five hydrophobic residues 
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(Ala, Val, Leu, Ile, and Phe) at position 87 and 328 in the active site of WT P450 BM3 (Seifert, 
Vomund et al. 2009). These positions have also been identified to be highly important in 
modulating the inverted enantioselectivity towards hydroxylation of cyclohexene-1-carboxylic 
acid methyl ester (Agudo, Roiban et al. 2012). Limonene can also be readily converted to perillyl 
alcohol, a tumor-retarding agent, with high selectivity (97%) by a triple variant, 
A264V/A328V/L437F (Seifert, Antonovici et al. 2011). Cyclopropyl containing fatty acids 
(radical clocks), primarily employed to probe the P450 reaction mechanism, can also be oxidized 
by WT P450 BM3 (Cryle, Stuthe et al. 2004; Cryle, de Montellano et al. 2005). Thiafatty acids, 
also used as mechanistic probes, has been shown to be hydroxylated by WT P450 BM3 and its 
T268A variant (Cryle and De Voss 2006). WT P450 BM3 also oxidizes α- and β-thujone, 
components of absinthe, into a variety of products (Jiang, He et al. 2006). Achiral substrate 
derivatives are also hydroxylated to high diastereoselectivity by the WT P450 BM3 and its 
variants (Munzer, Meinhold et al. 2005). Branched fatty acids and their derivatives can be 
utilized for the synthesis of macrolide antibiotics upon hydroxylation by WT P450 BM3 and its 
variants (Budde, Morr et al. 2006).                                                
 
1.3 P450 electron transfer 
 
1.3.1 Classification of P450 based on electron transfer systems  
P450s have been broadly classified into several classes depending upon their electron transfer 
systems (Figure 5; Hannemann, Bichet et al. 2007), and are summarized here. 
 
1.3.1.1 Class I 
Majority of bacterial and eukaryotic mitochondrial P450s have been designated as class I P450 
systems (Hannemann, Bichet et al. 2007). Each member is comprised of three independently 
expressed proteins: an NAD(P)H binding FAD-containing reductase domain which transfers 
electrons to ferredoxin, which ultimately reduces the cytochrome P450 (Hannemann, Bichet et 
al. 2007). In contrast to bacterial systems which have soluble individual components, only the 
ferredoxin, found in the mitochondrial matrix, is soluble in the eukaryotic systems (Hannemann, 
Bichet et al. 2007). A representative example of class I P450 systems in bacteria is P450cam 
from Pseudomonas putida. P450cam confers on the bacterium the ability to metabolize D-
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camphor and uses it as a sole carbon source (Pylypenko and Schlichting 2004; McLean, Sabri et 
al. 2005). The crystal structures of all the constituents of the system are known (Poulos, Finzel et 
al. 1985; Sevrioukova, Garcia et al. 2003; Pylypenko and Schlichting 2004; Sevrioukova, Li et 
al. 2004). The FAD-harboring putidaredoxin reductase is an obligate NADH binding protein as it 
lacks the NADPH binding sequence (Gunsalus and Sligar 1978; Peterson, Lorence et al. 1990). 
Electrons are finally relayed, one at a time, to the heme-binding P450cam through the iron-sulfur 
protein, putidaredoxin (Gunsalus and Sligar 1978; McLean, Sabri et al. 2005). Mitochondrial 
class I P450 systems are mainly implicated in the biosynthesis of cholesterol-based steroid 
hormones, vitamin D, and bile acids (Hannemann, Bichet et al. 2007). 
 
1.3.1.2 Class II 
Class II P450 systems are mostly prevalent in eukaryotes and act on a range of endogenous and 
exogeneous compounds (Hannemann, Bichet et al. 2007). Members of this class generally 
comprise of two membrane-integrated proteins: cytochrome P450 and a reductase consisting of 
FMN- and FAD-containing NADPH binding domains (Hannemann, Bichet et al. 2007). 
Microsomal P450 systems belonging to this class also have additional electron transfer proteins, 
cytochromes b5, which transfer electrons to cytochrome P450 after receiving them either from 
cytochrome b5- or P450 reductase (Porter 2002). A soluble P450 system from Streptomyces 
carbophilus consisting of P450sca and a (FAD- and FMN containing) reductase domain which 
binds NADH has also been shown to belong to this class (Hannemann, Bichet et al. 2007). 
 
1.3.1.3 Class III 
Members of class III differ from those of class I in having an FMN binding protein instead of an 
iron-sulfur protein (Hannemann, Bichet et al. 2007). A well-known example of this class is the 
P450cin system from Citrobacter braakii (Hawkes, Adams et al. 2002; Meharenna, Li et al. 
2004). Electrons are transferred from the electron source, NAD(P)H, by the FAD-containing 
ferredoxin reductase to the FMN-containing cindoxin which ultimately reduces P450cin 
(Hawkes, Adams et al. 2002; Meharenna, Li et al. 2004). 
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1.3.1.4 Class IV    
This class includes thermophilic P450 systems such as CYP119 from Sulfolobus solfataricus, an 
acidothermophilic archeon (Wright, Harris et al. 1996; Hannemann, Bichet et al. 2007). 
Members are usually NAD(P)H binding P450s that do not require a redox partner for obtaining 
reducing equivalents (Puchkaev and Ortiz de Montellano 2005; Hannemann, Bichet et al. 2007). 
 
1.3.1.5 Class V 
This class of P450 systems consists of a naturally fused P450 with a ferredoxin domain through a 
linker peptide that accepts reducing equivalents from another separate NAD(P)H-dependent 
reductase (Hannemann, Bichet et al. 2007). A representative example of such a P450 system is 
the sterol 14α-demethylase CYP51, the only existing P450 in Methylococcus capsulates 
(Jackson, Lamb et al. 2002). 
 
1.3.1.6 Class VI 
Class VI P450 systems share similar structural organization with members from the preceding 
class but differ in the presence of a flavodoxin, instead of ferredoxin, naturally fused to P450 
(Hannemann, Bichet et al. 2007). Reducing equivalents are obtained from an NAD(P)H-
dependent FAD-binding reductase (Hannemann, Bichet et al. 2007). A well-known example is 
the hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)-degrading system encoded by a P450-like 
gene, XlpA, in Rhodococcus rhodocrous (Seth-Smith, Rosser et al. 2002; Rylott, Jackson et al. 
2006). 
 
1.3.1.7 Class VII 
This class constitutes P450 systems which consist of a naturally fused P450 with its reductase 
domain – an NADH-dependent complex of FMN and ferredoxin domains – on the same 
polypeptide chain (Hannemann, Bichet et al. 2007). The first such system described was 
P450Rhf from Rhodococcus sp. strain NCIMB 9784 (Roberts, Grogan et al. 2002). 
 
1.3.1.8 Class VIII 
P450 systems belonging to class VIII display similar modular arrangement to those of class VII 
but differ in having an FAD containing NADPH binding domain instead of a ferredoxin domain 
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(Hannemann, Bichet et al. 2007). Electrons are transferred from NADPH through a naturally 
fused diflavin reductase domain to the heme domain (Hannemann, Bichet et al. 2007). A 
thoroughly investigated P450 system of this class is P450 BM3 from the soil bacterium, Bacillus 
megaterium (Miura and Fulco 1974; Hannemann, Bichet et al. 2007). 
 
1.3.1.9 Class IX 
P450nor, also known as nitric oxide reductase, from Fusarium oxysporum has been assigned to 
this class (Kizawa, Tomura et al. 1991; Takaya, Suzuki et al. 1999; Daiber, Shoun et al. 2005; 
Hannemann, Bichet et al. 2007). This represents the only soluble P450 system known in 
eukaryotes (Kizawa, Tomura et al. 1991; Takaya, Suzuki et al. 1999). 
 
1.3.1.10 Class X 
P450 systems in this class do not require molecular oxygen or NAD(P)H or the reductase domain 
for catalysis, and source their electrons from other molecules such as substrates (Hannemann, 
Bichet et al. 2007). Examples of this system include allene oxide synthase CYP74A, 
hydroperoxide lyase CYP74B/C, and divenyl ether synthase CYP74D (Lau, Harder et al. 1993; 
Shibata, Matsui et al. 1995; Itoh and Howe 2001). 
 
1.3.2 Engineering of P450s for alternative electron transfer systems  
Electrochemical engineering of P450s has been excellently reviewed elsewhere (Hlavica 2009). 
Dehalogenation of pentachloroethane was the first reaction reported to be successfully driven by 
P450cam based on commercially cheaper reducing agents, titanium(III)citrate or sodium 
dithionite, other than the natural electron source, NADH (Li and Wackett 1993). The same 
reaction has also been shown to be efficiently catalyzed in the presence of a light-triggered 
EDTA/proflavin (3,6-diaminoacridine) set-up (Li and Wackett 1993). Dithionite was later also 
found out to be an attractive candidate to substitute for NADPH in the hydroxylation of palmitic 
acid by P450 BM3 (Fang and Halpert 1996). It has been shown that a truncated (∆2-27) P450 
2B4 from rabbit can yield a catalytically self-sufficient complex in the presence of riboflavin, 
and can be photoactivated to form products with EDTA as a source of electrons, and aniline or 
aminopyrine as substrates (Shumyantseva, Bulko et al. 1999; Shumyantseva, Bulko et al. 2002).  
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Figure 5: Electron transfer chain variations available in different classes of P450s. Figure has been taken 
from (Hannemann, Bichet et al. 2007).       
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Photoactivated reduction of P450 1A2 has been reported in the presence of safranine T as a 
mediator of electron transfer upon illumination with a xenon flash lamp (Nakano, Konami et al. 
1995). Photo-inducible redox triggers have been developed that link ruthenium-contained 
complexes to the active site of P450s via substrate-conjugated electron-tuneling 
aliphatic/aromatic wires (Dmochowski, Dunn et al. 2002; Belliston-Bittner, Dunn et al. 2005; 
Hlavica 2009).  
Immobilization of P450s on the surface of electrodes has also been reported to varying degrees 
of success (Hlavica 2009). WT P450cam and a surface-modified variant, deficient with five 
surface cysteine residues, have been immobilized on bare edge-plane graphite electrodes 
(Kazlauskaite, Westlake et al. 1996; Lo, Wong et al. 1999). Surface engineering, however, later 
turned out to be of negligible significance (Lo, Wong et al. 1999). An electron transfer rate of 5 
s-1 was achieved when human P450 2E1 was immobilized on a bare glassy carbon electrode 
(Fantuzzi, Fairhead et al. 2004).  
Electrochemically driven hydroxylation of fatty acids by immobilizing fused heme-reductase 
complex of rat P450 4A1 on platinum gauze electrodes with cobalt(III)sepulchrate (Co(III)Sep) 
as an electroactive mediator was first reported by Faulkner (Faulkner, Shet et al. 1995). Similar 
studies have also been conducted for P450c17, P450 1A2, and P450 3A4 (Estabrook, Faulkner et 
al. 1996; Estabrook, Shet et al. 1996). Co(III)Sep and 1,1’-dicarboxycobaltocene have been 
shown to successfully reduce P450 BM3 immobilized on a bare glassy carbon electrode (Udit, 
Arnold et al. 2004). Instances also abound for the immobilization of P450s on surface-modified 
electrodes, specifically designed to promote better interaction with deposited proteins (Hlavica 
2009). Surface accessible cysteines of P450 2E1 were covalently linked to cystamine/maleimide-
coated gold electrodes, and the resulting assembly yielded reversible electrochemical signals of 
an active enzyme with an electron transfer rate of 10 s-1 (Fantuzzi, Fairhead et al. 2004). Human 
P450 3A4 has also been successfully immobilized on the surface of gold electrodes surface-
modified with a layer of polycation, poly-(dimethyldiallylammonium chloride) (PDDA), 
enabling the electrode to be used as a biosensor for the detection of drugs and drug metabolites 
(Joseph, Rusling et al. 2003). Platinum disk electrodes containing a layer of 
ethylenediamine/glutaraldehyde matrix achieved fast steady-state electrochemical responses for 
P450cam in Co(III)Sep supplemented buffer systems (Iwuoha, Joseph et al. 1998). Screen 
printed (SP) thick graphite electrodes coupled with an organic semiconductor 7,7,8,8,-
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tetracyanoquinodimethane was immobilized with P450scc and P450sccK201E variant, and was 
employed to detect three forms of cholesterol: free, low-density lipoprotein, and high-density 
lipoprotein (Antonini, Ghisellini et al. 2004). P450cam hosted in lipid films such as Dimyristoyl-
L-α-phosphatidylcholine (DMPC) and didodecyldimethylammonium bromide (DDAB), which 
mimic biological membranes, displayed injection of electrons into the enzyme during catalytic 
oxidations in the presence of molecular oxygen (Zhang, Nassar et al. 1997). Edge-plan pyrolytic 
graphite (EPG) electrodes carrying P450cin, 1,8-cineol-metabolizing P450 from Citrobacter 
braakii, immobilized in DDAB films show reversible electrochemical properties (Aguey-Zinsou, 
Bernhardt et al. 2003). In almost similar settings full-length P450 BM3 and its isolated heme 
domain exhibited excellent electron transfer rates, 138 s-1 and 221 s-1, respectively (Fleming, 
Tian et al. 2003), while P450 27B1 displayed 3.5 s-1 (Rhieu, Ludwig et al. 2009). The latter study 
has been regarded as an important step toward developing a biosensor for measuring vitamin D 
in serum (Rhieu, Ludwig et al. 2009). High turnovers for the conversion of styrene to styrene 
oxide were attained as compared to conventional (electrode-free) methods when a film of P450 
1A2 with polystyrene sulfonate (PSS) was coated on a carbon cloth (CC) electrode (Estavillo, Lu 
et al. 2003). Enhanced coupling efficiencies and higher catalytic activities of human P450 3A4 
were achieved towards its substrate, erythromycin, when chimeric proteins consisting of P450 
3A4 fused either to the reductase domain of P450 BM3 or flavodoxin of Desulfovibrio vulgaris 
were immobilized on PDDA-modified glassy carbon electrodes or thiol reactive cystamine-
maleimide modified gold electrodes (Dodhia, Sassone et al. 2008). A reversible electron transfer 
rate has been obtained by immobilizing P450 2B6 on the surface of glassy carbon electrodes in 
the presence of zirconium dioxide and colloidal paltin (Peng, Yang et al. 2008). Even though 
literature is replete with instances from successful immobilization of P450s on electrodes, not 
many reports provide information on electrochemically driven biocatalytic conversions under 
such settings (Hlavica 2009).                                                                  
 
1.3.3 Electron transfer in P450 BM3  
The redox potential of the heme-iron has been reported to be much more positive in the 
substrate-bound form than in the resting state, thus favoring the transfer of electrons from the 
FMN to the heme (Li and Poulos 1999). Interestingly, the natural electron donor, NADPH, 
inactivates the enzyme in the substrate-free form instead of reducing the heme-iron (Narhi and 
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Fulco 1986; Li, Darwish et al. 1991). Biochemical studies reveal that the FMN semiquinone, a 
single-electron reduced form, is the main electron donor in P450 BM3, as it exhibits a lower 
redox potential than the hydroquinone, a two-electron reduced form (Sevrioukova, Truan et al. 
1996). As pre-incubation with NADPH in the substrate-free form inactivates the enzyme, it is 
likely that the complete reduction of the FMN to hydroquinone is the prime source of 
inactivation (Narhi and Fulco 1986; Li, Darwish et al. 1991; Sevrioukova, Truan et al. 1996; 
Murataliev and Feyereisen 1996). The heme-iron shows a substantially reduced redox potential 
as compared to FMN under these circumstances, and a three-electron reduced form, i.e. FMN 
hydroquinone and FAD semiquinone is mainly accumulated upon transfer of electrons from 
NADPH (Murataliev and Feyereisen 1996).  
However, the inactive three-electron reduced reductase does not exist under steady-state turnover 
conditions, (Murataliev, Klein et al. 1997) as the substrate-bound heme domain exhibits an 
elevated redox potential (Daff, Chapman et al. 1997) which allows the release of electrons from 
a two-electron reduced state of reductase domain (both FMN and FAD in their semiquinone 
forms) towards the heme-iron. It is also noteworthy that the binding of carbon monoxide (CO) 
alone is sufficient, in the absence of substrate, to switch-on the transfer of electrons from the 
FMN semiquinone to the heme, most likely by raising the heme-iron redox potential (Hazzard, 
Govindaraj et al. 1997). Valuable insights can also be obtained regarding the electron transfer 
pathway from the crystal structure of a complex between the heme and FMN-binding domains of 
P450 BM3 (PDB code: 1BVY; Sevrioukova, Li et al. 1999). The structural data reveal that the 
interdomain electron transfer between heme and FMN domains is promoted by complementary 
electrostatic potentials at the interface (Sevrioukova, Li et al. 1999). The availability of a very 
few direct contacts between the two domains is also suggestive of a weak interaction 
(Sevrioukova, Li et al. 1999). Of particular importance is the hydrogen bonding interaction 
between a conserved basic residue, His100, on the C-helix (Glu93-Leu104) in the heme domain 
and Glu494 on the FMN-binding domain (Sevrioukova, Li et al. 1999). This interaction has been 
regarded to play an important role in the interdomain electron transfer (Sevrioukova, Li et al. 
1999). The structure also sheds light on the basis for higher redox potential of anionic FMN 
hydroquinone than the neutral FMN semiquinone (Sevrioukova, Li et al. 1999). The FMN is 
primarily surrounded by neutral and hydrophobic amino acids which most likely destabilize 
FMN semiquinone, and would stabilize FMN hydroquinone, resulting in a higher redox potential 
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for the latter than the former (Sevrioukova, Li et al. 1999). Further studies also implicate the 
conserved Cys999 from the FAD-binding domain in facilitating hydride transfer from NADPH 
to FAD (Roitel, Scrutton et al. 2003). Cys999 also stabilizes the binding of NADP+ to the two-
electron reduced FAD domain, and delivery of electrons from FAD by rapid transfer to FMN 
helps release NADP+ from the enzyme (Roitel, Scrutton et al. 2003). It has been demonstrated 
that Phe393 also facilitates electron transfer from the reductase domain to the heme-iron and 
ultimately to molecular oxygen (Ost, Miles et al. 2001). Trp1046 covers the FAD cofactor and 
also modulates the cofactor selectivity (Neeli, Girvan et al. 2005; Joyce, Ekanem et al. 2012). 
 
1.3.4 P450 BM3 and alternative cofactor systems 
A major limitation obstructing the utilization of monoxygenases for in vitro biocatalytic 
conversions is the high cost of cofactors, such as NADPH or NADH, employed for such 
reactions (Vilker, Reipa et al. 1999). Importantly, in the substrate-free form the cofactor 
inactivates P450s (Murataliev, Klein et al. 1997). This necessitates a tight control of cofactor-to-
substrate concentration to ensure the availability of active P450 monooxygenase in the reaction 
system (Schwaneberg, Appel et al. 2000). However, such a scenario can be avoided by using 
direct electrode based or mediated alternative cofactor systems (Armstrong and Wilson 2000; 
Schwaneberg, Appel et al. 2000). Direct electron transfer systems incorporate direct and 
mediator-less transfer of electrons between a biomolecule and the electrode (Nazor 2007; Ruff 
2012). However, a major challenge in designing such a system is how to interface the protein and 
the electrode such that the catalytic activity and redox properties of the protein are not 
compromised (Wollenberger, Spricigo et al. 2008). For this purpose, conducting polymers are 
routinely used, as they can provide a broad range of options for the entrapment of enzymes and 
their immobilization on electrodes (Bartlett and Whitaker 1987; Bartlett and Whitaker 1987; 
Bartlett and Whitaker 1988; Malitesta, Palmisano et al. 1990; Cooper and Hall 1992; Groom and 
Luong 1993; Chaubey, Pande et al. 2000). Mediated electron transfer systems involve mediators 
which are small electroactive compounds that can efficiently shuttle electrons between protein 
and the electrode (Nazor 2007; Ruff 2012). 
For P450 BM3, Schmid and coworkers described the first report on the replacement of an 
electrode/NADPH with cheap zinc dust as the electron source, and Co(III)Sep as a mediator of 
‘electrical communication’ (Schwaneberg, Appel et al. 2000). A combination of Zn/Co(III)Sep 
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was shown to be sufficient for performing catalysis with P450 BM3 (Schwaneberg, Appel et al. 
2000; Udit, Arnold et al. 2004). This strategy has also been employed successfully to establish 
the first medium-throughput-screening protocol for the directed evolution of a P450 enzyme 
towards mediated electron transfer (Nazor and Schwaneberg 2006). Subsequent screening efforts 
led to the identification of highly active and reductase-independent P450 BM3 variants (Nazor, 
Dannenmann et al. 2008; Zhao, Guven et al. 2011). P450 BM3 M7 variant, harboring three 
substitutions (F87A, V281G, M354S) in the heme domain, was subsequently obtained which 
showed highest activity towards the Zn/Co(III)Sep mediated electron transfer system, and was 
superior to the wild-type (WT) enzyme in terms of thermal- and storage stability when 
immobilized on a matrix containing DEAE-650S, k-carrageenan, and glutaraldehyde (Zhao, 
Guven et al. 2011), thus allowing the application of P450 BM3 for preparative conversions. 
Based on the mutagenesis results, it has been proposed that the mediator, Co(III)Sep, might be 
implicated in enhancing electron transfer rates by associating with the substrate access channel 
(Nazor and Schwaneberg 2006; Nazor, Dannenmann et al. 2008).  
Trp1046 is the most extensively targeted residue for mutagenesis in the reductase domain of 
P450 BM3 (Whitehouse, Bell et al. 2012). Substitution of Trp1046 for Ala results in an NADH-
dependent P450 BM3 monoxygenase which is able to substitute NADPH as an electron source 
for hydroxylation of lauric acid (Neeli, Roitel et al. 2005). A similar trend has also been 
observed for W1046S variant which exhibits substantially increased affinity towards binding of 
NADH (Maurer, Kuhnel et al. 2005). A double mutant (R966D/W1046S) has been shown to be 
catalytically driven based on NADH instead of NADPH, and shows preference for the former 
over the latter (Maurer, Kuhnel et al. 2005). The identified variant also retains, as opposed to the 
WT enzyme, selectivity for less expensive biomimetic 1,4-NADH cofactors over NADPH in its 
ability to reduce cytochrome  C (Ryan, Fish et al. 2008). Two synergistic substitutions 
(K972A/W1046A) in the reductase domain completely abolish selectivity for NADPH in favor 
of NADH (Dunford, Girvan et al. 2009). Interestingly, residues Arg966 and Lys972 interact with 
2’-phosphate group of NADPH and are also conserved in diflavin reductases (Joyce, Ekanem et 
al. 2012), while Trp1046 shields the isoalloxazine ring of FAD (Maurer, Kuhnel et al. 2005; 
Dunford, Girvan et al. 2009; Joyce, Ekanem et al. 2012). Other approaches to substitute the 
natural cofactor in P450 BM3 include peroxide shunt pathway (Cirino and Arnold 2003) and 
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photochemical systems (Ener, Lee et al. 2010; Tran, Huynh et al. 2011; Lee, Kwon et al. 2012; 
Tran, Huynh et al. 2012).  
 
1.4 Brief overview of X-ray crystallography 
Macromolecular X-ray crystallography has made commendable progress since the determination 
of first crystal structure of myoglobin to 6 Å resolution decades ago (Kendrew, Bodo et al. 
1958), and this technique can be undoubtedly regarded as a ‘gold standard’ when it comes to 
structural elucidation of macromolecules. Subsequent recognition of the Protein Data Bank 
(PDB) (Bernstein, Koetzle et al. 1977; Berman, Westbrook et al. 2000) as a world-wide 
repository of bio-macromolecular structures provided a unique platform for sharing structural 
information among scientists across the globe. Recent years have witnessed exponential growth 
in the deposition of X-ray crystal structures in the PDB, an observation that reflects plausible 
advancements made towards easier use of tools for obtaining good diffraction quality crystals, 
data collection, structure solution, and refinement.  
Different aspects of X-ray crystallography have been excellently reviewed elsewhere 
(Wlodawer, Minor et al. 2008), and important concepts which might be helpful in discerning 
cirtical features of macromoecular crystal structures are outlined here (Figure 6). X-ray 
crystallography experiments depend on the scattering of X-rays by the electrons of the molecule 
under investigation (Wlodawer, Minor et al. 2008). Owing to the intrinsic molecular symmetry 
available in a crystal, the scattered X-rays get amplified substantially in selected directions and 
are weakened to a good deal in other directions. The outcome is mainly determined by the 
dimension of the crystal unit cell and the wavelength of the X-rays, which usually corresponds to 
interatomic distances. However, the extent to which diffracted rays interfere, hence the intensity 
of each ray, in a given direction depends on the arrangement of all atoms in the unit cell. Large 
unit cells lead to the collection of more diffracted beams, also termed as reflections, and vice 
versa (Wlodawer, Minor et al. 2008). As each reflection has two components, amplitude and 
phase, only the former can be obtained from reflection intensities, while the information about 
reflection phases is lost during a diffraction experiment. Nevertheless, methods exist in X-ray 
crystallography which can be used to determine phases. These methods provide preliminary 
information about electron-density distribution in the crystal, and can ultimately lead to the 
construction of a reliable structural model of the macromolecule (Wlodawer, Minor et al. 2008). 
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In principle, an electron-density map can be computed by Fourier transformation of observed 
reflection amplitudes (Fobs) and their phases. As phases are not available from the diffraction 
experiment, these are calculated (φ calc) from the model in hand, and the resulting map (Fobs, φ 
calc) provides initial description of the true model (Wlodawer, Minor et al. 2008). The structural 
model can be refined by fine-tuning its different parameters to obtain the best correlation 
between observed reflection amplitudes (Fobs) and amplitudes calculated from the model 
(Fcalc), and this agreement is reflected in the residual or crystallographic R-factor (Wlodawer, 
Minor et al. 2008). During the course of refinement, iterative rounds of automated optimization 
and manual corrections are performed, and parameters of the model such as cartesian coordinates 
of atoms and the ‘temperature factor’ (also termed as B-factor), a measure of mobility in space, 
are refined (Wlodawer, Minor et al. 2008). The process of refinement is guided by 
stereochemical restraints, the libraries of which are derived from structures of small molecules 
(Hendrickson 1985; Engh and Huber 1991; Kleywegt and Jones 1995; Allen 2002). A difference 
map (Fobs-Fcalc, φ calc), which reflects disparity between the true and the modeled structures, 
can be calculated by using differences between the observed and calculated amplitudes, and 
calculated phases (Wlodawer, Minor et al. 2008). Such a map shows missing parts of the model 
as positive map contours, while wrongly modeled parts are depicted as negative map contours. 
Another map (2Fobs-Fcalc, φ calc) can be obtained by superposition of (Fobs, φ calc) and (Fobs-
Fcalc, φ calc) maps, and displays the model electron density as well as parts needing corrections 
(Wlodawer, Minor et al. 2008). It is customary to contour the (2Fobs-Fcalc, φ calc) map at 1σ 
level while the (Fobs-Fcalc, φ calc) map at 3σ level, where σ represents the root mean square 
difference of all map points from the average value. A special type of difference map, called as 
‘omit map’, can be computed in which Fcalc are calculated by deleting a given segment of the 
model to show an unbiased representation of the omitted part (Wlodawer, Minor et al. 2008). 
Proteins may contain regions of static or dynamic disorders (Wlodawer, Minor et al. 2008). In 
the former, a given part of the protein adopts different conformations in different unit cells, while 
the latter stems from elevated mobility or vibration of a given fragment in each unit cell. At low 
resolutions such parts of proteins are not interpretable. Some solvent molecules, especially the 
‘bulk solvent’ at the surface, often remain disordered, and it has been observed that the more is 
the bulk solvent, the poorer is the diffraction-quality or the resolution of the crystal (Wlodawer, 
Minor et al. 2008). The solvent content can be estimated from the protein size and the volume of 
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the crystal unit cell by using Matthews coefficient (Matthews 1968; Wlodawer, Minor et al. 
2008). 
Important criteria to evaluate the quality of the diffraction data are: resolution, signal-to-noise 
ratio, completeness, and Rmerge (overall and in the highest resolution shell) (Wlodawer, Minor 
et al. 2008). Resolution, denoted in Å, represents the minimum spacing of crystal lattice planes 
that still offer measurable X-ray diffractions, and corresponds to the minimum distance between 
entities that can be differentiated in electron-density maps (Wlodawer, Minor et al. 2008). 
However, the stated resolution of a structure can sometimes be misleading and should be judged 
in reference to other described parameters of the given data. If signal-to-noise ratio I/σ(I) > 2.0 
i.e., when the average ratio of reflection intensity to its estimated error is greater than two, then it 
suggests that the crystal can diffract to a better resolution but the latter has been curtailed by the 
experimenter (Wlodawer, Minor et al. 2008). It is also very important to collect a complete data 
set to the resolution limit of diffraction in order to perform successful refinement. Furthermore, 
accurate data at low resolutions should also be collected for phasing, as high-resolution 
intensities are often not too strong to provide useful information for phasing (Wlodawer, Minor 
et al. 2008). During a diffraction experiment, many reflections (and their symmetry equivalents) 
are measured more than one time, and the intensities of such reflections have to be averaged in a 
process called ‘scaling and merging’ which results in obtaining a set of unique reflection 
intensities (Wlodawer, Minor et al. 2008). The accuracy of the averaged intensities can be 
evaluated by Rmerge, also called as Rsym or Rint, which is the spread of individual intensities of 
all symmetry-equivalent reflections, and Rmerge values of < 4-5% represent a good set of 
diffraction data (Wlodawer, Minor et al. 2008). It has been found that high multiplicity (or 
redundancy) of measurements is fruitful to improve the quality of the resulting merged data set 
(Wlodawer, Minor et al. 2008). However, care must be taken as prolonged measurements may 
lead to radiation damage caused by ionizing radiations in protein crystals. Attention should also 
be paid to rapid decay of diffraction power, as it may also lead to the collection of incomplete 
data sets. Therefore, data completeness, i.e., the collection of all theoretically possible unique 
reflections in the obtained data set is also an important criterion to assess the quality of the 
collected data (Wlodawer, Minor et al. 2008). 
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Figure 6: A simplified scheme of 
purification of the protein of interest to homogeneity
diffraction-quality crystals, X-ray diffraction of the yielded crystals 
processing of the harvested data with the help of softwares 
molecular replacement (MR) protocol of the AutoRickshaw server (Panjikar, Parthasarathy et al. 2005)
calculate the electron density map
coordinates with COOT (Emsley and Cowtan 2004), REFMAC
(Afonine, Grosse-Kunstleve et al. 2012)
1.3 Schrödinger, LLC).      
 
Widely used indicators to evaluate the quality of a crystal structure are:
ramachandran plot (Wlodawer, Minor et al. 2008
fractions) describes overall disparity between experimentally observed structure factor 
amplitudes (Fobs) and calculated structure factor amplitudes (Fcalc) derived from the model 
(Wlodawer, Minor et al. 2008
 
the X-ray crystallography of proteins. The process entails: the 
, identification of crystallization conditions to obtain 
to collect h
such as XDS package (Kabsch 2010) and the 
, and final model building, refinement, and analysis of the r
 (Murshudov, Vagin et al. 1997), 
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). R-factors of < 10%, < 20%, and < 30% correspond to the best 
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refined, well-refined, and poorly refined protein crystal structures, respectively. A variation of 
the R-factor, called as R-free, is also used to assess the quality of the model. R-free is calculated 
for a given number of randomly selected reflections that have never been a part of model 
refinement (Wlodawer, Minor et al. 2008). High values of R-free reflect over-fitting or over-
interpretation of the experimental data as well as any bias introduced into the model during 
refinement. Usually, R-free should not exceed R-factor by more than 7% (Wlodawer, Minor et 
al. 2008). RMSD represents stereochemical differences of model from typical geometrical 
parameters (Wlodawer, Minor et al. 2008). Good-quality structures with medium-to-high 
resolution usually have ~ 0.02 Å RMSD for bonds (Wlodawer, Minor et al. 2008). 
Ramachandran plot (Ramakris.C and Ramachan.Gn 1965), calculated by PROCHECK 
(Laskowski, Macarthur et al. 1993) or MOLPROBITY (Davis, Murray et al. 2004) programs, 
points out possible errors in the model by mapping pairs of φ/ψ torsion angles of the protein 
backbone against the expected contours (Wlodawer, Minor et al. 2008). 
 
1.5 Motivation 
P450 BM3 catalyzes ‘dream reactions’ by using molecular oxygen in water at room temperature 
to hydroxylate C-H bonds or to epoxidize a wide range of substrates (Miura and Fulco 1975; 
Capdevila, Wei et al. 1996; Ost, Miles et al. 2000; Appel, Lutz-Wahl et al. 2001; Carmichael and 
Wong 2001; Li, Schwaneberg et al. 2001). P450 BM3 preferentially catalyzes subterminal 
hydroxylations of C12-C16 fatty acids (Miura and Fulco 1975; Narhi and Fulco 1986). P450 
BM3 variants that exhibit altered and inverted enantiopreference for styrene epoxidation have 
been reported (Li, Ogawa et al. 2001; Tee and Schwaneberg 2006; Huang, Cullis et al. 2011; 
Whitehouse, Bell et al. 2012). Styrene oxides and its derivatives are versatile intermediates in the 
synthesis of valuable chemicals such as antidiabetic agents and dopamine agonists (Pfeiffer, 
Wilson et al. 1982; Bloom, Dutia et al. 1992; Tee and Schwaneberg 2006; Huang, Cullis et al. 
2011). Interestingly, an exchange of a single amino acid to a positively charged residue at 
position 184 in P450 BM3 variant 5F5 (F87A, T235A; R selectivity 26.6% ee) inverts the 
enantioselectivity of styrene epoxidation towards S-styrene oxide (Tee and Schwaneberg 2006); 
even though Ala184 is located far away from the active site (~18 Å; Tee and Schwaneberg 
2006). The latter findings, combined with excellent catalytic properties, make P450 BM3 an 
ideal candidate for studying the enantioselective styrene epoxidation and to explore how a single 
Introduction  33  
 
charged surface residue inverts the enantioselectivity in P450 BM3 variants 5F5 A184K (F87A, 
T235A, A184K; S selectivity 27.3% ee) and 5F5 A184R (F87A, T235A, A184R; S selectivity 
26.5% ee) (Tee and Schwaneberg 2006). For P450 BM3, substrate-complexed crystal structures 
of the wild-type and variants have been solved in the presence of fatty-acids or structurally 
related substrates (Whitehouse, Bell et al. 2012). To date, none of the deposited structures of 
P450 BM3 depicts the bound substrate in a productive binding mode (Whitehouse, Bell et al. 
2012). Crystal structures with productive substrate binding modes are important to explain the 
mechanistic roles of individual residues which govern the enantiopreference of styrene 
epoxidation in P450 BM3, and can provide the needed insights into styrene binding modes 
which, in turn, will deepen our understanding on enantioselective hydroxylation of aromatic 
compounds with P450 BM3 and other monooxygenases in general. Results obtained from the 
crystallization and structure determination of P450 BM3 styrene epoxidation variants (5F5, 5F5 
A184K, 5F5 A184R; Tee and Schwaneberg 2006) in complex with styrene can be found in 
Chapter I of this thesis.  
The electron transfer mechanism of P450 BM3 is also worth-exploring. P450 BM3 catalyzes the 
hydroxylation of long chain fatty acids with the highest known catalytic efficiency ever reported 
for a P450 (Capdevila, Wei et al. 1996; Huang, Westlake et al. 2007; Whitehouse, Bell et al. 
2012). The outstanding catalytic ability of P450 BM3 has generally been attributed to its unique 
naturally fused modular assembly of catalytic heme and FMN/FAD-containing diflavin reductase 
domains on a single polypeptide chain which renders P450 BM3 self-sufficient (Narhi and Fulco 
1986). For catalysis to occur, the enzyme sources electrons from NADPH, an obligate two 
electron donor, and relays them singly via the reductase domain to the catalytic heme domain 
(Ortiz de Montellano 2010). The requirement for a commercially expensive electron source 
obstructs the industrial exploitation of P450 BM3, thus stimulating considerable interest into 
enzyme reengineering efforts aimed at successfully driving P450 BM3 based on alternative and 
cost-effective cofactor systems (O'Reilly, Kohler et al. 2011). Hence, variants have been 
engineered which circumvent the requirement for the expensive cofactor (NADPH), and can be 
catalytically driven based on commercially cheaper electron sources (Estabrook, Shet et al. 1996; 
Schwaneberg, Appel et al. 2000; Maurer, Kuhnel et al. 2005; Neeli, Roitel et al. 2005; Nazor and 
Schwaneberg 2006; Nazor, Dannenmann et al. 2008; Dunford, Girvan et al. 2009). For P450 
BM3, Schmid and coworkers described the first report on the replacement of an 
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electrode/NADPH with cheap zinc dust as the electron source (Schwaneberg, Appel et al. 2000). 
In this set-up, cobalt (III) sepulchrate (Co(III)Sep) served as a mediator of the ‘electronic 
communication’ between the enzyme and the electron source (Schwaneberg, Appel et al. 2000). 
This strategy was also successfully applied in establishing the first medium-throughput-screening 
protocol for the directed evolution of a P450 enzyme towards mediated electron transfer (Nazor 
and Schwaneberg 2006). Subsequent screening efforts led to the identification of highly active 
and reductase-independent P450 BM3 variants (Nazor, Dannenmann et al. 2008; Zhao, Guven et 
al. 2011). P450 BM3 M7 variant, harboring three substitutions (F87A, V281G, M354S) in the 
heme domain, was subsequently obtained which showed the highest activity towards the 
Zn/Co(III)Sep mediated electron transfer system, and was superior to the wild-type (WT) 
enzyme in terms of thermal- and storage stability when immobilized on a matrix containing 
DEAE-650S, k-carrageenan, and glutaraldehyde (Zhao, Guven et al. 2011), thus allowing the 
application of P450 BM3 for preparative conversions. Therefore, crystal structures of P450 BM3 
M7 variant in complex with Co(III)Sep can provide valuable structural insights into the enzyme-
mediator ‘crosstalk’ at the molecular level, and help understand mechanistic roles of important 
substitutions in promoting enzymatic activity based on the alternative cofactor system (Zhao, 
Guven et al. 2011). A structural account of the ‘electronic communication’ between the mediator 
and P450 BM3 M7 heme doamin variant is described in Chapter II of this thesis.  
A major challenge in the structural biology of P450 BM3 rests in elaborating the overall spatial 
organization of P450 BM3 domains (Whitehouse, Bell et al. 2012). Likely due to intrinsic 
structural flexibility associated with transfer of electrons from the NADPH-binding diflavin 
reductase domain to the substrate binding catalytic heme domain, the structure of the full-length 
enzyme (containing both domains) has not been reported so far (Girvan, Seward et al. 2007; 
Huang, Westlake et al. 2007). However, a truncated complex of the WT catalytic heme domain 
and the FMN binding domain has been structurally solved which depicts the FMN domain at the 
proximal surface of the heme domain (Sevrioukova, Li et al. 1999). Moreover, a double variant 
(C773A/C999A) of the FAD/NADPH binding domain has been structurally solved recently that 
was specifically engineered aimed at yielding successful crystals for diffraction (Joyce, Ekanem 
et al. 2012). However, mutagenesis studies have demonstrated that Cys999 is catalytically 
important (Roitel, Scrutton et al. 2003), and C999A variants of the reductase as well as of the 
isolated FAD/NADPH binding domains exhibit substantially reduced electron transfer properties 
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based on either NADPH or NADH (Roitel, Scrutton et al. 2003). These finding necessitate the 
availability of the crystal structure of WT FAD/NADPH binding domain to explore how Cys999 
and other catalytically important residues are spatially oriented in the WT. Solved crystal 
structure of the WT FAD/NADPH binding domain would help us highlight structural differences 
between the C773A/C999A (Joyce, Ekanem et al. 2012) and the WT FAD/NADPH binding 
domains, and elucidate how different residues might be implicated in the electron transfer. 
Moreover, the structural data can also be helpful in rationalizing the importance of substitutions 
previously reported to switch cofactor specificity in P450 BM3 (Dunford, Girvan et al. 2009; 
Maurer, Kuhnel et al. 2005; Neeli, Roitel et al. 2005). Salient structural features of the WT 
FAD/NADPH binding domain, and its comparison with the reported structure of C773A/C999A 
variant (Joyce, Ekanem et al. 2012) can be found in Chapter III of this thesis. 
Finally, crystal structures of the FMN binding domain of P450 BM3 were solved in order to 
understand the role of T577G substitution in promoting the direct electron transfer between P450 
BM3 and the conducting polymer, Baytron P or Clevios P (a complex of two polymers: poly 
(3,4-ethylenedioxythiophene) and (polystyrenesulfonic acid)) (Nazor 2007) (www.clevios.com). 
Moreover, crystal structures of two aromatic hydroxylation variants (AD3: R47Q, Y51F, I401M, 
and AD4: R47S, Y51W, I401M) have been determined to rationalize the biochemically observed 
hydroxylation pattern of aromatic compounds by these variants (Dennig, Marienhagen et al. 
2012). Results originating from the crystallization of these variants are summarized in Chapter 
IV.  
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2. Materials and Methods: 
Chemicals used were of analytical reagent grade or higher quality, and were purchased from 
Sigma-Aldrich Chemie (Taufkirchen, Germany), Applichem (Darmstadt, Germany), and Carl 
Roth (Karlsruhe, Germany).  
 
Reagents: 
dNTP    mix        New    England    Biolabs, Frankfurt, Germany 
δ-aminolevulinic acid (ALA)   Sigma-Aldrich Saint-Louis, USA 
Cobalt (III) sepulchrate    Sigma-Aldrich Saint-Louis, USA 
TSK HW-55S chromatography matrix  Tosoh Bioscience GmbH, Stuttgart, Germany 
 
Enzymes:  
Restriction enzymes    New England Biolabs, Frankfurt, Germany 
Restriction enzymes    Fermentas, St. Leon-Rot, Germany 
PfuS DNA polymerase    Fermentas, St. Leon-Rot, Germany 
AcTEV protease  Invitrogen GmbH, Karlsruhe, Germany or in-house 
prepared batch 
Equipment: 
PCR Thermal cycler    Eppendorf, Hamburg, Germany 
(Mastercycler gradient) 
Centrifuges     Eppendorf, Hamburg, Germany 
NanoDrop photometer    NanoDrop Technologies, Delaware, USA 
High-pressure homogenizer   Avestin Europe GmbH, Mannheim, Germany 
(EmulsiFlex-C3) 
Äkta-Purifier     GE Healthcare, Uppsala, Sweden 
SDS-PAGE Mini-Protean apparatus  Bio-Rad Laboratories GmbH, München, Germany 
 
Consumables: 
Thin-walled PCR tubes (0.2 mL)   Multi-Ultra tubes, Carl Roth, Germany 
QIAquick PCR purification kit   Qiagen, Hilden, Germany 
QIAquick gel extraction kit   Qiagen, Hilden, Germany 
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Filters (0.45 µm)    Whatman GmbH, Dassel, Germany 
Filters (0.22 µm)    Sartorius AG, Goettingen, Germany 
Protino Ni-IDA 2000 packed columns  Macherey-Nagel, Düren, Germany 
PD-10 desalting columns  Amersham Biosciences Europe GmbH, Freiburg, 
Germany 
Amicon Ultra-4 centrifugal filters   Millipore, Schwalbach, Germany 
Dialysis membranes    Spectra/Por, Carl Roth GmbH, Karlsruhe, Germany 
Crystallization screening plates   Qiagen/Nextal, Canada 
 
Media compositions: 
LB medium 
Peptone (1.0%), yeast extract (0.5%), and NaCl (1.0%) in deionized water. Autoclaved and 
stored at room temperature. 
 
TB medium 
Solution A: Peptone (12 g), yeast extract (24 g), and glycerol (4 g) in 800 mL deionized water. 
Solution B: KH2PO4 (2.31 g), and K2HPO4 (12.54 g) in 200 mL deionized water. 
Both solutions were autoclaved separately and then combined under sterilized conditions. 
 
Media supplements: 
Kanamycin (Stock: 1000X) 
50 mg/mL in deionized water. Filter-sterilized through 0.22 µm filter (Sartorius AG, Goettingen, 
Germany), and stored at -20 °C.  
 
Trace element solution (Stock: 1000X) 
CaCl2.2H2O (0.5g), ZnSO4.7H2O (0.18g), MnSO4.H2O (0.1 g), Na2-EDTA (20.1 g), FeCl3.6H2O 
(16.7 g), CuSO4.5H2O (0.16 g), and CoCl2.6H2O (0.18 g) dissolved in 1L deionized water. 
Autoclaved and stored at 4 °C. 
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ALA (δ-aminolevulinic acid anhydride) (Stock: 1000X) 
500 mM in deionized water. Filter-sterilized through 0.22 µm filter (Sartorius AG, Goettingen, 
Germany), and stored at -20 °C. 
 
IPTG (Isopropyl-β-D-thiogalactoside) (Stock: 1000X) 
100 mM in deionized water. Filter-sterilized through 0.22 µm filter (Sartorius AG, Goettingen, 
Germany), and stored at -20 °C. 
 
Riboflavin (Stock: 333X) 
3 mg/mL in deionized water. Filter-sterilized through 0.22 µm filter (Sartorius AG, Goettingen, 
Germany), and stored at -20 °C. 
 
FMN (Flavin mononucleotide) (Stock: 250X) 
50 mM in deionized water. Filter-sterilized through 0.22 µm filter (Sartorius AG, Goettingen, 
Germany), and stored at -20 °C. 
 
Variants were cloned, expressed, and purified as described elsewhere (Kuper, Wong et al. 2007), 
after a few modifications. 
 
2.1 Cloning of P450 BM3 domains 
Thin-walled PCR tubes (Multi-Ultra tubes; 0.2 mL; Carl Roth, Germany) were used for all 
PCRs. The PCR volume was always 25 µL; larger volumes were prepared in multiple 25 µL 
PCRs. The amount of DNA was quantified with the help of a NanoDrop photometer (NanoDrop 
Technologies, Wilmington, Delaware, USA). All PCR purification and gel extraction steps were 
performed using QIAquick PCR purification kit (Qiagen, Hilden, Germany) and QIAquick gel 
extraction kit (Qiagen, Hilden, Germany), respectively. 
Amplification of the gene segment encoding individual P450 BM3 domains (Heme: Thr1-
Leu455/Arg471), (FMN: Asn479-Asn629/Leu630/Ser649), and (FAD/NADPH: Ala650-
Gly1048) was carried out through PCR by using oligonucleotide primers and conditions as listed 
in Table 2. For the PCR, 0.5 U PfuS DNA polymerase, 0.2 mM dNTP mix (New England 
Biolabs), 400 nmol of each primer and 100 ng template were used. Following gel extraction, 1 
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µg  PCR  amplicon  was  digested  with  40  U  EcoRI  for  6  h  at  37 °C  and subsequently gel-
purified. The PCR product was ligated to pETM-11 vector and, after transformation into E. coli 
DH5α cells, was transformed into E. coli BL21 Gold (DE3) expression hosts as described 
(Kuper, Wong et al. 2007). 
Table 2: PCR set-up for the isolation of the individual P450 BM3 domains. 
P450 domain PCR set-up 
Heme 
For P450 BM3 M7 variant (Thr1-Arg471): 
Forward primer: 5’-[Phos]CATGACAATTAAAGAAATGCCTC-3’ 
Reverse primer: 5’-CTGGAATTCTTATTAGCGTACTTTTTTAGCAGA-3’ 
For P450 BM3 5F5, 5F5K, and 5F5R variants (Thr1-Leu455): 
Forward primer: 5’-[Phos]CATGACAATTAAAGAAATGCCTC-3’ 
Reverse primer:  5’-CTGGAATTCTTAAAGCGGAATTTTTTTCGATTT-3’ 
Initial denaturation: 98 °C for 30 s,  
Amplification: (98 °C for 10 s, 55 °C for 15 s, 72 °C for 30 s) 25 cycles  
Final extension: 72 °C for 3 min 
FMN 
For FMN domain (Asn479-Leu630): 
Forward primer: 5’-[Phos]CATGAATACGCCGCTGCTT-3’ 
Reverse primer: 5’-CTGGAATTCTTAGAGGTTAAAGTAGGCTGC-3’ 
For FMN domain (Asn479-Asn629): 
Forward primer: 5’-[Phos]CATGAATACGCCGCTGCTT-3’ 
Reverse primer: 5’-CTGGAATTCTTAGTTAAAGTAGGCTGCTAC-3’ 
For FMN domain (Asn479-Ser649): 
Forward primer: 5’-[Phos]CATGAATACGCCGCTGCTT-3’ 
Reverse primer: 5’-CTGGAATTCTTAGCTGTCGACAAATTGAAG-3’ 
Initial denaturation: 98 °C for 30 s 
Amplification: (98 °C for 10 s, 55 °C for 15 s, 72 °C for 10 s) 25 cycles 
Final extension: 72 °C for 3 min 
FAD/NADPH 
For FAD/NADPH domain (Ala650-Gly1048): 
Forward primer: 5’-[Phos]CATGGCCGCGGATATGCCG-3’ 
Reverse primer: 5’-CTGGAATTCTTACCCAGCCCACACGTCTTTTGC-3’ 
Initial denaturation: 98 °C for 30 s 
Amplification: (98 °C for 10 s, 65 °C for 15 s, 72 °C for 30 s) 25 cycles 
Final extension: 72 °C for 3 min 
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2.2 Expression and purification of P450 BM3 domains 
An overnight culture of transformed cells was prepared by inoculating 5 mL of the LBkan 
medium with a single transformed colony. About 150 mL of the TBkan medium, taken in 1-L 
flasks, was supplemented with 150 µL of the trace elements solution. After inoculation with 750 
µL of the overnight culture, the medium was shaken at 37 °C, 250 rpm for 2-3 hours. When the 
OD600 reached 0.5-0.6, the expression was induced by adding isopropyl-β-D-thiogalactoside 
(IPTG, 100 µM), and the medium was also suplemented with δ-aminolevulinic acid anhydride 
(ALA, 0.5 mM) for the expression of the heme domain variants. For the FMN and FAD/NADPH 
binding domains, the expression was induced by IPTG (100 µM), and the media were 
supplemented with FMN (0.2 mM) and riboflavin (9 µg/mL), respectively, instead of ALA. 
After cultivating at 30 °C (heme domain) or 27 °C (FMN and FAD/NADPH binding domains) 
and 200 rpm for 12 hours, the cells were harvested by centrifugation at 4000 rpm, 4 °C for 15 
min. The cell pellets were stored at -20 °C for further use. 
For the purification of heme domain variants, the cell pellet was briefly thawed on ice, and was 
re-suspended in 15 mL of sodium phosphate buffer (50 mM NaH2PO4, 300 mM NaCl, pH 7.5). 
Cell disruption was performed through high-pressure homogenization (1500 bar, 2 passes; 
EmulsiFlex-C3; Avestin Europe GmbH, Mannheim, Germany). After centrifugation at 4 °C, 
13220 rpm for 30 min, the cell extract was clarified by passing the supernatant through a 0.45 
µm filter (Celtron 30; Whatman GmbH, Dassel, Germany). Purification of polyhistidine-tagged 
heme domains was performed by using Protino Ni-IDA 2000 packed column (Macherey-Nagel, 
Düren, Germany). The column was first equilibrated with 8 bed volumes of buffer (50 mM 
NaH2PO4, 300 mM NaCl, pH 7.5). After loading the clarified extract (5-7 mL), the column was 
washed with 10 bed volumes of buffer (50 mM NaH2PO4, 300 mM NaCl, pH 7.5). The column 
was then subjected to stringent washing with 6 bed volumes of buffer (50 mM NaH2PO4, 300 
mM NaCl, 5 mM imidazole, pH 7.5). Finally, the protein was eluted with 2 mL of the elution 
buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 7.5). PD-10 desalting column 
(Amersham Biosciences Europe GmbH, Freiburg, Germany) was subsequently used to remove 
imidazole. The column was first equilibrated with 25 mL buffer (50 mM NaH2PO4, pH 7.5), and 
then loaded with 2.5 mL of the protein sample. Finally, the protein was eluted with 3.5 mL of 
buffer (50 mM NaH2PO4, pH 7.5). The N-terminal his-tag was cleaved by using AcTEV protease 
(Invitrogen GmbH, Karlsruhe, Germany or in-house prepared batch). Ten mg of the protein was 
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incubated with 30 U AcTEV in 1X buffer (50 mM NaH2PO4, pH 7.5, 0.5 mM EDTA, 1 mM 
DTT) for ~ 10-16 hours at 30 °C. The cleaved polyhistidine-tag and the polyhistidine-tagged 
AcTEV protease were removed by loading the reaction mixture onto a new Protino Ni-IDA 2000 
packed column (Macherey-Nagel, Düren, Germany), pre-equilibrated with 8 bed volumes of 
buffer (50 mM NaH2PO4, pH 7.5). The collected flow-thoughs from the column were then 
subjected to anion-exchange chromatography, as described previously (Schwaneberg et al. 
1999). Finally, the protein was purified by size-exclusion chromatography. The protein (1 mL) 
was loaded onto the gel-filtration column (Matrix:  TSK HW-55S, Bed volume:  30 mL, Bed 
height:  40 cm, Column: Omnifit), pre-equilibrated overnight with buffer (50 mM MES, pH 6.5 
or 50 mM Tris, pH 7.5). Fractions collected were concentrated by using Amicon Ultra-4 
centrifugal filter (Millipore, Schwalbach, Germany) with a cut-off value of 30 kDa, and the 
protein concentration was determined by CO-difference spectra using ε = 91 mM-1 cm-1 (Omura 
and Sato 1964).  
The FMN binding domain was purified by following the same procedure as described for the 
heme domain, after a few modifications. Tris-HCl buffer (50 mM Tris-HCl, pH 7.5, 500 mM 
NaCl, 5% glycerol, 1 mM EDTA, 1 mM DTT) was used for cell resuspension, and NaH2PO4 was 
replaced with KPi during affinity chromatography. In order to remove imidazole, purified protein 
was dialysed overnight against buffer (50 mM KPi, pH 7.5) at 4 °C by using membranes with the 
cut-off value of 6-8 kDa (Spectra/Por, Carl Roth GmbH, Karlsruhe, Germany). Size exclusion 
chromatography was performed after equilibrating the column with buffer (50 mM NaH2PO4 pH 
7.5). After adding 4-fold molar excess of FMN, fractions collected were concentrated by using 
Amicon Ultra-4 centrifugal filter (Millipore, Schwalbach, Germany) with a cut-off value of 10 
kDa. The protein concentration was determined by using an extinction coefficient of 9.8 mM-1 
cm-1 at 466 nm (Sevrioukova, Truan et al. 1996).         
The FAD/NADPH binding domain was purified also by following the same procedure as 
described for the heme domain. Only Tris buffer (50 mM Tris, pH 7.5) was used for size 
exclusion chromatography. Fractions collected were concentrated by using Amicon Ultra-4 
centrifugal filter (Millipore, Schwalbach, Germany) with a cut-off value of 10 kDa. Prior to 
crystallization, the purified protein was mixed with 2 and 20 times molar excess of FAD and 
NADP+, respectively, followed by two cycles of concentration/dilution to remove excess 
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cofactors. The protein concentration was determined by TCA (trichloroacetic acid) method by 
using ε = 11.3 mM-1 cm-1 for the released FAD cofactor at 450 nm (Kurzban and Strobel 1986). 
Samples collected at various steps during purification were analyzed by SDS-PAGE. For this 
purpose, samples were electrophoresed through 10% (heme domain), 15% (FMN binding 
domain), and 12% (FAD/NADPH binding domain) acrylamide gels in a Bio-Rad Mini-Protean 
apparatus and subsequently visualized by Coomassie Blue staining. 
   
2.3 Crystallization of P450 BM3 domains 
Initial crystallization screening was performed at EMBL Hamburg’s High-throughput 
crystallization facility (Mueller-Dieckmann 2006). Growth conditions of crystals were further 
optimized by the hanging-drop vapor-diffusion method in crystallization screening plates 
(Qiagen/Nextal, Canada) at 4 °C with a drop size of 4 µL (2 µL protein sample and 2 µL mother 
liquor). The chemical composition of the mother liquor which successfully yielded crystals is 
given in the Appendix (Table 11). 
  
2.4 Data collection, model building and refinement 
Prior to data collection, crystals were soaked for few seconds in the reservoir solution 
supplemented with glycerol (15% v/v) for cryoprotection. X-ray diffraction data were collected 
on flash-cooled crystals at X13, EMBL/DESY (Hamburg, Germany) or SLS- X06DA (Villigen, 
Switzerland) beamlines. All datasets were processed with XDS package (Kabsch 2010) and 
structures were solved by using the molecular replacement (MR) protocol of the AutoRickshaw 
server (Panjikar, Parthasarathy et al. 2005). After manual modifications in COOT (Emsley and 
Cowtan 2004), models were iteratively refined with REFMAC (Murshudov, Vagin et al. 1997) 
and Phenix (Afonine, Grosse-Kunstleve et al. 2012). All structural figures were prepared with 
the program PyMOL (The PyMOL Molecular Graphics System, Version 1.3 Schrödinger, LLC). 
EMBL/DESY-Hamburg (Germany) and SLS-PSI (Switzerland) are thanked for granting the 
access to X13 and X06DA beamlines, respectively, for data collection. I am also thankful to Dr. 
Saravanan Panneerselvam (the contact person from our collaborators at EMBL/DESY-Hamburg) 
for extending me the help for data collection, processing, and refinement. 
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3. Results and Discussion: 
Chapter I: P450 BM3 crystal structures reveal the role of the charged surface 
residue 184 in inversion of enantioselective styrene epoxidation 
Styrene oxide and its derivatives are versatile intermediates in the synthesis of valuable 
chemicals such as antidiabetic agents and dopamine agonists (Pfeiffer, Wilson et al. 1982; 
Bloom, Dutia et al. 1992; Tee and Schwaneberg 2006; Huang, Cullis et al. 2011). However, the 
synthesis of chiral epoxides via chemical routes presents a significant challenge and their 
enzymatic production offers attractive alternatives (Tee and Schwaneberg 2006). Examples of 
natural epoxidation catalysts include monoxygenases such as styrene monoxygenase (Otto, 
Hofstetter et al. 2004), propane epoxygenase (Chan Kwo Chion, Askew et al. 2005), P450 BM3 
(Farinas, Alcalde et al. 2004), P450cam (Munge, Estavillo et al. 2003), P450 1A2 (Estavillo, Lu 
et al. 2003), P450terp (Fruetel, Mackman et al. 1994), chloroperoxidase (Ortiz de Montellano, 
Choe et al. 1987), and methane monoxygenase (Elliott, Zhu et al. 1997). However, limited 
literature exists on inverted enatioselectivity of oxidoreductases (Li, Ogawa et al. 2001; Reetz 
2006; Tee and Schwaneberg 2006; Tang, Li et al. 2010; Huang, Cullis et al. 2011; Reetz 2011). 
Recently, enantioselective styrene epoxidation catalyzed by cytochrome P450 BM3 has attracted 
much attention (Li, Ogawa et al. 2001; Tee and Schwaneberg 2006; Huang, Cullis et al. 2011; 
Whitehouse, Bell et al. 2012), due to its potential for industrial applications. P450 BM3 variants 
constructed by molecular engineering of individual active site residues have been reported that 
exhibit altered and inverted enantiopreference for styrene epoxidation (Li, Ogawa et al. 2001; 
Huang, Cullis et al. 2011; Whitehouse, Bell et al. 2012). Interestingly, an exchange of a single 
amino acid change to a positively charged residue at position 184, which is far from the active 
site (ca. 18 Å), inverts the enantioselectivity of styrene epoxidation in P450 BM3 variant 5F5 
(heme domain substitutions: F87A, T235A; R selectivity 26.6% ee) toward S-styrene oxide (Tee 
and Schwaneberg 2006). The latter findings, combined with excellent catalytic properties, make 
P450 BM3 an ideal candidate for studying the enantioselective styrene epoxidation and to 
explore how a single charged surface residue inverts the enantioselectivity in the P450 BM3 
variants 5F5 A184K (heme domain substitutions: F87A, T235A, A184K; S selectivity 27.3% ee) 
and 5F5 A184R (heme domain substitutions: F87A, T235A, A184R; S selectivity 26.5% ee), 
here-to-after referred to as 5F5K and 5F5R, respectively (Tee and Schwaneberg 2006). 
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Main results presented here are the crystal structures of 5F5 (F87A, T235A), 5F5K (F87A, 
T235A, A184K), and 5F5R (F87A, T235A, A184R) variants of P450 BM3 to explore the 
structural basis of the inverted enantioselectivity for styrene epoxidation (Tee and Schwaneberg 
2006). In total, five crystal structures were solved in styrene-free (StF) and styrene-bound (StB) 
forms to a resolution better than 1.9 Å (Table 3). Novel crystallization conditions have also been 
identified which yielded diffraction-quality crystals for 5F5K variant in the presence of styrene. 
However, attempts to crystallize 5F5K and 5F5R variants in the absence of styrene did not yield 
crystals with good diffraction-quality; probably due to high surface entropy associated with 
substitutions (Lys, Arg) at Ala184. 
 
1.1 Conformational changes in 5F5K StB and 5F5R StB structures 
Superposition with three wild-type substrate-bound (WTSB) forms (PDB codes: 1FAG, 1JPZ 
and 1ZO9) (Li and Poulos 1997; Haines, Tomchick et al. 2001; Hegde, Haines et al. 2007) by 
MUSTANGPP method (Konagurthu, Whisstock et al. 2006) for equivalent pairs of Cα atoms 
yields root mean square deviations (RMSDs) of 0.79 Å and 0.78 Å for 5F5K StB and 5F5R StB 
forms, respectively, whereas the RMSDs increase to 1.05 Å when compared to three wild-type 
substrate-free (WTSF) forms (PDB codes: 1BU7, 2HPD, and 2IJ2) (Ravichandran, Boddupalli et 
al. 1993; Sevrioukova, Li et al. 1999; Girvan, Seward et al. 2007), indicating that 5F5K StB and 
5F5R StB structures resemble the WTSB conformation better than that of WTSF forms (Table 4, 
Figure 7). The electron density for surface residues in the FG loop (Arg179-Gln206) and 
flanking helices are either unresolved or poorly defined in 5F5K StB and 5F5R StB structures, 
suggesting a high structural plasticity for this region. Residues in the F- (Pro172-Gln189) and G- 
(Glu200-Ser226) ‘lid domain’ helices have generally been associated with weak electron density 
in other P450 crystal structures (Hasemann, Ravichandran et al. 1994; Ost, Clark et al. 2003; 
Clark, Miles et al. 2006; Whitehouse, Yang et al. 2010). In addition to F- and G- helices, 
structural changes are observed additionally in C- (Glu93-Leu104) and H- (Leu233-Asn239) 
helices, and N-terminal residues of I-helix as well as in the loop connecting β1-1 (Gly37-Phe42) 
and β1-2 (Val48-Leu52) sheets. Most of these residues are part of the substrate access channel and 
are known to undergo substantial conformational changes in the WT structure upon substrate 
binding (Li and Poulos 1997; Haines, Tomchick et al. 2001; Joyce, Girvan et al. 2004). 
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Figure 7: Complete overlays showing the movements of the structural elements in 5F5K StB (cyan), 
5F5R StB (green), 5F5 dsA StB (yellow), 5F5 dsB StB (orange), WTSF (gray; PDB code 1BU7; 
Sevrioukova, Li et al. 1999), and WTSB (blue; PDB code 1JPZ; Haines, Tomchick et al. 2001). The 
bound styrene (in protein color code) and heme ligand (red) are shown as spheres. 
 
Substitution of Lys/Arg for Ala in 5F5K StB and 5F5R StB structures brings the side chain 
atoms of Lys/Arg184 in the F-helix closer to Asp80 on the B’-helix (Ser72-Gly83), establishing 
a salt-bridge between the oppositely charged residues (Figure 8). As a consequence, the F-helix 
is lifted up substantially and moves away from the active site. The latter is for instance 
documented by the distance between the Cα atoms of 184 and Leu437, which lies just above the 
active site, and which increases from 9 Å in WTSF structures (PDB codes: 1BU7 (Sevrioukova, 
Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 2IJ2 (Girvan, Seward et al. 2007)) 
to 14 Å in 5F5K StB and 5F5R StB structures (Table 5). 
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Table 4: RMSDs (Å) were calculated upon pairwise superposition of equivalent pairs of Cα atoms from 
individual monomers of the WT P450 BM3 and variants (5F5, 5F5K, and 5F5R; Tee and Schwaneberg 
2006) with the MUSTANGPP method (Konagurthu, Whisstock et al. 2006). WT structures are shown by 
their PDB codes: 1BU7 (Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 2IJ2 
(Girvan, Seward et al. 2007), 1JPZ (Haines, Tomchick et al. 2001), 1FAG (Li and Poulos 1997), 1ZO9 
(Hegde, Haines et al. 2007). WTSF: wild-type substrate-free. WTSB: wild-type substrate-bound. 
 
5F5K StB 5F5R StB 5F5 dsI StB 5F5 dsII StB 5F5 StF 
A B A B A B A B A B 
1BU7   
(WTSF) 
A 0.86 0.94 0.91 0.89 0.72 0.59 0.69 0.55 0.66 0.62 
B 1.11 1.17 1.10 1.21 0.68 0.76 0.65 0.71 0.90 0.93 
2HPD   
(WTSF) 
A 0.96 0.99 0.95 0.98 0.58 0.55 0.53 0.49 0.66 0.66 
B 1.13 1.20 1.07 1.17 0.66 0.76 0.64 0.74 0.87 0.95 
2IJ2   
(WTSF) 
A 1.19 1.28 1.18 1.26 0.74 0.84 0.73 0.81 0.97 1.04 
B 0.90 0.93 0.97 0.90 0.68 0.57 0.64 0.53 0.68 0.62 
1JPZ  
(WTSB) 
A 0.72 0.69 0.73 0.68 1.20 1.08 1.18 1.08 0.91 0.91 
B 0.70 0.80 0.72 0.76 1.14 1.11 1.13 1.11 0.88 0.95 
1FAG  
(WTSB) 
A 0.85 0.82 0.82 0.86 1.31 1.16 1.30 1.17 1.01 1.01 
B 0.86 0.88 0.84 0.88 1.32 1.18 1.31 1.19 1.02 1.03 
C 0.85 0.86 0.82 0.86 1.31 1.19 1.30 1.19 0.98 1.01 
D 0.84 0.83 0.83 0.86 1.30 1.16 1.30 1.17 1.02 1.01 
1ZO9  
(WTSB) 
A 0.76 0.71 0.77 0.68 1.23 1.06 1.22 1.06 0.92 0.89 
B 0.70 0.78 0.72 0.75 1.15 1.10 1.14 1.10 0.87 0.94 
5F5K 
StB 
A - 0.45 0.20 0.46 0.91 0.89 0.86 0.90 0.72 0.76 
B  - 0.42 0.24 0.96 0.77 0.96 0.83 0.76 0.65 
5F5R 
StB 
A   - 0.39 0.90 0.83 0.84 0.83 0.65 0.73 
B    - 0.98 0.84 0.93 0.84 0.71 0.66 
5F5 dsI 
StB 
A     - 0.42 0.14 0.42 0.57 0.68 
B      - 0.43 0.17 0.53 0.45 
5F5 dsII 
StB 
A       - 0.40 0.57 0.67 
B        - 0.54 0.45 
5F5 StF 
A         - 0.40 
B          - 
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Furthermore, a hydrogen bond between Tyr160 and His171 is lost, and causes the N-terminus of 
the F-helix to dislodge from its position. However, similar to WTSF forms (Sevrioukova, Li et 
al. 1999; Ravichandran, Boddupalli et al. 1993; Girvan, Seward et al. 2007), polar interactions 
(Ser176:Asp208, Arg179:Gln204, Arg179:Asp208) between F- and G- helices remain intact in 
5F5K StB and 5F5R StB structures and, as a consequence, both undergo concerted translocation 
which leads to opening of the substrate access channel, ultimately enabling the substrate 
(styrene) to enter the active site more readily in 5F5K StB and 5F5R StB structures (Figure 9). 
More notably, as seen in WTSB forms (Li and Poulos 1997; Haines, Tomchick et al. 2001; 
Hegde, Haines et al. 2007; Whitehouse, Yang et al. 2011; Whitehouse, Bell et al. 2012), 
truncation of Lys224:Asp251 and repositioning of Asp217:Arg255 ion-pair interactions in 5F5K 
StB and 5F5R StB structures result in the displacement of the C-terminal end of G-helix away 
from the I-helix (Glu252-Lys282) (Figure 8).  
 
Table 5: Cα- Cα distances (Å) between Leu437 and residues at position 184 in the WT P450 BM3 (PDB 
codes: 1BU7 (Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 2IJ2 (Girvan, 
Seward et al. 2007), 1JPZ (Haines, Tomchick et al. 2001), 1FAG (Li and Poulos 1997), 1ZO9 (Hegde, 
Haines et al. 2007)), and its variants (5F5, 5F5K, and 5F5R). Data were collected for 5F5K/R StB after 
co-crystallization with styrene. For 5F5, two datasets (ds) were collected after subjecting the styrene-
complexed crystals, obtained following co-crystallization, to additional soaking with styrene for short 
(dsI; 2-3 min) and long (dsII; 60 min) intervals. WTSF: wild-type substrate-free. WTSB: wild-type 
substrate-bound.  
 Monomer A Monomer B 
5F5K StB 14.77 14.34 
5F5R StB 14.58 14.18 
5F5 dsI StB 9.31 9.33 
5F5 dsII StB 9.22 9.29 
5F5 StF 9.47 9.38 
WTSF 
1BU7  8.95 9.67 
2HPD  9.32 9.62 
2IJ2 9.51 8.72 
WTSB 
1JPZ 7.80 7.77 
1FAG  7.87 7.93 
1ZO9  7.82 7.77 
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In additions to the normal hydrogen bonding pattern of the 
‘salt-ladder’ (Glu200:Arg203, Gln204:Glu207/Asp208, Lys210:Asp214, Lys218:Asp222) on 
G-helix enables the entire helix to move in a concerted manner with negligible distortions
(Figure 9). Due to the movement of F
(Pro142-Asn159) helices such as Phe81 and Phe158, respectively, are either reoriented or 
stabilized in single rotamer conformations.
 
  
Figure 8: Comparison of key polar interactions between 5F5K/R StB and 
bridges involving charged surface residues at position 184 in 5F5K StB (Lys184:Asp80) (cyan) and 5F5R 
StB (Arg184:Asp80) (green) structures as well as a water
Asp80 in 5F5 StB structures (yellow, brown). (
dsI StB (yellow) and 5F5 dsII StB (brown) structures that lead to destabilization of WTSF conformations 
in 5F5K StB (cyan) and 5F5R StB (green) structures.
 
elective Styrene Epoxidation in P450 BM3           
backbone atoms, the presence of a 
- and G- helices, residues on B’- 
 
5F5 StB structures. 
-mediated hydrogen bond between Lys187 and 
Left) shows the disruption of key contacts relative to 5F5 
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the 
 
(Ser72-Gly83) and E- 
(Right) Salt-
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Figure 9: Pairwise structural superposition of 
selective (5F5 dsI StB (yellow) and dsII StB (orange)
(red) and styrene (protein color code
Ala/Lys/Arg184) are shown as protein color
‘open’ substrate access channel, as a result of the movement of F
and 5F5R StB structures is clearly evident (
ladder’ is shown which runs across the entire G
represented in sticks and nitrogen atoms are colored in blue, oxygen a
green. 
 
The dislocation of F- and G- helices generates ample room for the reorientation of the N
half of the I-helix. The latter promotes insertion of a water molecule that ‘interrupts’ the 
hydrogen bonding pattern of the backbone atoms and, like WTSB forms, results in significant 
reduction of the I-helix kink (
et al. 2007; Whitehouse, Yang et al. 2011
disruption of the Ala264CO-Thr268NH hydrogen bond, two more backbone contacts (262CO
266NH and 265CO-269NH) are broken (
the movement of Gly265 away from the active site. 
the active site due to altered backbone interactions. 
elective Styrene Epoxidation in P450 BM3           
S-selective (5F5K StB (cyan) and 5F5R StB (green)
) variants is shown on the 
) are shown as sticks. The residue positions (Leu437, 
-coded spheres. In comparison to 5F5 StB structures, the 
- and G- surface helices, in 5F5K StB 
shown by a red double-arrow). On the 
-helix in P450 BM3. The participating residues are 
toms in red, and carbon atoms in 
Li and Poulos 1997; Haines, Tomchick et al. 2001
; Whitehouse, Bell et al. 2012
Table 6). The insertion of the water molecule 
The side chain of His266 
However, Glu267 moves into the active site 
50  
 
) and R-
left. The heme cofactor 
right, a typical ‘salt-
-terminal 
; Hegde, Haines 
). In addition to the 
-
leads to 
also retracts from 
Results and Discussion      Chapter I: Enantioselective Styrene Epoxidation in P450 BM3           51  
 
as a consequence of the repositioning of Lys440. In 5F5K StB and 5F5R StB structures, Lys440 
extends to form a hydrogen bond with the side chain of Ser270 which brings it into a steric clash 
with the side chain atoms of Glu267. As a consequence, Glu267 ‘moves’ towards the active site. 
Due to the repositioning of Lys440, nearby residues (Lys434- Leu439) on the loop between β1-4 
and β2-1 are also pulled towards Glu267 and change their positions. Whereas the remaining I-
helix residues at the N-terminal end are significantly dislocated: two of them (Arg255 and 
Phe261) are reoriented, with Arg255, as discussed above, ‘reshaping’ the Arg255:Asp217 salt-
bridge. 
 
1.2 Comparison of 5F5 structures with 5F5K StB and 5F5R StB structures 
Interestingly, 5F5 StB structures resemble WTSF forms (PDB codes: 1BU7 (Sevrioukova, Li et 
al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 2IJ2 (Girvan, Seward et al. 2007)) more 
than WTSB forms (PDB codes: 1FAG (Li and Poulos 1997), 1JPZ (Haines, Tomchick et al. 
2001), 1ZO9 (Hegde, Haines et al. 2007)) as revealed by the RMSDs which increase from 0.68 
Å and 0.64 Å in dsI and dsII to 1.18 Å when compared with WTSB forms (Table 4). However, 
subtle structural differences are observed in monomer B of 5F5 dsI StB structure in parts of I-
helix in which residues partially switch to the WTSB conformation. 5F5 StB structures deviate 
significantly from 5F5K/R StB structures, with an average RMSD of 0.88 Å (Table 4, Figure 
10). Key interactions which account for stabilizing the WTSF conformation remain remarkably 
intact in the 5F5 StB structures (Figure 8; Whitehouse, Yang et al. 2011; Whitehouse, Bell et al. 
2012). The side chain of Ala184 is on average 7 Å away from Asp80 and the side chain of 
Lys187 is pointing to Asp80 to form a water-mediated hydrogen bond in 5F5 structures. 5F5K 
StB and 5F5R StB structures show by substitution T235A an increase in flexibility of GH loop 
and the flanking helices. In 5F5 StB structures, this region is relatively stabilized by two polar 
interactions (Gln229:Asn239 and Asp231:His236) between the H-helix and GH loop. 
An important feature of 5F5 StB structures is that the I-helix is substantially kinked near the 
active site (Figure 11), unlike 5F5K/R StB structures. The kink angle varies between 13-15 
degrees in 5F5 StB structures to 8-12 degrees in 5F5K/R StB structures. Disruption of three 
hydrogen bonds in 5F5K/R StB structures, as compared to only two in 5F5 StB structures, 
reduces the kink angle of the I-helix (Table 6). As the side chain of Ile153 has been resolved in 
two alternative conformations in 5F5 StB structures, more space is offered in one conformation 
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to the backbone atoms of Gly265 to partially flip away from the active site. Lys440 is highly 
mobile and participates in the formation of a water mediated hydrogen bond with Glu143 as well 
as it is linked to Glu442 through a salt-bridge in some monomers. 
Surprisingly, the 5F5 StF structure exhibits mixed features displayed by WTSF and WTSB 
forms, and its structural alignment yields RMSDs of 0.8 Å and 0.96 Å for the WTSF (PDB 
codes: 1BU7 (Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 2IJ2 
(Girvan, Seward et al. 2007)) and WTSB (PDB codes: 1FAG (Li and Poulos 1997), 1JPZ 
(Haines, Tomchick et al. 2001), 1ZO9 (Hegde, Haines et al. 2007)) forms, respectively (Table 4).  
 
 
Figure 10: Superposition of 5F5 and 5F5K/R to show the differences of styrene-complexed structures. 
(Top) The RMSD of Cα atoms of 5F5 dsII StB for pairwise superposition with 5F5K StB (blue) and 
WTSF (red; PDB code: 1BU7 (Sevrioukova, Li et al. 1999)) as a function of residue number. (Bottom) 
Structural overlay of 5F5 StB structures (yellow and orange) with 5F5K/R StB structures (cyan and 
green); heme shown in red and styrene in protein color-coded spheres (left). The regions displaying 
highest differences are shown in red, with minimum as blue and the intermediate as brown-green (right), 
with heme macrocycle and styrene displayed as gray spheres. 
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Table 6: Differences in the I-helix backbone conformations of the WT P450 BM3, and its variants (5F5, 
5F5K, and 5F5R). Hydrogen bond distances (Å) of the I-helix backbone (Ile258-Leu272) of 5F5 StB/F 
and 5F5K/R StB structures are summarized. Distances of residues with alternative conformations are 
shown in parentheses. In P450 BM3, the carbonyl oxygen of Ala264 is hydrogen-bonded to the iron-
coordinated or laterally-displaced axial water molecule in the active site (Haines, Tomchick et al. 2001). 
Substrate binding has generally been associated with insertion of a water molecule in the I-helix which 
leads to the movement of Gly265 away from the active site (Whitehouse, Bell et al. 2012). Moreover, the 
side chain of His266 appreciably rotates and retreats from the active site due to altered backbone 
interactions in WTSB forms (Whitehouse, Bell et al. 2012). Glu267 and Thr268 represent the highly 
conserved acid-alcohol pair in the P450 superfamily (Whitehouse, Bell et al. 2012). Thr268 plays a key 
role in proton delivery, dioxygen activation, and the stabilization of catalytic intermediates (Yeom, Sligar 
et al. 1995; Clark, Miles et al. 2006; Cryle and De Voss 2008). Backbone distances for WTSF are the 
average of three wild-type substrate-free structures (PDB codes: 1BU7 (Sevrioukova, Li et al. 1999), 
2HPD (Ravichandran, Boddupalli et al. 1993), and 2IJ2 (Girvan, Seward et al. 2007)). Backbone 
distances for WTSB are the average of three wild-type substrate-bound structures (PDB codes: 1JPZ 
(Haines, Tomchick et al. 2001), 1FAG (Li and Poulos 1997), and 1ZO9 (Hegde, Haines et al. 2007)). 
Hydrogen 
bond 
5F5K StB 5F5R StB 5F5 dsI StB 5F5 dsII StB 5F5 StF 
WTSF WTSB 
A B A B A B A B A B 
Ile258CO-
Leu262NH 
3.05 2.99 2.89 2.97 3.20 
3.22 
(3.05) 
3.30 3.26 2.87 2.69 3.29 2.87 
Ile259CO-
Ile263NH 3.27 3.32 3.21 3.28 2.97 
3.02 
(3.11) 2.97 3.05 3.16 2.99 2.96 3.01 
Thr260CO-
Ala264NH 2.73 2.76 2.76 2.82 2.80 
2.74 
(2.92) 2.71 2.74 2.75 2.72 2.85 2.80 
Phe261CO-
Gly265NH 2.82 2.80 2.87 2.80 3.09 
3.35 
(1.87) 
2.99 
(2.92) 
3.10 
(3.07) 2.51 2.39 2.96 2.90 
Leu262CO-
His266NH 4.02 4.04 4.07 3.99 
3.14 
(3.25) 
3.50 
(4.12) 3.11 3.27 3.89 3.99 3.08 3.81 
Ile263CO-
Glu267NH 3.32 3.31 3.25 3.30 4.79 
4.70 
(3.56) 4.75 4.62 3.47 3.48 4.75 3.17 
Ala264CO-
Thr268NH 4.78 4.95 4.86 4.87 4.55 
4.62 
(5.34) 4.66 4.62 4.94 4.86 4.64 4.80 
Gly265CO-
Thr269NH 5.91 5.97 5.75 5.89 
3.34 
(5.54) 
3.28 
(6.14) 
3.30 
(5.32) 
3.10 
(5.80) 6.14 5.89 3.34 6.02 
His266CO-
Ser270NH 3.06 3.11 3.12 3.17 3.11 
3.14 
(3.20) 3.12 3.11 2.93 3.05 3.19 3.02 
Glu267CO-
Gly271NH 3.17 3.13 3.14 3.11 2.83 2.87 2.80 2.83 3.21 3.31 2.88 3.05 
Thr268CO-
Leu272NH 2.99 2.98 3.04 2.99 2.97 3.08 2.98 3.05 2.96 3.06 3.07 3.00 
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The surface helices (F and G) are poorly resolved in the 5F5 StF structure, and the formation of 
stabilizing interactions similar to the WTSB conformation (Li and Poulos 1997; Haines, 
Tomchick et al. 2001; Hegde, Haines et al. 2007) is unlikely. Residues in the CD-loop (Pro105-
Lys113) region can switch their positions between 5F5K/R StB and 5F5 StB conformations 
which is accompanied by two rotamer orientations of Phe261. All other I-helix residues are 
found in similar conformations to that seen for 5F5K StB and 5F5R StB structures, with a water 
molecule inserted into the I-helix which reduces the kink angle (8°-9°). 
 
1.3 Styrene binding in 5F5, 5F5K, and 5F5R variants 
The observed electron density allows unambiguous positioning of styrene in 5F5K/R StB and 
5F5 dsI StB structures (Figure 12). Styrene is found in two different orientations in the 5F5 
variant depending on the duration of its soaking prior to data collection. In 5F5 dsI StB structure, 
which has been determined after brief soaking (2-3 min), the phenyl ring of styrene is pointing 
towards the heme and a water molecule is coordinated to the heme-iron as well as hydrogen 
bonded to the carbonyl oxygen of Ala264. In this orientation the distance between the iron and 
the vinyl tail of styrene is too long for an epoxidation to take place; it is therefore regarded as the 
‘non-productive’ and high-affinity binding mode of styrene.  In 5F5 dsII StB structure, which has 
been determined after a long soaking period (60 min), styrene can be found in two orientations: 
one similar to the non-productive binding mode and the other one in a catalytical orientation with 
with vinyl carbons positioned sufficiently close to the heme-iron. The latter conformation is 
regarded as the ‘productive’ and low-affinity binding mode of styrene (Figure 12).  
In addition to its interaction with the heme macrocycle, styrene is bound predominantly via 
hydrophobic interactions with side chains of Thr268 and Alanines 87, 264 and 328. In the non-
productive mode additional contacts are made with the side chains of Ile263 and Leu75 and 
Leu437 (Figure 13). These residues also make hydrophobic interactions with small ligands in 
recently reported structures of P450 BM3 muteins (Brustad, Lelyveld et al. 2012). In an attempt 
to better accommodate the bound ligand (dopamine; DA) in the active site, the side chain of 
Thr268 was shortened by replacing it with Ala (Brustad, Lelyveld et al. 2012). However, in the 
structures reported here, such an approach might not be fruitful, as Thr268 is a catalytically 
important residue and its substitution to Ala would likely ‘destroy’ its oxygen activating function 
(Yeom, Sligar et al. 1995; Clark, Miles et al. 2006; Cryle and De Voss 2008). Furthermore, 
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2001). This water is on average 7.18 Å and 6.38 Å away from the heme-iron in 5F5 StB and 5F5R/K StB 
structures, respectively, and is hydrogen bonded to carbonyl oxygens of Ile263 and Ala264 in addition to 
the side chain of Thr268. It appears that this water molecule is stabilized in the ‘groove’ upon binding of 
styrene in the close vicinity. However, none of the previously determined crystal structures of P450 BM3 
depicts a water molecule close to the bound substrate at this position. This water seems to be highly 
mobile in the absence of styrene, as its electron density is not well-defined in the 5F5 StF form. The 
availability of a large active site cavity with very few hydrogen bond donor/accepter residues and a not-
so-closely bound substrate in P450 BM3 seem to account for increased mobility of water at this position. 
Because of its interactions with catalytically important residues, it was suggested in other P450s that the 
existence of a water molecule at this ‘strategic’ position might be catalytically relevant (Schlichting, 
Berendzen et al. 2000). For clarity, residues on the B’-helix (Asn70-Asp84), except Leu75, are not 
shown. 
 
In 5F5K StB and 5F5R StB structures, however, Ala264 migrates away from the active site upon 
insertion of a water molecule into the I-helix that reduces the kink angle and exposes the pyrrole 
ring C partially, enabling the exposure of the pro-S face of styrene over the heme-iron (Figure 
14). Styrene binds relatively close to the heme as the vinyl tail is ~ 2.5 Å away from the iron, 
with its phenyl part sitting on the top of pyrrole ring A (Table 7). As expected, the structural 
supersposition with 5F5 StB brings the terminal carbon atom of styrene in 5F5K StB and 5F5R 
StB structures into a steric clash with the carbonyl oxygen of Ala264. The latter highlights the 
importance of the structural reorganization of the I-helix residues in 5F5K StB and 5F5R StB 
structures for the production of S-styrene epoxide as the preferred enantiomer (Figure 14). 
In comparison to 5F5 StF structure, styrene-bound forms have an ordered water molecule which 
sits near the vinyl part of styrene in the so-called ‘groove’ in the I-helix (Haines, Tomchick et al. 
2001). This water molecule is on average 7.18 Å and 6.38 Å away from the heme-iron in 5F5 
StB and 5F5K/R StB structures and is hydrogen bonded to carbonyl oxygens of Ile263 and 
Ala264 in addition to the side chain of Thr268. The water molecule which interrupts the normal 
hydrogen bonding pattern in the I-helix is not within the hydrogen bonding distance (more than 
3.6 Å away) in 5F5K/R StB structures. The distance to the terminal carbon of styrene in the 
productive orientation varies from 2.8 Å in 5F5K/R StB structures to ~ 5 Å in 5F5dsII StB 
structure. Furthermore, the ‘groove water’ is hydrogen bonded to one of the rotamers of Glu267 
either directly, as seen in 5F5R StB structure, or through one or more bridging water molecules. 
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It appears that this water molecule is stabilized in the ‘groove’ upon binding of styrene
close vicinity (Figure 13). In contrast, the electron density for this water molecule in 5F5 StF 
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‘productive’ binding mode. The minimum distance between the active site heme-iron and the 
vinyl tail of styrene is 2.37 Å. 
Table 7: Key active site distances between the heme-iron (Fe) and selected atoms in P450 BM3 variants 
(5F5, 5F5K, and 5F5R). 
 5F5K StB 5F5R StB 5F5 dsI StB [a] 5F5 dsII StB [b] 5F5 StF 
(See Fig. 14) (cyan) (green)  (orange)  
Ala264(Cα) 5.91 5.86 5.52 5.48 5.75 
Ala264(Cβ) 5.25 5.17 4.88 4.82 5.02 
Ala264(CO) 4.96 4.96 4.43 4.31 4.92 
Thr268(OH) 5.13 5.13 5.31 5.33 5.19 
Styrene (CAA) 
Productive 
Non-productive  
 
3.56 
- 
 
3.67 
- 
 
- 
7.94 
 
2.75 
7.86 
 
- 
- 
Styrene (CAB) 
Productive  
Non-productive  
 
2.51 
- 
 
2.46 
- 
 
- 
7.05 
 
3.56 
6.77 
 
- 
- 
Styrene (CAC) 
Productive  
Non-productive  
 
5.97 
- 
 
5.99 
- 
 
- 
4.76 
 
6.62 
5.12 
 
- 
- 
[a] Soaking time: 2-3 min, [b] Soaking time: 60 min 
 
None of the P450 BM3 structures deposited in the PDB so far displays the substrate sufficiently 
close to the heme-iron for oxidation to take place, suggesting that the structures were crystallized 
in a ‘pre-catalytic’ conformation (Whitehouse, Yang et al. 2011; Whitehouse, Bell et al. 2012). 
However, structures of P450 BM3 and its variants are known that were determined in the 
presence of small non-substrate ligands and display the bound ligand directly coordinated to the 
heme-iron (Kuper, Wong et al. 2007; Brustad, Lelyveld et al. 2012; Kuper, Tee et al. 2012). 
Therefore, the structures presented here allow for a detailed analysis of selectivity determining 
factors in P450 BM3 catalysis. 
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Overall, the backbone architecture of 5F5K/R StB structures is similar to WTSB forms (PDB 
codes: 1FAG (Li and Poulos 1997), 1JPZ (Haines, Tomchick et al. 2001), 1ZO9 (Hegde, Haines 
et al. 2007)), whereas an overlay of 5F5 StB structures with that of WTSF forms (PDB codes: 
1BU7 (Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 2IJ2 (Girvan, 
Seward et al. 2007)), on the other hand, reveals a high degree of similarity.  For P450 BM3, 
substrate binding is generally associated with a change in the overall conformation of the enzyme 
(Li and Poulos 1997; Haines, Tomchick et al. 2001; Whitehouse, Bell et al. 2012), though 
variants are known to display SB conformations even while crystallized in the absence of a 
substrate (Joyce, Girvan et al. 2004; Girvan, Toogood et al. 2009; Whitehouse, Bell et al. 2009; 
Whitehouse, Yang et al. 2010).  
It appears that the formation of Arg/Lys184:Asp80 ion-pair interaction facilitates the 
stabilization of 5F5K/R StB structures in the WTSB conformation (Li and Poulos 1997; Haines, 
Tomchick et al. 2001; Hegde, Haines et al. 2007). In 5F5K/R StB structures the F- and G- 
helices are lifted up and uncover most of the active site, thus paving way for the enhanced access 
of substrate and prompt release of the product. The latter results are consistent with our previous 
findings of significantly improved reaction kinetics for 5F5K (2.2-fold) and 5F5R (1.7-fold) 
variants when compared to the parent 5F5 (Tee and Schwaneberg 2006). The establishment of 
Arg/Lys184:Asp80 ion-pair interaction acts as a ‘support’ upon which the F- and G- helices are 
held at their new positions and helps transduce structural changes from the surface of the enzyme 
to the active site.  
It is suggested that the dislocation of F- and G- helices generates sufficient space for the 
reorientation of the I-helix residues, leading to the altered mode of styrene binding and, hence, 
inverted enantioselectivity. Similar to WTSB forms (Li and Poulos 1997; Haines, Tomchick et 
al. 2001; Hegde, Haines et al. 2007; Whitehouse, Yang et al. 2011; Whitehouse, Bell et al. 2012), 
a well resolved water molecule interrupts the normal hydrogen bonding pattern of the I-helix 
and, consequently, the kink angle is substantially reduced in 5F5K/R StB structures. Structural 
changes are also evident in C-, D-, and H- helices which further alleviate ‘strain’ in the I-helix. 
In 5F5 StB structures surface helices (F and G), which undergo substantial conformational 
changes upon substrate binding in WT structures (Li and Poulos 1997; Haines, Tomchick et al. 
2001; Hegde, Haines et al. 2007; Whitehouse, Yang et al. 2011; Whitehouse, Bell et al. 2012), 
are remarkably similar to WTSF forms (Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli 
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et al. 1993; Girvan, Seward et al. 2007). Moreover, the kink in I-helix is well-defined and a water 
molecule which interrupts the normal hydrogen bonding pattern in WTSB forms (Haines, 
Tomchick et al. 2001; Hegde, Haines et al. 2007; Whitehouse, Bell et al. 2012) is absent. 
Interestingly, 5F5 StF structure exhibits mixed features displayed by WTSB (Li and Poulos 
1997; Haines, Tomchick et al. 2001; Hegde, Haines et al. 2007) and WTSF (Sevrioukova, Li et 
al. 1999; Ravichandran, Boddupalli et al. 1993; Girvan, Seward et al. 2007) forms. It has been 
previously proposed that the WT enzyme alters its conformation between two distinct SF and SB 
forms and the binding of substrate stabilizes it in SB conformation (Joyce, Girvan et al. 2004). 
Taken together, our results suggest that styrene binding favors the stabilization of 5F5 variant in 
the WTSF conformation.  
Interestingly, styrene can be placed in a combination of catalytically productive and non-
productive orientations in the electron density of 5F5 dsII StB structure. In the non-productive 
mode, a water molecule is coordinated to the heme-iron which, in WT structures, is displaced to 
an ‘off-axial’ position upon binding of the substrate while also interacting with the backbone of 
Ala264 at the new position (Haines, Tomchick et al. 2001; Whitehouse, Yang et al. 2011; 
Whitehouse, Bell et al. 2012). Such a binding mode has also been identified in other P450s 
where a water molecule remains coordinated to the heme-iron in the presence of a ligand 
(Seward, Roujeinikova et al. 2006). In 5F5 StF structure, a water molecule is also coordinated to 
iron, and the heme is bound in two distinct conformations related by a 180° rotation around the 
axis passing through meso carbon bridges between the tetrapyrrole rings and bifurcating the two 
propionate groups. Structures of P450 are known where the heme displays inverted orientations 
but the physiological implications of this phenomenon have not been discerned yet (Leys, Mowat 
et al. 2003; Girvan, Seward et al. 2007; Whitehouse, Yang et al. 2010; Whitehouse, Yang et al. 
2011; Whitehouse, Bell et al. 2012). The presence of productive and non-productive styrene 
binding modes is supported by the slower reaction kinetics of the R-selective 5F5 variant (Tee 
and Schwaneberg 2006). The existence of a well-ordered water molecule in the helical groove 
upon styrene binding illustrates a preferred water binding site in the presence of styrene. 
However, none of the previously determined crystal structures of P450 BM3 depicts a water 
molecule close to the bound substrate at this position. This water seems to be highly mobile in 
the absence of styrene, as its electron density is not well-defined in StF form. The availability of 
a large active site cavity with very few hydrogen bond donor/accepter residues and a not-so-
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closely bound substrate in P450 BM3 seem to account for increased mobility of water at this 
position. Because of its interactions with catalytically important residues, it was suggested in 
other P450s that the existence of a water molecule at this ‘strategic’ position might be 
catalytically relevant (Schlichting, Berendzen et al. 2000). As the I-helix is kinked in 5F5 StB 
structures, Ala264 extends sufficiently over the heme pyrrole ring C, and an overlay with 
5F5K/R StB structures reveals that this would constrict the active site and sterically obstruct 
binding of styrene in pro-S orientation over the heme-iron.  
Because polar interactions such as hydrogen bonds are not involved in orienting styrene, 
computational studies in other P450s have predicted styrene to be quite mobile in the 
hydrophobic binding site, suggesting that steric factors likely control enantioselectivity (Fruetel, 
Collins et al. 1992). However, crystal structures of P450 BM3 variants in complex with 
dopamine and serotonin reveal that the active site water molecules as well as the backbone 
amides and carbonyls can be exploited by exocyclic hydroxyls to stabilize the bound ligands 
through hydrogen bonding networks (Brustad, Lelyveld et al. 2012). Moreover, based on 
modeling studies performed for P450 BM3 A82F and A82F/T438F variants, it has been 
proposed that the bulky side chains at positions 82 and 438 restrict styrene to bind mainly in pro-
R orientation in the active site (Huang, Cullis et al. 2011). When performed for F87G variant 
with 3-chlorostyrene as a ligand, the same docking exercise yielded no ‘orientational preference’ 
for styrene itself and it was thought that the enantioselectivity also depended on the type of 
ligand under investigation (Huang, Cullis et al. 2011). However, in our studies, the side chain of 
Phe87 comes into a steric clash with the phenyl ring of styrene in 5F5 StB and 5F5K/R StB 
structures upon superposition with WTSF (Sevrioukova, Li et al. 1999; Ravichandran, 
Boddupalli et al. 1993; Girvan, Seward et al. 2007) and WTSB structures (Li and Poulos 1997; 
Haines, Tomchick et al. 2001; Hegde, Haines et al. 2007), indicating that the F87A substitution 
is a prerequisite for generating sufficient space in the active site of these variants for binding of 
styrene. Structural rearrangements induced by remote substitutions (such as in position Ala184) 
were not considered in previous docking studies, despite that A184K and A184R substitutions 
govern the enantiopreference (Tee and Schwaneberg 2006). A smaller aliphatic hydrophobic 
residue such as Leu, Val, Ala, and Gly at position 87 also resulted in an increase in binding 
affinity for serotonin in variants of this enzyme (Brustad, Lelyveld et al. 2012). A subsequent 
variant generated by four active site substitutions (F87L, T438L, T268S, and L437Q) improved 
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serotonin binding ~ 4000 fold (Brustad, Lelyveld et al. 2012). In studies leading to engineering 
of P450 BM3 for improved enantioselective hydroxylation of cyclohexene-1-carboxylic acid 
methyl ester, it was found that valine residues at positions Phe87- and Ala328 promoted the 
enantioselectivity (96%) in the favor of the R alcohol as compared to the WT (34%) (Agudo, 
Roiban et al. 2012). Furthermore, a single substitution (A328S) in the WT enzyme was sufficient 
to invert the enantioselectivity in the favor of S alcohol (97%) (Agudo, Roiban et al. 2012). 
These findings highlight the importance of subtle structural manipulations of active site residues 
that can lead to dramatic alterations in affinity/enantioselectivity for new ligands.      
Interestingly, in most of the productive orientations the subterminal vinyl atom (CAB) is the 
nearest carbon atom accessible to the heme-iron (Table 7). It can therefore be inferred that the 
fatty acid substrate (in the productive mode) would also be positioned in a manner analogous to 
the productive binding mode of styrene, leading to subterminal fatty acid hydroxylations. In fatty 
acid complexed WT structures, the aromatic side chain of Phe87 obstructs substrate access to the 
heme-iron, resulting in ‘pre-catalytic’ substrate orientations (Whitehouse, Yang et al. 2011; 
Whitehouse, Bell et al. 2012). Structural data, in conjuction with previous modeling studies 
(Huang, Cullis et al. 2011), help identify ‘hotspots’ in the active site of 5F5, 5F5K, and 5F5R 
which can be targeted through protein engineering strategies in order to further improve/invert 
the enantioselectivity for styrene epoxidation in P450 BM3 (Figure 15).  
In summary, crystal structures of P450 BM3 variants were successfully determined in complex 
with styrene that offer highly plausible explanations for inverted enantioselectivity of styrene 
epoxidation (Tee and Schwaneberg 2006) which are determined by steric interactions between 
styrene and active site residues at positions 87 and 264. The latter provides a first structural 
understanding how a surface charged substitution inverts the enantiopreference of styrene 
epoxidation (Tee and Schwaneberg 2006). The obtained insights into P450 BM3 catalysis will 
help undertand and improve enantioselective hydroxylation of aromatic compounds with P450 
BM3 and other monooxygenases in general. 
 
1.5 Conclusions 
Crystal structures of P450 BM3 variants (5F5, 5F5K, 5F5R) in complex with styrene were 
successfully determined which are the first structures of P450 BM3 solved in the presence of a 
non-fatty acid-like substrate. The overall conformation of 5F5K StB and 5F5R StB structures is 
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similar to wild-type substrate
1JPZ (Haines, Tomchick et al. 2001), and 1ZO9 (Hegde, Haines et al. 2007))
StB resembles wild-type substrate
1999), 2HPD (Ravichandran, Boddupalli et al. 1993), and 2IJ2 (Girvan, Seward et al. 2007))
5F5 StF structure exhibits mixed features.
Figure 15: The ‘hotspots’ (Leu75, Val78, Ala82, Ala87, Ile153, Ile263, Ala264, Ala328, Leu437, Thr438) 
in the active site of P450 BM3 5F5/5F5K/5F5R variants
Positions 82, 87, 328, and 438 have been 
active site of P450 BM3 (Huang, Cullis et al. 2011). Ala87 (Phe87 in the WT) is the most extensively 
engineered residue in P450 BM3 and has been known to 
number of substrates (Whitehouse, Bell et al. 2012). Other residues (Leu75, Val78, Ala264, Leu437) are 
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pointing into the active site and their substitution can very likely alter binding modes of styrene in the 
active site of P450 BM3. Ile153 is located in the vicinity of I-helix and its engineering might result in the 
stabilization/reduction of the I-helix kink angle, thereby improving/inverting enantioselectivity of styrene 
epoxidation. Proteins are colored grey except the side chains of identified residues and the I helix (5F5K 
(cyan), 5F5R (green), 5F5 dsI StB (yellow), 5F5 dsII StB (orange)). The heme cofactor is shown in red 
sticks. Residues Pro170-Arg190 are omitted for clarity. 
 
Solved crystal structures harbor the bound styrene in close proximity of the heme-iron in the 
active site, revealing molecular insights into ‘productive’ and ‘non-productive’ styrene binding 
modes. In the ‘productive’ mode, the vinyl tail of styrene is positioned just above the heme-iron. 
In the ‘non-productive’ mode, the phenyl part points towards the heme and a water molecule 
remains coordinated to the heme-iron, rendering epoxidation unfeasible in this orientation. The 
latter mode was only observed in 5F5 dsI StB and 5F5 dsII StB structures which were were 
solved after soaking the crystals with styrene-saturated cryobuffer additionally for brief (2-3 
min) and long (60 min) time intervals, respectively. In excellent agreement with the reported 
experimental data (Tee and Schwaneberg 2006), the bound styrene is oriented such that it would 
preferentially lead in the variants 5F5K and 5F5R to the formation S-styrene epoxide, and in 5F5 
variant to the formation of R-styrene epoxide. 5F5K/R StB crystal structures reveal the formation 
of an interhelical salt-bridge involving the charged surface residue at position 184 which causes 
that key structural elements adjacent to the active site are repositioned, leading to altered styrene 
binding geometries. Most notably are steric constraints imposed by active site residues which 
govern styrene binding modes and modulate the inverted enantioselectivity for styrene 
epoxidation in these variants. Due to the presence of a well-defined kink in the I-helix, Ala264 
completely covers the heme pyrrole ring C, and provides sufficient steric hindrance to prevent 
exposure of the pro-S face of styrene to the heme-iron which, as a result, promotes the formation 
of R-styrene epoxide as the preferred enantiomer in the 5F5 variant. On the other hand, in both 
the inverted S-selective variants (5F5K StB and 5F5R StB), Ala264 and Gly265 are located away 
from the active site upon insertion of a water molecule into the I-helix which reduces the kink 
angle, and thus partially unmask the pyrrole ring C and preferentially expose the pro-S face of 
styrene over the heme-iron.  
Solved crystal structures of P450 BM3 variants in complex with styrene provide on the 
molecular level a first explanation how a positively charged surface residue (at position 184) 
Results and Discussion      Chapter I: Enantios
 
inverts the enantiopreference of styrene epoxidation in 
The obtained insights into productive and non
understanding on enantioselective hydroxylation of aromatic compounds with 
other monooxygenases in general.
Summary Figure: A graphical depiction which shows that an electrostatic interaction on the 
surface due to the presence of a novel salt
changes in the S-selective variants (5F5K/5F5R) 
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4694-4696.  
elective Styrene Epoxidation in P450 BM3           
P450 BM3 (Tee and Schwaneberg 2006
-productive styrene binding modes will deepen our 
   
-bridge (Lys/Arg184:Asp80) triggers conformational 
such that the kink in the I
R-selective variant (5F5), leading to altered styrene binding
Master (M.Sc. Molecular Life Science) 
" (Aamir Shehzad, 2010, Jacobs 
 
Chemical Communications
and Ulrich Schwaneberg (2013). 
" Chemical Communications (Cambridge, England)
67  
). 
P450 BM3 and 
 
-helix is significantly 
 
:           
"P450 BM3 
 49(41): 
Results and Discussion      Chapter II: Mediated Electron Transfer system in P450 BM3            68  
 
Chapter II: Crystal structure of P450 BM3 M7 heme domain variant 
complexed with cobalt (III) sepulchrate 
The excellent catalytic efficiency of P450 BM3 towards hydroxylation of long chain fatty acids 
has generally been ascribed to its unique naturally fused modular assembly of catalytic heme and 
FMN/FAD-containing diflavin reductase domains on a single polypeptide chain which renders 
P450 BM3 catalytically self-sufficient (Narhi and Fulco 1986). For catalysis to occur, the 
enzyme sources electrons from NADPH, an obligate two electron donor, and relays them singly 
via the reductase domain to the catalytic heme domain (Ortiz de Montellano 2010). P450 BM3 
variants are known which can oxidize non-natural substrates, making P450 BM3 an attractive 
candidate for use in biotechnology (Whitehouse, Bell et al. 2012). However, the requirement for 
a commercially expensive electron source, NADPH, obstructs the industrial exploitation of P450 
BM3, thus stimulating considerable interest into enzyme reengineering efforts aimed at 
successfully driving P450 BM3 based on alternative and cost-effective cofactor systems 
(O'Reilly, Kohler et al. 2011). Attempts have been made towards immobilization of P450 BM3 
on the surface of a variety of electrodes (Hlavica 2009), enabling direct electrochemical 
reduction of the enzyme in the absence of the natural cofactor (Panicco, Astuti et al. 2008; 
Hlavica 2009; Sadeghi, Fantuzzi et al. 2011). For P450 BM3, Schmid and coworkers described 
the first report on the replacement of an electrode/NADPH with cheap zinc dust as the electron 
source, with cobalt (III) sepulchrate (Co(III)Sep) serving as a mediator of ‘electrical 
communication’ between the enzyme and the electron source (Schwaneberg, Appel et al. 2000). 
This strategy was also successfully employed for establishing the first medium-throughput-
screening protocol for the directed evolution of a P450 enzyme towards mediated electron 
transfer (Nazor and Schwaneberg 2006). Subsequent screening efforts led to the identification of 
highly active and reductase-independent P450 BM3 variants (Nazor, Dannenmann et al. 2008; 
Zhao, Guven et al. 2011). The final P450 BM3 M7 variant, harboring three substitutions (F87A, 
V281G, M354S) in the heme domain, was subsequently obtained which showed the highest 
activity towards the Zn/Co(III)Sep based electron transfer system, and was superior to the wild-
type (WT) enzyme in terms of thermal- and storage stability when immobilized on a 
chromatographic matrix containing DEAE-650S, k-carrageenan, and glutaraldehyde (Zhao, 
Guven et al. 2011), thus allowing the application of P450 BM3 for preparative conversions. 
Based on the mutagenesis results, it has been previously proposed that the mediator, Co(III)Sep, 
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might be implicated in enhancing electron transfer rates by associating with the substrate access 
channel (Nazor and Schwaneberg 2006; Nazor, Dannenmann et al. 2008). Here, the crystal 
structures of the heme domain of the P450 BM3 M7 variant (Zhao, Guven et al. 2011) alone and 
in complex with Co(III)Sep are presented which provide valuable structural insights into the 
enzyme-mediator ‘crosstalk’ at molecular level, and unravel mechanistic roles of important 
substitutions in promoting the enzymatic activity. 
 
1.1 Overall structure 
Crystallization conditions similar to those previously reported for P450 BM3 (Hegde, Haines et 
al. 2007; Haines, Chen et al. 2008) proved successful for obtaining diffraction-quality crystals of 
P450 BM3 M7 heme domain variant (Zhao, Guven et al. 2011). Crystals diffracted to 2.0 Å 
resolution, and each asymmetric unit consists of two protein monomers (A and B). The RMSD 
between Cα atom positions in both monomers is ~ 0.7 Å, indicating that protein monomers in the 
asymmetric unit share similar conformations (Table 8). Structural superposition for equivalent 
pairs of Cα atoms reveals that both structures resemble wild-type substrate-free (WTSF) forms 
(PDB codes: 1BU7 (Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 
2IJ2 (Girvan, Seward et al. 2007)) more than wild-type substrate-bound (WTSB) forms (Table 8; 
PDB codes: 1FAG (Li and Poulos 1997), 1JPZ (Haines, Tomchick et al. 2001), 1ZO9 (Hegde, 
Haines et al. 2007)). The latter findings are also in agreement with the hydrogen bonding pattern 
among backbone atoms in the I-helix of P450 BM3 M7 structures which resembles WTSF forms 
(Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli et al. 1993; Girvan, Seward et al. 2007) 
and departs from WTSB forms (Table 9; Li and Poulos 1997; Haines, Tomchick et al. 2001; 
Hegde, Haines et al. 2007).    
 
1.2 Binding of cobalt (III) sepulchrate 
Co(III)Sep can be modeled into electron density (Figure 16) on the surface of the protein at the 
entrance of the substrate access channel. Interestingly, the electron density for Co(III)Sep can 
only be found in monomer B in the asymmetric unit, and residues in the close proximity on the 
FG loop exhibit very high B-factor values. The corresponding region in monomer A is 
completely disordered, explaining the absence of electron density for Co(III)Sep in this 
monomer. However, conformational changes can only be seen on the surface in the vicinity of 
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Figure 16: Electron density surrounding Co(III)Sep
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structure. The potential was calculated by using PDB2PQR server (Dolinsky, Nielsen et al. 2004) and 
Adaptive Poisson-Boltzmann Solver (APBS) (Baker, Sept et al. 2001) plug-in in PyMOL (The PyMOL 
Molecular Graphics System, Version 1.2r1 DeLano Scientific LLC). 
 
1.3 Discussion 
Crystal structures of P450 BM3 M7 heme domain variant (Zhao, Guven et al. 2011) alone and in 
complex with Co(III)Sep are conformationally similar to WTSF forms (PDB codes: 1BU7 
(Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), and 2IJ2 (Girvan, 
Seward et al. 2007)), in stark contrast to the Ru-photosensitizer conjugated crystal structure of 
P450 BM3 K97C variant (Ener, Lee et al. 2010) which resembles WTSB forms (PDB codes: 
1FAG (Li and Poulos 1997), 1JPZ (Haines, Tomchick et al. 2001), and 1ZO9 (Hegde, Haines et 
al. 2007)). The electron density for Co(III)Sep can be found on the surface of the protein at the 
entrance of the substrate access channel, a position similar to the binding of ruthenium (Ru) 
photosensitizers covalently linked to substrates in other P450 structures (Dmochowski, Crane et 
al. 1999; Dunn, Dmochowski et al. 2001). The Co-Fe distance between Co(III)Sep and the heme 
is 36.30 Å which renders the prospect of a direct interaction between the two cofactors 
unfeasible, raising the possibility that alternative routes might exist to shuttle electrons from 
Co(III)Sep to the active site heme-iron. For instance, electrons can be tunneled to the iron atom 
through the protein backbone atoms of Asn192-Leu188, then via main or side chain atoms of 
Ala74-Leu75 to heme propionate, and can ultimately reach the heme-iron (Figure 17). Another 
possible route can incorporate the bound substrate itself, and such a scenario bears a striking 
analogy to the electron transfer observed in P450cam bound to ruthenium sensitizer-linked 
substrates (Dmochowski, Crane et al. 1999; Wilker, Dmochowski et al. 1999; Dunn, 
Dmochowski et al. 2001). In this case, electrons can be transferred from Co(III)Sep to the bound 
substrate through the backbone atoms of Asn192-Leu188, and can be finally relayed to the 
heme-iron directly by the substrate (Figure 17). This would avoid the wasteful use of electrons in 
the absence of a bound substrate in the active site, as substrate binding is known to trigger an 
increase in heme-iron reduction potential in P450 BM3 (Ost, Clark et al. 2003). In WTSB forms, 
substrate is tethered in the active site through electrostatic interactions between carboxylic 
groups of fatty acid substrates and side chain atoms of Arg47/Tyr51 located at the ‘mouth’ of 
substrate access channel (Li and Poulos 1997; Haines, Tomchick et al. 2001; Hegde, Haines et 
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Table 8: RMSDs (Å) were calculated upon pairwise superposition of equivalent pairs of Cα atoms from 
individual monomers of the P450 BM3 M7 variant (Zhao, Guven et al. 2011) (in Co(III)Sep-bound and 
Co(III)Sep-free forms) with the MUSTANGPP method (Konagurthu, Whisstock et al. 2006). WT P450 
BM3 structures are represented by their PDB codes: 1BU7 (Sevrioukova, Li et al. 1999), 2HPD 
(Ravichandran, Boddupalli et al. 1993), 2IJ2 (Girvan, Seward et al. 2007), 1JPZ (Haines, Tomchick et al. 
2001), 1FAG (Li and Poulos 1997), 1ZO9 (Hegde, Haines et al. 2007). WTSF: wild-type substrate-free. 
WTSB: wild-type substrate-bound. 
 
M7-Co(III)Sep M7 
A B A B 
WTSF 
1BU7 
A 0.57 0.45 0.55 1.01 
B 0.65 0.96 0.66 0.42 
2HPD 
A 0.43 0.58 0.38 0.82 
B 0.62 0.88 0.72 0.47 
2IJ2 
A 0.68 0.99 0.79 0.48 
B 0.56 0.43 0.49 0.89 
WTSB 
1JPZ 
A 1.15 1.00 1.19 1.37 
B 1.14 1.01 1.18 1.36 
1FAG 
A 1.22 1.03 1.21 1.48 
B 1.23 1.05 1.24 1.43 
C 1.21 1.04 1.23 1.46 
D 1.23 1.04 1.23 1.42 
1ZO9 
A 1.14 0.99 1.18 1.41 
B 1.14 1.00 1.19 1.37 
Mediated 
Electron 
Transfer 
M7-Co(III)Sep 
A - 0.65 0.34 0.71 
B  - 0.62 0.91 
M7 
A   - 0.71 
B    - 
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Table 9: Differences in the I-helix backbone conformations of the WT P450 BM3 and its M7 variant 
(Zhao, Guven et al. 2011) (in Co(III)Sep-bound and Co(III)Sep-free forms). Hydrogen bond distances (Å) 
of the I-helix backbone (Ile258-Leu272) of M7 and M7-Co(III)Sep structures are summarized. Backbone 
distances for WTSF are the average of three wild-type substrate-free structures (PDB codes: 1BU7, 
2HPD, and 2IJ2) (Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli et al. 1993; Girvan, Seward et 
al. 2007; Shehzad, Panneerselvam et al. 2013). Backbone distances for WTSB are the average of three 
wild-type substrate-bound structures (PDB codes: 1JPZ, 1FAG, and 1ZO9) (Haines, Tomchick et al. 
2001; Li and Poulos 1997; Hegde, Haines et al. 2007; Shehzad, Panneerselvam et al. 2013). 
 
Hydrogen bond 
M7-Co(III)Sep M7 
WTSF WTSB 
A B A B 
Ile258CO-Leu262NH 3.30 3.33 3.25 3.39 3.29 2.87 
Ile259CO-Ile263NH 2.96 2.99 2.90 3.00 2.96 3.01 
Thr260CO-Ala264NH 2.80 2.73 2.80 2.74 2.85 2.80 
Phe261CO-Gly265NH 2.99 3.10 2.94 2.94 2.96 2.90 
Leu262CO-His266NH 3.17 3.25 3.05 3.21 3.08 3.81 
Ile263CO-Glu267NH 4.68 4.42 4.54 4.63 4.75 3.17 
Ala264CO-Thr268NH 4.72 4.74 4.67 4.55 4.64 4.80 
Gly265CO-Thr269NH 3.16 3.25 3.37 3.44 3.34 6.02 
His266CO-Ser270NH 3.14 3.10 3.05 3.24 3.19 3.02 
Glu267CO-Gly271NH 2.96 3.10 2.96 2.67 2.88 3.05 
Thr268CO-Leu272NH 3.04 2.93 3.08 2.99 3.07 3.00 
 
Crystal structures of individual domains of P450 BM3 are now available. However, the full-
length P450 BM3 has not been structurally resolved yet, likely due to the intrinsic flexibility 
associated with the electron transfer from the reductase domain to the heme domain (Girvan, 
Seward et al. 2007; Huang, Westlake et al. 2007). The largest construct of P450 BM3 in the 
Protein Data Bank (PDB) (Bernstein, Koetzle et al. 1977; Berman, Westbrook et al. 2000) 
consists of a truncated complex of heme and FMN binding domains which depicts the electron-
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shuttling FMN domain at the proximal surface of the heme domain (Sevrioukova, Li et al. 1999). 
However, the structural data reported here reveal the presence of the mediator on the distal side. 
This is fairly comprehensible, as the putative docking site of the natural redox partner on the 
proximal side of the heme domain in P450 BM3 is substantially positively charged 
(Sevrioukova, Li et al. 1999) which effectively disfavors the binding of similarly charged 
molecules, such as Co(III)Sep, at the proximal face. It is therefore desirable that any mediator 
that is likely to shuttle electrons to the heme domain in P450 BM3 must possess an appropriate 
positive charge which would enable it to communicate productively with the catalytic heme 
domain for its reduction. The association of Co(III)Sep at the distal surface corroborates our 
previous propositions (Nazor and Schwaneberg 2006; Nazor, Dannenmann et al. 2008), and 
suggests that the heme domain alone is sufficient to receive electrons. The latter is also 
evidenced by our protein engineering studies which demonstrate that reductase-deficient variants 
of P450 BM3 ‘addicted’ to Co(III)Sep based alternative cofactor system retain 89% of the kcat 
values when compared to the corresponding full-length P450 BM3 variants (Nazor, Dannenmann 
et al. 2008). Electron transfer in the absence of a redox partner protein has also been observed in 
other naturally occurring P450s which consist of heme domains alone (Lau, Harder et al. 1993; 
Shibata, Matsui et al. 1995; Itoh and Howe 2001; Hannemann, Bichet et al. 2007). 
 
1.4 Conclusions 
Crystal structures of P450 BM3 M7 heme domain variant (F87A, V281G, M354S; Zhao, Guven 
et al. 2011) have been successfully solved in the presence and absence of Co(III)Sep which 
provide plausible explanations for the transfer of electrons by the mediator. The overall 
conformation of the Co(III)Sep-bound and Co(III)Sep-free forms of P450 BM3 M7 heme 
domain variant resembles WTSF forms (Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli 
et al. 1993; Girvan, Seward et al. 2007). Electron density for Co(III)Sep was located on the 
surface of the protein at the entrance of substrate access channel on the distal face, a position far 
from the active site. Binding of Co(III)Sep and increased flexibility of residues in the immediate 
vicinity likely facilitate the accommodation of substrate in the binding pocket. Electrons can be 
shuttled from the mediator to the heme either through main chain and side chain atoms of the 
protein or may involve the bound substrate. The latter would ensure that the transfer of electrons 
is regulated based on the availability of the substrate in the binding pocket which is known to 
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trigger a positive shift in the heme reduction potential in P450 BM3. The structural evidence also 
indicates that the use of a positively charged mediator is important to effectively reduce the 
catalytic heme domain. Solved crystal structures help us diagnose the molecular basis for 
‘addiction’ of P450 BM3 variants to Co(III)Sep, and open avenues for future design of highly 
selective variants of P450 BM3 or structurally related monooxygenases towards alternative and 
cost-effective cofactor systems.       
Preliminary results from Chapter II also appear in my Master (M.Sc. Molecular Life Science) 
thesis entitled, "Crystallization of P450 BM3 Variants for Better Understanding of Alternative 
Cofactor Systems and Stereoselective Styrene Epoxydation" (Aamir Shehzad, 2010, Jacobs 
University Bremen, Germany). 
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Chapter III: Crystal structure of wild-type FAD/NADPH binding domain of 
P450 BM3 monooxygenase 
Likely due to intrinsic structural flexibility associated with the transfer of electrons from the 
NADPH-binding diflavin reductase domain to the substrate binding catalytic heme domain, the 
structure of the full-length enzyme (containing both the domains) has not been reported so far 
(Girvan, Seward et al. 2007; Huang, Westlake et al. 2007). However, a truncated complex of the 
WT catalytic heme domain and the FMN binding domain has been structurally solved 
(Sevrioukova, Li et al. 1999). Moreover, the crystal structure of a double variant 
(C773A/C999A) of the FAD/NADPH binding domain has been recently reported that was 
specifically engineered aimed at yielding successful crystals for diffraction (Joyce, Ekanem et al. 
2012). However, mutagenesis studies have demonstrated that Cys999 is catalytically important 
(Roitel, Scrutton et al. 2003), and C999A variants of the reductase as well as of the isolated 
FAD/NADPH binding domains exhibit substantially reduced electron transfer properties based 
on either NADPH or NADH (Roitel, Scrutton et al. 2003). These finding necessitate the 
availability of the crystal structure of WT FAD/NADPH binding domain to explore how Cys999 
and other catalytically important residues are spatially oriented in the WT. Here the crystal 
structure of the FAD/NADPH binding domain of WT P450 BM3 is presented which has been 
crystallized in the presence of NADP+ in a different oligomeric state as compared to the 
C773A/C999A variant (Joyce, Ekanem et al. 2012). The solved crystal structure of the WT 
FAD/NADPH binding domain provides an opportunity to highlight differences between both the 
structures, and to elucidate how different residues, especially cysteines, might be implicated in 
the electron transfer or structural organization of the FAD/NADPH binding domain. 
 
1.1 Wild-type crystallization 
It has been previously reported that the WT FAD/NADPH binding domain is not amenable to 
crystallization (Joyce, Ekanem et al. 2012). However, our crystallization efforts suggest that the 
temperature of the set-up plays an important role in obtaining suitable crystals for diffraction. 
Moreover, freshly purified protein takes 3-4 weeks to crystallize whereas an older batch stored at 
4 °C for several weeks yields crystals within a few days. It appears that the disulfide bond 
formation between cysteine residues (discussed below) improves the entropy of the protein, thus 
reducing time needed for crystal formation. 
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1.2 Overall structure 
The crystal belonged to space group P2
diffracted to a resolution of 2.7
and 21.7%, respectively. The N
Similar to the reported variant 
visible (Figure 18). 
Figure 18: Cartoon representation of the FAD/NADPH binding domain of WT 
monooxygenase. The FAD (green) and NADP
present in an extended conformation. The nicotinamide moity of NADP
(Leu728-His737) is shown with dotted lines.
 
1.3 FAD binding site 
The FAD isoalloxazine ring is sandwiched between aromatic side chains of Trp1046 and Tyr829, 
serving as stacking residues. The pyrimidine side of the isoalloxazine ring forms extensive 
hydrogen bonding interactions with surrounding residues as well as with
molecules. The xylene ring side of FAD is surface
12121 with one protein monomer per asymmetric unit, and 
 Å. The R-factor and R-free values of the final model are 17.5% 
-terminal residues (Ala650-Met653) are completely disordered. 
(Joyce, Ekanem et al. 2012), one loop (Leu728
+ (yellow) ligands are shown in sticks. The FAD ligand is 
+ is disordered.
 
 two tightly bound water 
-exposed, strongly suggesting that in the 
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-His737) is also not 
 
P450 BM3 
 The missing loop 
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holoenzyme the FMN domain would interact through this side and receive the reducing 
equivalents from FAD. The latter also has an extended co
helix (Ile863-Leu871) is pointing to
chains from Ser865, Arg827, Tyr860, and Gln756. The polypeptide segment Val846
almost parallel to the ribityl pyrop
adenosine portion is staked by Trp854 and Tyr860
Figure 19: Residues surrounding the FAD cofactor in 
BM3. The isoalloxazine ring of FAD (colored green) is stacked by Trp1046 and Tyr829, while the 
adenosine part is covered by Trp854 and Tyr860.
FAD cofactor.  
 
1.4 NADP
+
 binding site
The adenine part of NADP+ is partially covered by the phenolic side chain of Tyr974. The 2’
phosphate group is involved in hydrogen bonding interactions with side chains of Ser965, 
Arg966, and Tyr974. The pyrophosphate portion is stabilized by its interactions with Ser847 and 
Thr905. The nicotinamide moity of NADP
nformation. The N
 the pyrophosphate group of FAD, which is stabilized by side 
hosphate chain of FAD. Similar to isoalloxazine ring, the 
 (Figure 19). 
the WT FAD/NADPH binding domain of P450 
 The green mesh depicts the omit Fo
 
+ is completely disordered (Figure 20)
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-terminus of the 
-Val849 is 
 
-Fc map around the 
-
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1.5 Discussion 
The WT FAD/NADPH binding domain of P450 BM3 was crystallized under different conditions 
to that reported previously for the variant 
P212121 space group with one protein monomer per asymmetric unit, as opposed to P3
group and two monomers per asymmetric unit in the case of the variant 
2012). It, however, remains unclear if the difference in crystal symmetry originates d
protein primary structure or as a result of different crystallization conditions. The latter also 
depart from the previous report 
was introduced prior to crystallization trials
additional soaking with the ligand was performed before 
 
Figure 20: Residues surrounding the NADP
BM3. The adenine portion of NADP
Tyr974, and Arg966 interact with the 2’
Fo-Fc map around the NADP+ cofactor.
 
(Joyce, Ekanem et al. 2012). Crystals belonged to 
(Joyce, Ekanem et al. 2012) in terms of the NADP
 of the WT FAD/NADPH binding domain 
the data collection.
+ cofactor in the WT FAD/NADPH binding domain of P450 
+ (colored yellow) is covered by Tyr974. The side chains of 
-phosphate group of the ligand. The green mesh depicts the omit 
 
 80  
121 space 
(Joyce, Ekanem et al. 
ue to altered 
+ addition, as it 
and no 
 
Ser965, 
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The isoalloxazine ring of FAD is covered by Trp1046 (Figure 19). This feature is consistent with 
other structurally resolved reductase domains of P450 monoxygenases which also depict 
isoalloxazine rings covered by an aromatic residue (Wang, Roberts et al. 1997). The bulky side 
chain at the corresponding position has been suggested to swing away from the isoalloxazine 
ring in order to facilitate direct interaction of nicotinamide part of NADP+ with FAD for its 
reduction (Hubbard, Shen et al. 2001). Trp1046 is also the most extensively targeted residue for 
mutagenesis in the reductase domain of P450 BM3 (Whitehouse, Bell et al. 2012). Substitution 
of Trp for Ala at position 1046 resulted in NADH-dependent P450 BM3 monoxygenase that 
could substitute NADPH as an electron source for the hydroxylation of lauric acid (Neeli, Roitel 
et al. 2005). A similar trend could also be observed for a W1046S variant that exhibited 
substantially increased affinity towards the binding of NADH (Maurer, Kuhnel et al. 2005).                
Residues surrounding the 2’-phosphate group of NADP+ in P450 BM3 (Ser965, Arg966, 
Lys972, and Tyr974; Figure 20) are also conserved in diflavin reductases (Figure 22; Maurer, 
Kuhnel et al. 2005; Dunford, Girvan et al. 2009), and mutagenesis studies demonstrate that these 
residues play a pivotal role in cofactor specificity in P450 BM3 (Dunford, Girvan et al. 2009; 
Maurer, Kuhnel et al. 2005). Two synergistic substitutions (K972A/W1046A) in the reductase 
domain completely abolished selectivity for NADPH in favor of NADH (Dunford, Girvan et al. 
2009). Another double mutant (R966D/W1046S) could be catalytically driven based on NADH 
instead of NADPH, and showed preference for the former over the latter cofactor (Maurer, 
Kuhnel et al. 2005). 
The crystal structure of the WT FAD/NADPH binding domain is similar to structure of 
C773A/C999A variant in terms of its global architecture (Joyce, Ekanem et al. 2012). In the WT 
FAD domain, Cys773 forms an intramolecular disulfide bridge with Cys810. The formation of a 
disulfide bridge in the WT structure results in shortening of the adjacent helix (His776-Ala782) 
by one complete helical turn as compared to the C773A/C999A structure (Joyce, Ekanem et al. 
2012). As a consequence, the salt-bridge between Glu816 and Lys770 is also not formed in the 
WT structure, and Lys770 is surface-exposed, likely contributing to increased surface-entropy 
which compromises the diffraction-quality of the crystals (Figure 21).  
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Figure 21: Structural changes which occur on the surface due to the formation of a novel disulfide bridge 
in the WT FAD/NADPH binding domain
(green; Joyce, Ekanem et al. 2012)
WT P450 BM3 FAD/NAPDH binding domain
by one complete helical turn as compared to C773A/C999A struct
consequence, the salt-bridge between Glu816 and Lys770 is also not formed in the WT structure, and 
Lys770 is surface-exposed. 
 
 On the other hand, C999A substitution 
structural differences. Nevertheless, subtle changes in the 
residues are evident (Figure 23)
the side chains of Asp1044 and Trp1046
Cys999, Asp1044 and Ser830 
hydride transfer pathway in other diflavin reductases 
et al. 2003), while Trp1046, as d
 (cyan) of P450 BM3 as compared to the 
. The formation of a disulfide bridge between Cys773 and Cys810 
 results in shortening of the adjacent helix (His776
ure (Joyce, Ekanem et al. 2012)
(Joyce, Ekanem et al. 2012) does not lead to large 
side chain positions of surrounding 
. Due to the presence of a larger side chain (Cys999) in the WT, 
 in close proximity are slightly displaced. Together with 
constitute a highly conserved triad which has been implicated in 
(Hubbard, Shen et al. 2001
iscussed above, shields the isoalloxazine ring of FAD. 
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C773A/C999A variant 
in 
-Ala782) 
. As a 
; Roitel, Scrutton 
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Figure 22: The multiple sequence alignment of the WT FAD/NADPH binding domain of P450 BM3 with 
other structurally related proteins (represented by four-letter PDB codes: 4DQL (Joyce, Ekanem et al. 
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2012), 1F20 (Zhang, Martasek et al. 2001)
2009), 3QFS (Xia, Panda et al. 2011)
2007)). The alignment was computed with ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/), and the figure was generated by using the ESPRIPT server 
(Gouet, Robert et al. 2003). Secondary structure elements (α helices as coils, and β sheets as arrows) 
corresponding to WT P450 BM3 FAD/NADPH binding domain are depicted on the top of the alignment.
Figure 23: Structural superposition of t
et al. 2001; Roitel, Scrutton et al. 2003)
binding domain of P450 BM3 (cyan) and its
Subtle structural changes in the positions of Asp1044 and Trp1046 
 
For P450 BM3, mutagenesis studies have suggested that the primary role of Cys999 is to 
promote the rate of hydride transfer from NADPH to FAD 
Substitution of C999A has been shown to result in a more rapid release of NADP
enzyme (Roitel, Scrutton et al. 2003
and stabilizes the binding of NADP
et al. 2003). As is the case with analogous Cys at the corresponding positions in other P450s, the 
, 1JA0 (Hubbard, Shen et al. 2001), 3ES9 
, 1DDI (Gruez, Pignol et al. 2000), and 2QTL
via the European Bioinformatics Institute server 
he ‘catalytic triad’ (Ser830, Cys999, and Asp1044; 
 which surrounds the FAD cofactor in 
 C773A/C999A variant (green; Joyce, Ekanem et al. 2012)
are evident. 
(Roitel, Scrutton et
), suggesting that Cys999 enhances hydride transfer to FAD 
+ to the two-electron-reduced FAD domain 
 84  
(Hamdane, Xia et al. 
 (Wolthers, Lou et al. 
 
 
Hubbard, Shen 
the WT FAD/NADPH 
. 
 al. 2003). 
+ from the 
(Roitel, Scrutton 
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rate of FAD reduction is significantly reduced in C999A P450 BM3 reductase and FAD domains 
(Roitel, Scrutton et al. 2003). In human NR1, the corresponding residue is Ala549, and hydride 
transfer is fully rate-limiting (Finn, Basran et al. 2003; Roitel, Scrutton et al. 2003). All these 
findings suggest that small structural perturbations due to C999A substitution can lead to drastic 
changes in enzyme catalysis. 
 
1.6 Conclusions 
Crystal structure of the wild-type (WT) FAD/NADPH binding domain of P450 BM3 has been 
solved to 2.7 Å resolution. The electron density for FAD and NADP+ ligands could be clearly 
observed. However, in the latter case the nicotinamide moity, which has been suggested to 
interact with the isoalloxazine ring of the FAD cofactor in other P450s (Hubbard, Shen et al. 
2001), is disordered. The isoalloxazine ring is also sandwiched between two aromatic residues, 
Trp1046 and Tyr829. Similar residues also stack the adenosine part of FAD. The NADP+ is 
covered by Tyr974, and the 2’-phosphate group is surrounded by Ser965, Arg966, Lys972, and 
Tyr974. Mutagenesis studies demonstrate that these residues play a key role in modulating 
cofactor selectivity in P450 BM3 (Maurer, Kuhnel et al. 2005). The crystal structure of WT 
FAD/NADPH domain also provides us with an opportunity to compare its structural features 
with the crystal structure of recently solved C773A/C999A variant (Joyce, Ekanem et al. 2012). 
Subtle structural differences can likely be attributed to the introduced substitutions (Joyce, 
Ekanem et al. 2012). The C773A/C999A variant (Joyce, Ekanem et al. 2012) is deficient with 
one disulfide bridge formed between Cys773 and Cys810 in the WT structure. The truncation of 
the disulfide bridge due to C773A substitution leads to the formation of a new salt-bridge 
(Glu816:Lys770) between neighbouring residues in the C773A/C999A variant (Joyce, Ekanem 
et al. 2012). In the WT structure, the salt-bridge is not observed, and Lys770 is surface-exposed, 
likely contributing to increased surface-entropy and compromising the diffraction-quality of the 
crystals. Asp1044 and Trp1046 in the vicinity of C999A substitution (Joyce, Ekanem et al. 2012) 
are slightly displaced in the WT FAD/NADPH binding domain. Trp1046 has also been shown to 
be a major determinant of cofactor specificity in P450 BM3 (Maurer, Kuhnel et al. 2005; Neeli, 
Roitel et al. 2005). 
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Chapter IV: Summary of miscellaneous structures: 
 
1.1 WT and T577G FMN domains 
An alternative cofactor system which involves direct transfer of electrons from the electron 
source to P450 BM3 has been described by Nazor (Nazor 2007; Ruff 2012). In this system, 
electrons are sourced from Baytron P or Clevios P which is a complex of two polymers: PEDOT 
(poly (3,4-ethylenedioxythiophene)) and PSS (polystyrenesulfonic acid) (www.clevios.com; 
Nazor 2007; Ruff 2012). The mixture consists of short segments of PEDOT bound to longer 
chains of PSS (Luo, Mohamed Ali et al. 2008; Ruff 2012). The overall charge of the complex is 
goverened by the amount of PSS which acts as a counter-ion and prevents the oxidation of 
PEDOT, as the conductivity of the complex decreases with increasing the ratio of PSS 
(Groenendaal, Jonas et al. 2000; Ruff 2012). Depending on the formulation, the conductivity of 
the mixture ranges between metals and semiconductors (www.clevios.com; Nazor 2007; Ruff 
2012). 
Full-length P450 BM3 harboring two substitutions, one in the heme domain (Y51F) and the 
other in the FMN binding domain (T577G), has been demonstrated to catalyze the hydroxylation 
of 3-phenoxytoluene in the presence of Clevios P as the sole electron source (Nazor 2007). In 
order to structurally investigate the role of T577G substitution in modulating the electronic 
properties (Nazor 2007), attempts were made to crystallize the WT and T577G FMN binding 
domains in the presence of Clevios P and its individual polymer components.  
The crystallization of the wild-type and T577G FMN domains proved successful after 
identifying new conditions (Appendix; Table 11). The crystals diffracted to higher resolutions, 
however, no structural differences could be attributed to T577G substitution upon superposition 
of WT and T577G FMN domain structures (Figure 24). Crystals could not be obtained in the 
presence of Clevios P, as the crystallization set-up suffered from technical limitations due to 
instantaneous precipitation of the protein in the presence of Clevios P or its individual polymers. 
Crystallization at very low concentrations (PSS 0.36%, PEDOT 0.24%, PEDOT/PSS (whole 
polymer) 0.025%) were also not fruitful, as the crystals diffracted to low resolutions, and neither 
the polymers nor any structural difference was observed after structure solution. Due to these 
limitations, any further experimental work in this regard was discontinued. 
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Figure 24: Structural superposition of 
(cyan) of P450 BM3 is shown for monomers A (
 
1.2 Aromatic hydroxylation variants
Atomic resolution crystal structures of P450 BM3 
I401M, and AD4: R47S, Y51W
(Dennig, Marienhagen et al. 2012
the binding of the substrate (p
exocyclic aromatic hydroxylation
were obtained under previously reported crystallization conditions for P450 BM3 
Yang et al. 2011). Crystals diffracted to 
group with two monomers (A and B) in the asymmetric unit.
Structural superposition with three
2HPD, and 2IJ2) (Ravichandran, Boddupalli et al. 1993
Seward et al. 2007) by MUSTANGPP method 
equivalent pairs of Cα atoms yields ro
Chapter IV: Miscellaneous structures            
the WT FMN domain (green) and T577G FMN 
left) and monomers B (right).  
 
heme domain variants (AD3
, I401M), implicated in the aromatic hydroxylation
), were determined to gain insights into the molecular basis 
-xylene) within the active site and to rationalize 
 (Dennig, Marienhagen et al. 2012). Diffraction
a resolution better than 1.5 Å, and belonged to 
  
 wild-type substrate-free (WTSF) forms (PDB codes: 1BU7,
; Sevrioukova, Li et al. 1999
(Konagurthu, Whisstock 
ot mean square deviations (RMSDs) of 0.63 Å and 0.62 Å 
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domain variant 
: R47Q, Y51F, 
 of p-xylene 
for 
the regioselective 
-quality crystals 
(Whitehouse, 
P21 space 
 
; Girvan, 
et al. 2006) for 
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for AD3 and AD4 structures, respectively, whereas the RMSDs increase to 1.3 Å and 1.25 Å, 
respectively, when compared to three wild-type substrate-bound (WTSB) forms (PDB codes: 
1FAG, 1JPZ and 1ZO9) (Li and Poulos 1997; Haines, Tomchick et al. 2001; Hegde, Haines et al. 
2007), indicating that the AD3 and AD4 structures are similar to WTSF forms and deviate 
appreciably from WTSB forms (Table 10, Figure 25).  
Upon comparison with WTSF forms (Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli et 
al. 1993; Girvan, Seward et al. 2007), no structural changes can be attributed to substitutions 
incorporated at positions 47, 51, and 401 in AD3 and AD4 structures, and the electron density at 
these positions as well as in the surrounding residues is well-defined. Furthermore, polar 
interactions which stabilize WTSF forms (Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli 
et al. 1993; Girvan, Seward et al. 2007; Whitehouse, Bell et al. 2012) remain remarkably intact 
in AD3 and AD4 structures. One of the substitutions (I401M) lies on the proximal side of the 
heme, while the other two (AD3: R47Q, Y51F, and AD4: R47S, Y51W) ‘gate’ the substrate 
access channel on the distal side. Notably, Arg47 and Tyr51 make polar interactions with fatty-
acids substrates in the WTSB forms (Li and Poulos 1997; Haines, Tomchick et al. 2001; Hegde, 
Haines et al. 2007; Whitehouse, Bell et al. 2012). The presence of a relatively shorter polar 
residue (at position 47), and a more hydrophobic residue (at position 51) at the ‘mouth’ of the 
substrate binding pocket likely promotes the access of anisole (an aromatic substrate) for the 
enzyme, as supported also by the kinetic data (Dennig, Marienhagen et al. 2012). Substitutions at 
position 401 have been previously shown to enhance the catalytic efficiency of the enzyme 
towards small aromatic substrates (Whitehouse, Bell et al. 2009), and favorable electronic 
configurations of the heme-iron have been suggested to accelerate such catalysis (Whitehouse, 
Bell et al. 2009; Whitehouse, Bell et al. 2012). In AD3 and AD4 structures, no conformational 
rearrangement can be attribued to I401M substitution, pointing again to the possibility that the 
observed increase in catalytic activity towards aromatic hydroxylation (Dennig, Marienhagen et 
al. 2012) might be due to elevated redox potential of the heme-iron. However, it is interesting to 
find that unlike AD3 and AD4 variants, which are structurally similar to WTSF forms 
(Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli et al. 1993; Girvan, Seward et al. 2007), 
previously reported ‘activity enhancer’ (I401P variant) displays structural features shared by 
WTSB forms (Li and Poulos 1997; Haines, Tomchick et al. 2001; Hegde, Haines et al. 2007; 
Whitehouse, Bell et al. 2009; Whitehouse, Bell et al. 2012). On the other hand, aromatic 
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hydroxylation variants (Dennig, Marienhagen et al. 2012) resemble I401P structure by exhibiting 
inverted conformations for heme in the active site, and a smeared electron density for axially 
coordinated water molecule to the heme-iron, the physiological implications of these phenomena 
have not been discerned yet (Whitehouse, Bell et al. 2009; Whitehouse, Bell et al. 2012).  
Similar to WTSF forms (Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli et al. 1993; 
Girvan, Seward et al. 2007), the I-helix (Glu252-Lys282) is substantially kinked near the active 
site, and a water molecule which interrupts the given hydrogen bonding pattern to relieve the 
kink angle in WTSB forms (Haines, Tomchick et al. 2001; Hegde, Haines et al. 2007; 
Whitehouse, Bell et al. 2012) is absent in AD3 and AD4 structures. The kink angle varies 
between 14.2°-17°. The helix is bent centered on Gly265, and the side chain of Thr268 forms a 
direct hydrogen bond with the carbonyl oxygen of Ala264 to establish the kink. Unlike WTSB 
forms, a water molecule stays in the so-called ‘groove’ of the I-helix (Haines, Tomchick et al. 
2001; Whitehouse, Yang et al. 2011; Whitehouse, Bell et al. 2012). However, structures of AD3 
and AD4 variants slightly depart from the WTSF forms (Sevrioukova, Li et al. 1999; 
Ravichandran, Boddupalli et al. 1993; Girvan, Seward et al. 2007) in the arrangement of active 
site water molecules, though mostly found at similar positions. Well-ordered water molecules, 
not seen in WTSF forms (Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli et al. 1993; 
Girvan, Seward et al. 2007), exist that interact with the backbone atoms of active site residues. 
Specifically, a water molecule is hydrogen bonded to the carbonyl oxygen of Leu437, while 
another one also interacts with that of Thr436. An additional water molecule also sits near the β1-
4 sheet above the heme and is involved in hydrogen bonding interactions with carbonyl oxygens 
of Ala328 and Ala330. Active site residues share similar side chain conformations with WTSF 
forms (Sevrioukova, Li et al. 1999; Ravichandran, Boddupalli et al. 1993; Girvan, Seward et al. 
2007), except Leu437 which occupies a slightly different position. 
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Table 10: RMSDs (Å) were calculated upon pairwise superposition of equivalent pairs of Cα atoms of the 
WT P450 BM3 and its aromatic hydroxylation variants (Dennig, Marienhagen et al. 2012) with the 
MUSTANGPP method (Konagurthu, Whisstock et al. 2006). WT P450 BM3 structures are represented 
by their PDB codes: 1BU7 (Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 
2IJ2 (Girvan, Seward et al. 2007), 1JPZ (Haines, Tomchick et al. 2001), 1FAG (Li and Poulos 1997), 
1ZO9 (Hegde, Haines et al. 2007). WTSF: wild-type substrate-free. WTSB: wild-type substrate-bound. 
 AD3 AD4 
A B A B 
WTSF 
1BU7 
A 0.791 0.668 0.753 0.552 
B 0.581 0.637 0.606 0.768 
2HPD 
A 0.579 0.509 0.550 0.470 
B 0.671 0.635 0.603 0.716 
2IJ2 
A 0.560 0.650 0.628 0.756 
B 0.667 0.591 0.644 0.452 
WTSB 
1JPZ 
A 1.326 1.258 1.278 1.131 
B 1.245 1.229 1.230 1.163 
1FAG 
A 1.399 1.313 1.405 1.216 
B 1.331 1.328 1.358 1.238 
C 1.329 1.334 1.406 1.230 
D 1.341 1.320 1.407 1.217 
1ZO9 
A 1.310 1.242 1.262 1.118 
B 1.252 1.234 1.239 1.161 
Aromatic 
hydroxylation 
variants 
AD3 
A - 0.250 0.296 0.447 
B  - 0.280 0.397 
AD4 
A   - 0.445 
B    - 
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Figure 25: Complete overlays showing the movements of the structural elements in AD3 (cyan), AD4 
(green), WTSF (gray; PDB code 1BU7 (Sevrioukova, Li et al. 1999)), and WTSB (blue; PDB code 1JPZ 
(Haines, Tomchick et al. 2001)) forms of P450 BM3. The heme ligand is shown as red sphere. As can be 
seen, AD3 and AD4 structures (green and cyan) resemble the WTSF conformation better than that of the 
WTSB form. 
 
Preliminary results originating from the crystallization of WT and T577G FMN domains also 
appear in my Master (M.Sc. Molecular Life Science) thesis entitled, "Crystallization of P450 
BM3 Variants for Better Understanding of Alternative Cofactor Systems and Stereoselective 
Styrene Epoxydation" (Aamir Shehzad, 2010, Jacobs University Bremen, Germany). 
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4. Summary: 
P450 BM3 preferentially catalyzes the subterminal hydroxylation of long chain fatty acids by 
sourcing electrons from the natural cofactor (NADPH) with the highest known catalytic 
efficiency ever reported for a P450 (Capdevila, Wei et al. 1996; Huang, Westlake et al. 2007; 
Whitehouse, Bell et al. 2012). However, P450 BM3 variants generated through protein 
reengineering strategies have been reported which can functionalize non-natural substrates, and 
can be catalytically driven based on alternative and cost-effective cofactor systems (O'Reilly, 
Kohler et al. 2011; Whitehouse, Bell et al. 2012). In this thesis entitled, ‘Insights into the 
Structural Basis for Activity and Selectivity of P450 BM3 Monooxygenase’, crystal structures of 
P450 BM3 variants implicated in enantioselective styrene epoxidation (Tee and Schwaneberg 
2006) and the Zn/Co(III)Sep based alternative cofactor system (Zhao, Guven et al. 2011) were 
successfully solved. The structural data provided valuable insights into the mechanistic roles of 
important substitutions which govern inverted enantioselectivity for styrene epoxidation (Tee 
and Schwaneberg 2006) and the cofactor specificity in P450 BM3 (Zhao, Guven et al. 2011).   
Chapter I of this thesis elaborates results obtained from the crystallization of styrene epoxidation 
variants (Tee and Schwaneberg 2006). Crystal structures of P450 BM3 variants (5F5, 5F5K, 
5F5R) in complex with styrene were successfully determined to a resolution better than 1.9 Å 
which are the first structures of P450 BM3 solved in the presence of a non-fatty acid-like 
substrate. Previously reported crystallization conditions for P450 BM3 proved successful for 
obtaining diffraction quality crystals (Hegde, Haines et al. 2007; Haines, Chen et al. 2008). 
Attempts were made to crystallize the heme domain variants in the styrene-bound (StB) and 
styrene-free (StF) forms. However, good diffraction-quality crystals could not be obtained for 
5F5K (F87A, A184K, T235A) and 5F5R (F87A, A184R, T235A) without styrene, likely due to 
high surface-entropy associated with the A184K and A184R substitutions. For 5F5 variant 
(F87A, T235A) two datasets (ds) were collected after soaking the crystal into styrene-saturated 
cryosolution for brief (2-3 min; dsI) and long (60 min; dsII) time intervals.  
The structural data reveal that the overall StB conformation of the S-selective variants, 5F5K StB 
and 5F5R, is similar to the wild-type substrate-bound (WTSB) forms (PDB codes: 1FAG (Li and 
Poulos 1997), 1JPZ (Haines, Tomchick et al. 2001), and 1ZO9 (Hegde, Haines et al. 2007)), 
while that of the R-selective variant, 5F5, resembles wild-type substrate-free (WTSF) forms 
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(PDB codes: 1BU7 (Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 
and 2IJ2 (Girvan, Seward et al. 2007)). 5F5 StF structure exhibits mixed features. Solved crystal 
structures harbor the bound styrene in close proximity of the heme-iron in the active site, and 
reveal hitherto unobserved ‘productive’ and ‘non-productive’ substrate binding modes in P450 
BM3. In the ‘productive’ mode, the vinyl tail of styrene is positioned sufficiently close to the 
heme-iron for epoxidation to take place. In the ‘non-productive’ mode, the phenyl part points 
towards the heme and a water molecule remains coordinated to the heme-iron, rendering 
epoxidation unfeasible in this orientation. In excellent agreement with reported experimental data 
(Tee and Schwaneberg 2006), the bound styrene is oriented such that it would preferentially lead 
in the variants 5F5K and 5F5R to the formation of the S-styrene epoxide, and in the 5F5 variant 
to the formation of R-styrene epoxide. In 5F5 StB structures, the I-helix (Glu252-Lys282) is 
substantially kinked near the active site due to which Ala264 completely covers the heme pyrrole 
ring C, and provides sufficient steric hindrance to prevent exposure of the pro-S face of styrene 
to the heme-iron which, as a result, promotes the formation of R-styrene epoxide as the preferred 
enantiomer in the 5F5 variant. 
Substitution of Ala for Lys at position 184 leads to the formation of a new inter-helical salt-
bridge at the surface in 5F5K StB and 5F5R StB structures which causes the repositioning of the 
structural elements that are adjacent to the active site and, as a consequence, styrene binding 
geometries are altered as compared to the R-selective 5F5 variant. In the inverted S-selective 
variants, 5F5K StB and 5F5R StB, Ala264 and Gly265 are located away from the active site 
upon insertion of a water molecule into the I-helix which reduces the kink angle, and thus the 
pyrrole ring C is partially unmasked. Hence, the pro-S face of styrene is preferentially exposed 
over the heme-iron in the S-selective variants.  
Crystal structures of P450 BM3 variants in complex with styrene elucidate how a positively 
charged surface residue (at position 184) inverts the enantiopreference of styrene epoxidation in 
P450 BM3 (Tee and Schwaneberg 2006). Structural insights into the molecular basis for the 
enantioselective styrene epoxidation in P450 BM3 variants can very likely be generalized to 
structurally related monooxygenases and substrates. 
In Chater II of this thesis, crystal strucures of P450 BM3 M7 heme domain variant (F87A, 
V281G, M354S; Zhao, Guven et al. 2011) in the presence and absence of cobalt (III) sepulchrate 
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(Co(III)Sep) have been described. These crystal structures were determined to understand the 
role of the mediator, Co(III)Sep, in the electron transfer process based on the alternative cofactor 
system (Schwaneberg, Appel et al. 2000; Nazor and Schwaneberg 2006; Nazor, Dannenmann et 
al. 2008; Zhao, Guven et al. 2011). The structural data reveal that the overall conformation of the 
P450 BM3 M7 heme domain variant resembles the WTSF forms (PDB codes: 1BU7 
(Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), and 2IJ2 (Girvan, 
Seward et al. 2007)). The crystal structure of P450 BM3 M7 heme domain variant in complex 
with Co(III)Sep depicts the mediator at the entrance of the substrate access channel on the distal 
face, a position far from the active site and distinct from the binding of the natural redox partner 
on the proximal face of the heme in P450 BM3 (Sevrioukova, Li et al. 1999). The association of 
Co(III)Sep at the distal surface corroborates our previous propositions (Nazor and Schwaneberg 
2006; Nazor, Dannenmann et al. 2008), and suggests that the heme domain alone is sufficient to 
receive electrons. The structural evidence indicates that any mediator which is employed to 
shuttle electrons to the heme domain in P450 BM3 must possess an appropriate positive charge 
which would enable it to communicate productively with the catalytic heme domain for its 
reduction, and may also implicate the bound substrate in the active site. Solved crystal structures 
deepened our understanding on the cofactor selectivity in P450 BM3 which will clearly aid in the 
design of highly selective variants of P450 BM3 or structurally related monooxygenases towards 
alternative and cost-effective cofactor systems. 
In Chapter III of this thesis, the crystal structure of the wild-type (WT) FAD/NADPH binding 
domain has been presented which sheds light on the structural basis for the cofactor selectivity in 
P450 BM3. The electron density for FAD and NADP+ ligands could be clearly observed. 
However, in the latter case the nicotinamide moity, which has been suggested to interact with the 
isoalloxazine ring of the FAD cofactor in other P450s (Hubbard, Shen et al. 2001), is disordered. 
The isoalloxazine ring of FAD is sandwiched between two aromatic residues, Trp1046 and 
Tyr829. Similar residues also stack the adenosine part of FAD. The NADP+ is covered by 
Tyr974, and the 2’-phosphate group is surrounded by Ser965, Arg966, Lys972, and Tyr974. 
Mutagenesis studies demonstrate that these residues play a key role in modulating cofactor 
selectivity in P450 BM3 (Maurer, Kuhnel et al. 2005). The crystal structure of WT 
FAD/NADPH domain allows us to compare its structural features with the crystal structure of 
recently solved C773A/C999A variant (Joyce, Ekanem et al. 2012). Subtle structural differences 
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can likely be attributed to the introduced substitutions (Joyce, Ekanem et al. 2012). The variant is 
lacking one disulfide bridge (Joyce, Ekanem et al. 2012) formed between Cys773 and Cys810 in 
the WT structure. The truncation of the disulfide bridge due to C773A substitution leads to the 
formation of a new salt-bridge (Glu816:Lys770) between neighbouring residues (Joyce, Ekanem 
et al. 2012). In the WT structure, the salt-bridge is not observed, and Lys770 is surface-exposed, 
likely contributing to increased surface-entropy which compromises the diffraction-quality of the 
crystals. Asp1044 and Trp1046 in the vicinity of C999A substitution (Joyce, Ekanem et al. 2012) 
are slightly displaced in the WT FAD/NADPH binding domain. Trp1046 has also been shown to 
be a major determinant of cofactor specificity in P450 BM3 (Maurer, Kuhnel et al. 2005; Neeli, 
Roitel et al. 2005). 
At the end, structural features of the WT and T577G FMN domains, and the heme domains of 
aromatic hydroxylation variants (Dennig, Marienhagen et al. 2012) of P450 BM3 have been 
highlighted. Solved structures reveal that the introduced substitutions do not cause any 
significant structural perturbations, and the variants resemble their corresponding wild-type 
domains. The crystallization of the wild-type and T577G FMN domains proved successful after 
identifying new conditions. The crystals diffracted to good resolutions, however, no structural 
differences could be attributed to T577G substitution upon superposition with the WT domain. 
Crystals could not be obtained in the presence of Clevios P, as the crystallization set-up suffered 
from technical limitations due to instantaneous precipitation of the protein in the presence of 
Clevios P or its individual polymers. Crystallization at very low concentrations (PSS 0.36%, 
PEDOT 0.24%, PEDOT/PSS (whole polymer) 0.025%) were also not fruitful, as the crystals 
diffracted to low resolutions, and neither the polymers nor any structural difference was observed 
after structure solution. 
Crystal structures of AD3 and AD4 variants of P450 BM3 heme domain variants were 
determined to understand the role of substitutions distantly located from the active site in 
efficient aromatic hydroxylation of p-xylene (Dennig, Marienhagen et al. 2012). Structural 
comparison reveals that the backbone architecture of both the variants resembles WTSF forms 
(PDB codes: 1BU7 (Sevrioukova, Li et al. 1999), 2HPD (Ravichandran, Boddupalli et al. 1993), 
and 2IJ2 (Girvan, Seward et al. 2007)) more than WTSB forms (PDB codes: 1FAG (Li and 
Poulos 1997), 1JPZ (Haines, Tomchick et al. 2001) and 1ZO9 (Hegde, Haines et al. 2007)). Such 
an outcome is, however, not surprising as the variants were crystallized without the substrate, 
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and the incorporated substitutions are located at positions (47, 51, and 401) far from the active 
site. One of the substitutions (I401M) lies on the proximal side of the heme, while the other two 
(AD3: R47Q, Y51F, and AD4: R47S, Y51W) ‘gate’ the substrate access channel on the distal 
side. The presence of a relatively shorter polar residue (Ser47/Gln47), and a more hydrophobic 
residue (Phe51/Trp51) at the ‘mouth’ of the substrate binding pocket, compared to the WTSB 
forms (Li and Poulos 1997; Haines, Tomchick et al. 2001; Hegde, Haines et al. 2007; 
Whitehouse, Bell et al. 2012), likely promote substrate access for the enzyme, as supported also 
by the kinetic data (Dennig, Marienhagen et al. 2012). In AD3 and AD4 structures, no 
conformational rearrangement can be attributed to the I401M substitution, pointing to a 
possibility that the observed increase in catalytic activity towards aromatic hydroxylation 
(Dennig, Marienhagen et al. 2012) might be due to an elevated redox potential of the heme-iron. 
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5. Appendix: 
Table 11: The chemical composition of the mother liquor which successfully yielded crystals for 
individual domains of P450 BM3. 
Heme domain 
0.2 M MgCl2, 0.1 M HEPES   
(pH 7.5), 20-30% isopropanol 
0.2 M MgCl2, 0.1 M HEPES    
(pH 7.5), 0.24 M sodium 
malonate, 20-24% isopropanol 
0.2 M MgCl2, 0.1 M HEPES 
(pH 7.5), 0.22 M KCl,          
26-30% isopropanol 
0.2 M MgCl2, 0.1 M HEPES   
(pH 7.5), 20-30% PEG 400 
0.2 M MgCl2, 0.1 M HEPES    
(pH 7.5), 0.24 M sodium 
malonate, 20-24% PEG 400 
0.2 M MgCl2, 0.1 M HEPES 
(pH 7.5), 0.22 M KCl, 26-30% 
PEG 400 
0.1 M MES (pH 6.5),               
0.2-0.3 M magnesium formate 
0.1 M HEPES (pH 7.5),           
0.2-0.3 M magnesium formate 
0.1 M Tris (pH 8.5),            
0.2-0.3 M magnesium formate 
0.1 M Tris (pH 8.5),                
0.24 M sodium malonate,        
0.2-0.3 M magnesium formate 
0.1 M Tris (pH 8.5), 0.11 M KCl, 
0.2-0.3 M magnesium formate 
0.2 M MgCl2, 0.1 M HEPES 
(pH 7.5), 0.2 M magnesium 
formate, 20-22% PEG 400 
0.2 M MgCl2,                            
0.2-0.3 M magnesium formate 
0.2 M magnesium formate,       
0.1 M MES (pH 6.5),                
10-15% PEG 3350 
0.1-0.16 M MgCl2,               
0.1 M MES (pH 6.5),             
9-20% PEG 3350 
0.16 M MgCl2, 0.1 M MES     
(pH 6.5), 15-20% PEG 2000 
MME 
0.3 M magnesium formate,        
0.1 M Tris (pH 8.5), 0.11 M KCl 
0.3 M magnesium formate,  
0.1 M Tris (pH 8.5),             
0.2 M sodium malonate 
FMN domain 
0.1 M magnesium formate,      
10-20% PEG 3350 
0.1 M sodium acetate (pH 4.6), 
1.5-3.0 M NaCl 
0.1 M sodium acetate (pH 4.6), 
2.5-4.0 M ammonium acetate 
0.2 M MgSO4, 10-20% PEG 3350 
0.2 M MgCl2, 0.1 M MES        
(pH 6.5), 10-20% PEG 3350 
 
FAD/NADPH domain 
0.1 M Tris (pH 8.5),                     
1 mM NADP+, 0.1-0.15 M 
MgCl2, 8-29% PEG3350 
0.1 M Tris (pH 8.5),                     
1 mM NADP+, 0.4 M magnesium 
formate, 9% PEG 3350 
0.1 M Hepes (pH 7.5),          
0.4 M magnesium formate,  
9% PEG 3350 
0.15 M Tris (pH 8.5),                   
1 mM NADP+, 5 mM MgCl2,   
0.8 M NaCl, 21% PEG 3350 
0.1M Tris (pH 8.5),                      
1 mM NADP+, 0.2M KCl,      
15% PEG 3350 
0.15 M HEPES, (pH 7.5),       
5 mM MgCl2, 0.8 M NaCl, 
21% PEG 3350 
0.1 M magnesium formate,      
12-20% PEG 3350 
0.1 M HEPES (pH 7.5),           
0.15 M MgCl2 , 17% PEG 3350 
0.1 M MES (6.5),                 
0.1 M magnesium formate,  
12-20 % PEG 3350 
0.1 M Tris (pH 8.5),                     
1 mM NADP+, 0.1 M LiCl ,   
28% PEG 6000 
0.1 M Tris (pH 8.5),                     
1 mM NADP+,                         
0.15 M ammonium acetate,     
15% PEG 6000 
0.1 M Tris (pH 8.5),                
1 mM NADP+, 0.1 M MgCl2, 
15% PEG 6000 
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Figure 26: Representative crystals of 
obtained by the hanging-drop vapor
Canada) in the presence of reservoir solution
19% PEG 3350 for 5F5 heme domain variant (a), 300 mM magnesium formate, 100 mM Tris (pH 8.5), 
and 200 mM sodium malonate for 5F5K heme domain variant cocrystallized with styrene (b), 100 mM 
MgCl2, 100 mM MES (pH 6.5), and 12% PEG 3350 for M7 he
100 mM Tris (pH 8.5), and 17% PEG 3350 for AD3 heme domain variant 
Tris (pH 8.5), and 15% PEG 3350 for AD4 heme domain variant 
20% PEG 3350 for T577G FMN doma
for WT FMN domain (g), and 200 mM MgCl
FAD/NADPH binding domain (h).
 
 
 
 
 
the individual P450 BM3 domains. Diffraction
-diffusion method at 4 °C in crystallization screening plates (Nextal, 
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2, 100 mM MES (pH 6.5), and 19% PEG 3350 for WT 
     
98  
 
-quality crystals were 
H 6.5), and 
 200 mM MgCl2, 
2, 100 mM 
Appendix 
 
Figure 27: Parts of the styrene ligand
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Figure 28: Parts of the heme cofactor.
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Figure 29: Parts of the FMN cofactor.
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Figure 30: Parts of the FAD cofactor.
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Figure 31: Parts of the NADP+ ligand.
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